CN112442013A - Compound as thyroid hormone beta receptor agonist and application thereof - Google Patents
Compound as thyroid hormone beta receptor agonist and application thereof Download PDFInfo
- Publication number
- CN112442013A CN112442013A CN202010912749.9A CN202010912749A CN112442013A CN 112442013 A CN112442013 A CN 112442013A CN 202010912749 A CN202010912749 A CN 202010912749A CN 112442013 A CN112442013 A CN 112442013A
- Authority
- CN
- China
- Prior art keywords
- atoms
- radical
- alkylene
- group
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 201
- 239000005495 thyroid hormone Substances 0.000 title claims abstract description 34
- 229940036555 thyroid hormone Drugs 0.000 title claims abstract description 34
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 title claims abstract description 28
- 102000012740 beta Adrenergic Receptors Human genes 0.000 title claims abstract description 15
- 108010079452 beta Adrenergic Receptors Proteins 0.000 title claims abstract description 15
- 229940044601 receptor agonist Drugs 0.000 title abstract description 5
- 239000000018 receptor agonist Substances 0.000 title abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 51
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims abstract description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 23
- 201000010099 disease Diseases 0.000 claims abstract description 22
- -1 C1-6Alkylthio radical Chemical class 0.000 claims description 263
- 125000004429 atom Chemical group 0.000 claims description 200
- 150000003254 radicals Chemical class 0.000 claims description 134
- 125000000623 heterocyclic group Chemical group 0.000 claims description 132
- 125000001072 heteroaryl group Chemical group 0.000 claims description 84
- 125000004432 carbon atom Chemical group C* 0.000 claims description 65
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 54
- 229910052805 deuterium Inorganic materials 0.000 claims description 54
- 125000000217 alkyl group Chemical group 0.000 claims description 49
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 45
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 45
- 229910052801 chlorine Inorganic materials 0.000 claims description 40
- 229910052731 fluorine Inorganic materials 0.000 claims description 40
- 229910052794 bromium Inorganic materials 0.000 claims description 39
- 229910052740 iodine Inorganic materials 0.000 claims description 39
- 108090000721 thyroid hormone receptors Proteins 0.000 claims description 37
- 102000004217 thyroid hormone receptors Human genes 0.000 claims description 37
- 229910052799 carbon Inorganic materials 0.000 claims description 34
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 34
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 33
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 32
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 32
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 32
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 31
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 28
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 27
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 24
- 125000002837 carbocyclic group Chemical group 0.000 claims description 23
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 22
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 21
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 19
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 18
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 18
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 18
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 18
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 17
- 125000003282 alkyl amino group Chemical group 0.000 claims description 17
- 239000000651 prodrug Substances 0.000 claims description 15
- 229940002612 prodrug Drugs 0.000 claims description 15
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 13
- 239000003937 drug carrier Substances 0.000 claims description 13
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 claims description 13
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 11
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 11
- 239000003981 vehicle Substances 0.000 claims description 11
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 10
- 239000002207 metabolite Substances 0.000 claims description 10
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 10
- 201000001320 Atherosclerosis Diseases 0.000 claims description 9
- 239000012453 solvate Substances 0.000 claims description 9
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 8
- 208000008589 Obesity Diseases 0.000 claims description 8
- 125000002541 furyl group Chemical group 0.000 claims description 8
- 208000003532 hypothyroidism Diseases 0.000 claims description 8
- 230000002989 hypothyroidism Effects 0.000 claims description 8
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 8
- 235000020824 obesity Nutrition 0.000 claims description 8
- 125000003386 piperidinyl group Chemical group 0.000 claims description 8
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 8
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 7
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 7
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 7
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 7
- 125000002883 imidazolyl group Chemical group 0.000 claims description 7
- 125000002757 morpholinyl group Chemical group 0.000 claims description 7
- 125000002971 oxazolyl group Chemical group 0.000 claims description 7
- 125000004193 piperazinyl group Chemical group 0.000 claims description 7
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 7
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 7
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 7
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 7
- 125000005958 tetrahydrothienyl group Chemical group 0.000 claims description 7
- 125000000335 thiazolyl group Chemical group 0.000 claims description 7
- 125000001544 thienyl group Chemical group 0.000 claims description 7
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 7
- 201000002510 thyroid cancer Diseases 0.000 claims description 7
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 6
- 208000004930 Fatty Liver Diseases 0.000 claims description 6
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims description 6
- 208000029078 coronary artery disease Diseases 0.000 claims description 6
- 208000010706 fatty liver disease Diseases 0.000 claims description 6
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 6
- 208000030159 metabolic disease Diseases 0.000 claims description 6
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 6
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 230000001476 alcoholic effect Effects 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 206010063075 Cryptogenic cirrhosis Diseases 0.000 claims description 3
- 208000003816 familial cirrhosis Diseases 0.000 claims description 3
- 208000011460 glycogen storage disease due to glucose-6-phosphatase deficiency type IA Diseases 0.000 claims description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 96
- 238000006243 chemical reaction Methods 0.000 description 89
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 89
- 239000007787 solid Substances 0.000 description 73
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 63
- 239000000243 solution Substances 0.000 description 61
- 239000000203 mixture Substances 0.000 description 50
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 48
- 150000002500 ions Chemical class 0.000 description 46
- 238000004949 mass spectrometry Methods 0.000 description 45
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 44
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 44
- 125000001424 substituent group Chemical group 0.000 description 40
- 238000000034 method Methods 0.000 description 35
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 34
- 239000012065 filter cake Substances 0.000 description 32
- 238000005160 1H NMR spectroscopy Methods 0.000 description 31
- 239000000460 chlorine Substances 0.000 description 30
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 29
- 125000002947 alkylene group Chemical group 0.000 description 29
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 27
- 238000012360 testing method Methods 0.000 description 27
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 23
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 23
- 238000004128 high performance liquid chromatography Methods 0.000 description 22
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 22
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 21
- 150000001721 carbon Chemical group 0.000 description 21
- 229910052757 nitrogen Inorganic materials 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 20
- 239000002904 solvent Substances 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 17
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 17
- 235000019441 ethanol Nutrition 0.000 description 17
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 17
- 239000003208 petroleum Substances 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 125000003118 aryl group Chemical group 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 125000001188 haloalkyl group Chemical group 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 125000003545 alkoxy group Chemical group 0.000 description 14
- 125000004122 cyclic group Chemical group 0.000 description 14
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 13
- 239000002585 base Substances 0.000 description 13
- 125000000753 cycloalkyl group Chemical group 0.000 description 13
- HSOGVWWWGVFXGF-UHFFFAOYSA-N ethyl n-(2-cyanoacetyl)carbamate Chemical compound CCOC(=O)NC(=O)CC#N HSOGVWWWGVFXGF-UHFFFAOYSA-N 0.000 description 13
- 125000004438 haloalkoxy group Chemical group 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 235000010288 sodium nitrite Nutrition 0.000 description 13
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 12
- 108010071769 Thyroid Hormone Receptors beta Proteins 0.000 description 12
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
- 125000004414 alkyl thio group Chemical group 0.000 description 12
- 125000006413 ring segment Chemical group 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 229910052739 hydrogen Inorganic materials 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 239000012074 organic phase Substances 0.000 description 11
- 229910000027 potassium carbonate Inorganic materials 0.000 description 11
- 229910052717 sulfur Inorganic materials 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- 239000001632 sodium acetate Substances 0.000 description 10
- 235000017281 sodium acetate Nutrition 0.000 description 10
- 238000000967 suction filtration Methods 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 125000003342 alkenyl group Chemical group 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 125000002619 bicyclic group Chemical group 0.000 description 8
- 239000000969 carrier Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 8
- FCDBEIIBODDDEJ-UHFFFAOYSA-N 1,3-dichloro-2-iodo-5-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(Cl)=C(I)C(Cl)=C1 FCDBEIIBODDDEJ-UHFFFAOYSA-N 0.000 description 7
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 7
- 102000007330 LDL Lipoproteins Human genes 0.000 description 7
- 108010007622 LDL Lipoproteins Proteins 0.000 description 7
- 125000000304 alkynyl group Chemical group 0.000 description 7
- 125000003277 amino group Chemical group 0.000 description 7
- 125000004103 aminoalkyl group Chemical group 0.000 description 7
- 125000004181 carboxyalkyl group Chemical group 0.000 description 7
- 125000004966 cyanoalkyl group Chemical group 0.000 description 7
- 239000002270 dispersing agent Substances 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 125000002950 monocyclic group Chemical group 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 238000003419 tautomerization reaction Methods 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 6
- 150000001204 N-oxides Chemical class 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 125000004452 carbocyclyl group Chemical group 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000011259 mixed solution Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 229940048181 sodium sulfide nonahydrate Drugs 0.000 description 5
- WMDLZMCDBSJMTM-UHFFFAOYSA-M sodium;sulfanide;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[SH-] WMDLZMCDBSJMTM-UHFFFAOYSA-M 0.000 description 5
- 125000003003 spiro group Chemical group 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000000375 suspending agent Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 241000288906 Primates Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 235000021068 Western diet Nutrition 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000001270 agonistic effect Effects 0.000 description 4
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000000346 nonvolatile oil Substances 0.000 description 4
- 235000011056 potassium acetate Nutrition 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- 238000004293 19F NMR spectroscopy Methods 0.000 description 3
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 3
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 3
- OKZUJPRSCYPODK-UHFFFAOYSA-N 6-(2,6-dichloro-4-nitrophenoxy)-3,4-dihydro-1H-quinolin-2-one Chemical compound ClC1=C(OC=2C=C3CCC(NC3=CC=2)=O)C(=CC(=C1)[N+](=O)[O-])Cl OKZUJPRSCYPODK-UHFFFAOYSA-N 0.000 description 3
- PRSVRYCHQAVAJM-UHFFFAOYSA-N 7-hydroxy-1,3,4,5-tetrahydro-1-benzazepin-2-one Chemical compound N1C(=O)CCCC2=CC(O)=CC=C21 PRSVRYCHQAVAJM-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 101150065749 Churc1 gene Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 206010020850 Hyperthyroidism Diseases 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 102100038239 Protein Churchill Human genes 0.000 description 3
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 238000003149 assay kit Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 229940110456 cocoa butter Drugs 0.000 description 3
- 235000019868 cocoa butter Nutrition 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 239000012050 conventional carrier Substances 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 208000007345 glycogen storage disease Diseases 0.000 description 3
- 150000002367 halogens Chemical group 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 229940079101 sodium sulfide Drugs 0.000 description 3
- 229910052979 sodium sulfide Inorganic materials 0.000 description 3
- ZGHLCBJZQLNUAZ-UHFFFAOYSA-N sodium sulfide nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[S-2] ZGHLCBJZQLNUAZ-UHFFFAOYSA-N 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 2
- MDCRRXNPQLRWDS-UHFFFAOYSA-N 6-hydroxy-4,4-dimethyl-1,3-dihydroquinolin-2-one Chemical compound C1=C(O)C=C2C(C)(C)CC(=O)NC2=C1 MDCRRXNPQLRWDS-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 238000003718 Dual-Luciferase Reporter Assay System Methods 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241000254158 Lampyridae Species 0.000 description 2
- 238000013231 NASH rodent model Methods 0.000 description 2
- CUODJFYDPWSMMN-UHFFFAOYSA-N O=C1CCCC2=CC(OC3=C(Cl)C=C(C=C3Cl)N(=O)=O)=CC=C2N1 Chemical compound O=C1CCCC2=CC(OC3=C(Cl)C=C(C=C3Cl)N(=O)=O)=CC=C2N1 CUODJFYDPWSMMN-UHFFFAOYSA-N 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000242739 Renilla Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 238000011914 asymmetric synthesis Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000003081 coactivator Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 239000007933 dermal patch Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 238000013210 evaluation model Methods 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000012224 gene deletion Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 210000005161 hepatic lobe Anatomy 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 229940102213 injectable suspension Drugs 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- HKLGTEAHOIDGHV-UHFFFAOYSA-N n-(4-hydroxyphenyl)-3-methylbut-2-enamide Chemical compound CC(C)=CC(=O)NC1=CC=C(O)C=C1 HKLGTEAHOIDGHV-UHFFFAOYSA-N 0.000 description 2
- GHNFZPUZIVOQFO-UHFFFAOYSA-N n-(4-methoxyphenyl)-3-methylbut-2-enamide Chemical compound COC1=CC=C(NC(=O)C=C(C)C)C=C1 GHNFZPUZIVOQFO-UHFFFAOYSA-N 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 102000006255 nuclear receptors Human genes 0.000 description 2
- 108020004017 nuclear receptors Proteins 0.000 description 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000013582 standard series solution Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- LKOVPWSSZFDYPG-WUKNDPDISA-N trans-octadec-2-enoic acid Chemical compound CCCCCCCCCCCCCCC\C=C\C(O)=O LKOVPWSSZFDYPG-WUKNDPDISA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- KAFZOLYKKCWUBI-HPMAGDRPSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-3-amino-2-[[(2s)-2-[[(2s)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-5-methylhexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CCC(C)C)C(=O)N[C@@H](CN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O)C(=O)CCC1CCCCC1 KAFZOLYKKCWUBI-HPMAGDRPSA-N 0.000 description 1
- LJIOTBMDLVHTBO-CUYJMHBOSA-N (2s)-2-amino-n-[(1r,2r)-1-cyano-2-[4-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]phenyl]cyclopropyl]butanamide Chemical compound CC[C@H](N)C(=O)N[C@]1(C#N)C[C@@H]1C1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCN(C)CC2)C=C1 LJIOTBMDLVHTBO-CUYJMHBOSA-N 0.000 description 1
- TWYYFYNJOJGNFP-CUXYNZQBSA-N (2s,4r,5s,6s)-2-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-2-carbamoyl-4-[[(e,4s,6s)-4,6-dimethyloct-2-enoyl]oxymethyl]-5-hydroxy-1,3-dioxane-4,5,6-tricarboxylic acid Chemical compound O1[C@H](C(O)=O)[C@](C(O)=O)(O)[C@](COC(=O)/C=C/[C@@H](C)C[C@@H](C)CC)(C(O)=O)O[C@]1(C(N)=O)CCC(=C)[C@@H](OC(C)=O)[C@H](C)CC1=CC=CC=C1 TWYYFYNJOJGNFP-CUXYNZQBSA-N 0.000 description 1
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 1
- PNHBRYIAJCYNDA-VQCQRNETSA-N (4r)-6-[2-[2-ethyl-4-(4-fluorophenyl)-6-phenylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1CCC=1C(CC)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 PNHBRYIAJCYNDA-VQCQRNETSA-N 0.000 description 1
- FRJJJAKBRKABFA-TYFAACHXSA-N (4r,6s)-6-[(e)-2-[6-chloro-4-(4-fluorophenyl)-2-propan-2-ylquinolin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C(\[C@H]1OC(=O)C[C@H](O)C1)=C/C=1C(C(C)C)=NC2=CC=C(Cl)C=C2C=1C1=CC=C(F)C=C1 FRJJJAKBRKABFA-TYFAACHXSA-N 0.000 description 1
- UXKLQDCALAWFIU-VKNDCNMPSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-tetradecoxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCCCC)C1=CC=CC=C1 UXKLQDCALAWFIU-VKNDCNMPSA-N 0.000 description 1
- VGNCBRNRHXEODV-XXVHXNRLSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-6-dodecoxy-4,7-dihydroxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCC)C1=CC=CC=C1 VGNCBRNRHXEODV-XXVHXNRLSA-N 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- QRDAPCMJAOQZSU-KQQUZDAGSA-N (e)-3-[4-[(e)-3-(3-fluorophenyl)-3-oxoprop-1-enyl]-1-methylpyrrol-2-yl]-n-hydroxyprop-2-enamide Chemical compound C1=C(\C=C\C(=O)NO)N(C)C=C1\C=C\C(=O)C1=CC=CC(F)=C1 QRDAPCMJAOQZSU-KQQUZDAGSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- TUGFLGHTSGQDQE-UHFFFAOYSA-N 1,3-dibromo-2-fluoro-5-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(Br)=C(F)C(Br)=C1 TUGFLGHTSGQDQE-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- YKYWUHHZZRBGMG-JWTNVVGKSA-N 1-methyl-2-[[(1r,5s)-6-[[5-(trifluoromethyl)pyridin-2-yl]methoxymethyl]-3-azabicyclo[3.1.0]hexan-3-yl]methyl]benzimidazole Chemical compound C1([C@@H]2CN(C[C@@H]21)CC=1N(C2=CC=CC=C2N=1)C)COCC1=CC=C(C(F)(F)F)C=N1 YKYWUHHZZRBGMG-JWTNVVGKSA-N 0.000 description 1
- ZWFBAQAIVGHQLF-UHFFFAOYSA-N 1-methyl-4,5-dihydro-3h-1-benzazepin-2-one Chemical compound C1CCC(=O)N(C)C2=CC=CC=C21 ZWFBAQAIVGHQLF-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 1
- 229940114069 12-hydroxystearate Drugs 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- CODBZFJPKJDNDT-UHFFFAOYSA-N 2-[[5-[3-(dimethylamino)propyl]-2-methylpyridin-3-yl]amino]-9-(trifluoromethyl)-5,7-dihydropyrimido[5,4-d][1]benzazepine-6-thione Chemical compound CN(C)CCCC1=CN=C(C)C(NC=2N=C3C4=CC=C(C=C4NC(=S)CC3=CN=2)C(F)(F)F)=C1 CODBZFJPKJDNDT-UHFFFAOYSA-N 0.000 description 1
- QLVGHFBUSGYCCG-UHFFFAOYSA-N 2-amino-n-(1-cyano-2-phenylethyl)acetamide Chemical compound NCC(=O)NC(C#N)CC1=CC=CC=C1 QLVGHFBUSGYCCG-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- VJEBIHTVWPSCEM-UHFFFAOYSA-N 2-fluoro-1,3-dimethyl-5-nitrobenzene Chemical compound CC1=CC([N+]([O-])=O)=CC(C)=C1F VJEBIHTVWPSCEM-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 1
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
- 125000004922 2-methyl-3-pentyl group Chemical group CC(C)C(CC)* 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- KEZHRKOVLKUYCQ-UHFFFAOYSA-N 3,3-dimethyl-1h-indol-2-one Chemical compound C1=CC=C2C(C)(C)C(=O)NC2=C1 KEZHRKOVLKUYCQ-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- MWDVCHRYCKXEBY-LBPRGKRZSA-N 3-chloro-n-[2-oxo-2-[[(1s)-1-phenylethyl]amino]ethyl]benzamide Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(=O)CNC(=O)C1=CC=CC(Cl)=C1 MWDVCHRYCKXEBY-LBPRGKRZSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 1
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
- 125000004921 3-methyl-3-pentyl group Chemical group CC(CC)(CC)* 0.000 description 1
- YYPNJNDODFVZLE-UHFFFAOYSA-N 3-methylbut-2-enoic acid Chemical compound CC(C)=CC(O)=O YYPNJNDODFVZLE-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- XDCOYBQVEVSNNB-UHFFFAOYSA-N 4-[(7-naphthalen-2-yl-1-benzothiophen-2-yl)methylamino]butanoic acid Chemical compound OC(=O)CCCNCc1cc2cccc(-c3ccc4ccccc4c3)c2s1 XDCOYBQVEVSNNB-UHFFFAOYSA-N 0.000 description 1
- POILWHVDKZOXJZ-UHFFFAOYSA-N 4-hydroxypent-3-en-2-one Chemical compound CC(O)=CC(C)=O POILWHVDKZOXJZ-UHFFFAOYSA-N 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- UGSIRTRGNRRPSO-UHFFFAOYSA-N 5-(4-amino-2,6-dichlorophenoxy)spiro[1H-indole-3,1'-cyclopropane]-2-one Chemical compound NC1=CC(=C(OC=2C=C3C4(C(NC3=CC=2)=O)CC4)C(=C1)Cl)Cl UGSIRTRGNRRPSO-UHFFFAOYSA-N 0.000 description 1
- KUZSBKJSGSKPJH-VXGBXAGGSA-N 5-[(9R)-6-[(3R)-3-methylmorpholin-4-yl]-11-oxa-1,3,5-triazatricyclo[7.4.0.02,7]trideca-2,4,6-trien-4-yl]pyrazin-2-amine Chemical compound C[C@@H]1COCCN1c1nc(nc2N3CCOC[C@H]3Cc12)-c1cnc(N)cn1 KUZSBKJSGSKPJH-VXGBXAGGSA-N 0.000 description 1
- HIHOEGPXVVKJPP-JTQLQIEISA-N 5-fluoro-2-[[(1s)-1-(5-fluoropyridin-2-yl)ethyl]amino]-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile Chemical compound N([C@@H](C)C=1N=CC(F)=CC=1)C(C(=CC=1F)C#N)=NC=1NC=1C=C(C)NN=1 HIHOEGPXVVKJPP-JTQLQIEISA-N 0.000 description 1
- IVMYKLYNZCWHTC-UHFFFAOYSA-N 5-hydroxy-3,3-dimethyl-1h-indol-2-one Chemical compound C1=C(O)C=C2C(C)(C)C(=O)NC2=C1 IVMYKLYNZCWHTC-UHFFFAOYSA-N 0.000 description 1
- VLDMMYXXHAWANV-UHFFFAOYSA-N 5-hydroxyspiro[1H-indole-3,1'-cyclopropane]-2-one Chemical compound Oc1ccc2NC(=O)C3(CC3)c2c1 VLDMMYXXHAWANV-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- OYCQSBAIEJVKAN-UHFFFAOYSA-N 6-(4-amino-2,6-dichlorophenoxy)-3,4-dihydro-1H-quinolin-2-one Chemical compound Nc1cc(Cl)c(Oc2ccc3NC(=O)CCc3c2)c(Cl)c1 OYCQSBAIEJVKAN-UHFFFAOYSA-N 0.000 description 1
- RRELDGDKULRRDM-UHFFFAOYSA-N 6-[2-chloro-4-nitro-5-(oxan-4-yloxy)anilino]-3,4-dihydro-1H-quinolin-2-one Chemical compound [O-][N+](=O)c1cc(Cl)c(Nc2ccc3NC(=O)CCc3c2)cc1OC1CCOCC1 RRELDGDKULRRDM-UHFFFAOYSA-N 0.000 description 1
- XPXLYKINOZJGEX-UHFFFAOYSA-N 6-hydroxy-1,4-dihydro-3,1-benzoxazin-2-one Chemical compound N1C(=O)OCC2=CC(O)=CC=C21 XPXLYKINOZJGEX-UHFFFAOYSA-N 0.000 description 1
- HOSGXJWQVBHGLT-UHFFFAOYSA-N 6-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical compound N1C(=O)CCC2=CC(O)=CC=C21 HOSGXJWQVBHGLT-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GAHMCUIGTHMIFD-UHFFFAOYSA-N 7-hydroxy-4h-1,4-benzoxazin-3-one Chemical compound N1C(=O)COC2=CC(O)=CC=C21 GAHMCUIGTHMIFD-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- 108010083590 Apoproteins Proteins 0.000 description 1
- 102000006410 Apoproteins Human genes 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- LXLKOKRKUKEXFJ-UHFFFAOYSA-N BrC1=C(OC=2C=CC3=C(CCCC(N3)=O)C2)C(=CC(=C1)[N+](=O)[O-])Br Chemical compound BrC1=C(OC=2C=CC3=C(CCCC(N3)=O)C2)C(=CC(=C1)[N+](=O)[O-])Br LXLKOKRKUKEXFJ-UHFFFAOYSA-N 0.000 description 1
- HAOCRQHEYCBESX-UHFFFAOYSA-N C1CCC2=CC(OC3=C(C)C=C(N)C=C3C)=CC=C2NC1=O Chemical compound C1CCC2=CC(OC3=C(C)C=C(N)C=C3C)=CC=C2NC1=O HAOCRQHEYCBESX-UHFFFAOYSA-N 0.000 description 1
- GCDLQDVDDORKIS-UHFFFAOYSA-N CC1=C(OC=2C=CC3=C(CCCC(N3)=O)C2)C(=CC(=C1)[N+](=O)[O-])C Chemical compound CC1=C(OC=2C=CC3=C(CCCC(N3)=O)C2)C(=CC(=C1)[N+](=O)[O-])C GCDLQDVDDORKIS-UHFFFAOYSA-N 0.000 description 1
- QCMHGCDOZLWPOT-FMNCTDSISA-N COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 Chemical compound COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 QCMHGCDOZLWPOT-FMNCTDSISA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- CYSWUSAYJNCAKA-FYJFLYSWSA-N ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O Chemical compound ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O CYSWUSAYJNCAKA-FYJFLYSWSA-N 0.000 description 1
- VFFXEUHQVRQWEE-UHFFFAOYSA-N ClC1=C(OC2=CC3=C(NC(OC3)=O)C=C2)C(=CC(=C1)[N+](=O)[O-])Cl Chemical compound ClC1=C(OC2=CC3=C(NC(OC3)=O)C=C2)C(=CC(=C1)[N+](=O)[O-])Cl VFFXEUHQVRQWEE-UHFFFAOYSA-N 0.000 description 1
- KJAFVKUODHMLBP-UHFFFAOYSA-N ClC1=C(OC=2C=C3C(C=NC3=CC2)(C)C)C(=CC(=C1)[N+](=O)[O-])Cl Chemical compound ClC1=C(OC=2C=C3C(C=NC3=CC2)(C)C)C(=CC(=C1)[N+](=O)[O-])Cl KJAFVKUODHMLBP-UHFFFAOYSA-N 0.000 description 1
- VQSAGHSFLQTGOP-UHFFFAOYSA-N ClC1=C(OC=2C=C3C(CC(NC3=CC=2)=O)(C)C)C(=CC(=C1)[N+](=O)[O-])Cl Chemical compound ClC1=C(OC=2C=C3C(CC(NC3=CC=2)=O)(C)C)C(=CC(=C1)[N+](=O)[O-])Cl VQSAGHSFLQTGOP-UHFFFAOYSA-N 0.000 description 1
- KJYRDOLSBNMHTO-UHFFFAOYSA-N ClC1=C(OC=2C=C3C=CC(NC3=CC=2)=O)C(=CC(=C1)[N+](=O)[O-])Cl Chemical compound ClC1=C(OC=2C=C3C=CC(NC3=CC=2)=O)C(=CC(=C1)[N+](=O)[O-])Cl KJYRDOLSBNMHTO-UHFFFAOYSA-N 0.000 description 1
- OJKDCGIQELOPRI-UHFFFAOYSA-N ClC1=C(OC=2C=C3CC4(C(NC3=CC=2)=O)CC4)C(=CC(=C1)[N+](=O)[O-])Cl Chemical compound ClC1=C(OC=2C=C3CC4(C(NC3=CC=2)=O)CC4)C(=CC(=C1)[N+](=O)[O-])Cl OJKDCGIQELOPRI-UHFFFAOYSA-N 0.000 description 1
- DXLFYHJITWIPCL-UHFFFAOYSA-N ClC1=C(OC=2C=C3CCC(N(C3=CC=2)C)=O)C(=CC(=C1)[N+](=O)[O-])Cl Chemical compound ClC1=C(OC=2C=C3CCC(N(C3=CC=2)C)=O)C(=CC(=C1)[N+](=O)[O-])Cl DXLFYHJITWIPCL-UHFFFAOYSA-N 0.000 description 1
- DAZVCFHDNHUCAK-UHFFFAOYSA-N ClC1=C(OC=2C=CC3=C(OCC(N3)=O)C=2)C(=CC(=C1)[N+](=O)[O-])Cl Chemical compound ClC1=C(OC=2C=CC3=C(OCC(N3)=O)C=2)C(=CC(=C1)[N+](=O)[O-])Cl DAZVCFHDNHUCAK-UHFFFAOYSA-N 0.000 description 1
- QBXVXKRWOVBUDB-GRKNLSHJSA-N ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C Chemical compound ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C QBXVXKRWOVBUDB-GRKNLSHJSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000011845 Iodide peroxidase Human genes 0.000 description 1
- 108010036012 Iodide peroxidase Proteins 0.000 description 1
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 102000057248 Lipoprotein(a) Human genes 0.000 description 1
- 108010033266 Lipoprotein(a) Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- XCOBLONWWXQEBS-KPKJPENVSA-N N,O-bis(trimethylsilyl)trifluoroacetamide Chemical compound C[Si](C)(C)O\C(C(F)(F)F)=N\[Si](C)(C)C XCOBLONWWXQEBS-KPKJPENVSA-N 0.000 description 1
- HPKJGHVHQWJOOT-ZJOUEHCJSA-N N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide Chemical compound C1C(CCCC1)C[C@H](NC(=O)C=1NC2=CC=CC=C2C=1)C(=O)N[C@@H](C[C@H]1C(=O)NCC1)C=O HPKJGHVHQWJOOT-ZJOUEHCJSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 1
- TZCCKCLHNUSAMQ-DUGSHLAESA-N NC(=O)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)Cc5cccs5)C(=O)N Chemical compound NC(=O)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)Cc5cccs5)C(=O)N TZCCKCLHNUSAMQ-DUGSHLAESA-N 0.000 description 1
- MNPMCJJGZDEUJH-UHFFFAOYSA-N NC1=CC(=C(OC2=CC3=C(NC(OC3)=O)C=C2)C(=C1)Cl)Cl Chemical compound NC1=CC(=C(OC2=CC3=C(NC(OC3)=O)C=C2)C(=C1)Cl)Cl MNPMCJJGZDEUJH-UHFFFAOYSA-N 0.000 description 1
- PBILXFIUKPWMBC-UHFFFAOYSA-N NC1=CC(=C(OC=2C=C3C(C(NC3=CC=2)=O)(C)C)C(=C1)Cl)Cl Chemical compound NC1=CC(=C(OC=2C=C3C(C(NC3=CC=2)=O)(C)C)C(=C1)Cl)Cl PBILXFIUKPWMBC-UHFFFAOYSA-N 0.000 description 1
- VQDADPJMFMKPEK-UHFFFAOYSA-N NC1=CC(=C(OC=2C=C3C(CC(NC3=CC=2)=O)(C)C)C(=C1)Cl)Cl Chemical compound NC1=CC(=C(OC=2C=C3C(CC(NC3=CC=2)=O)(C)C)C(=C1)Cl)Cl VQDADPJMFMKPEK-UHFFFAOYSA-N 0.000 description 1
- FFULQSPWOVNZHY-UHFFFAOYSA-N NC1=CC(=C(OC=2C=C3C=CC(NC3=CC=2)=O)C(=C1)Cl)Cl Chemical compound NC1=CC(=C(OC=2C=C3C=CC(NC3=CC=2)=O)C(=C1)Cl)Cl FFULQSPWOVNZHY-UHFFFAOYSA-N 0.000 description 1
- MTXFAXYPMZARDU-UHFFFAOYSA-N NC1=CC(=C(OC=2C=C3CC4(C(NC3=CC=2)=O)CC4)C(=C1)Cl)Cl Chemical compound NC1=CC(=C(OC=2C=C3CC4(C(NC3=CC=2)=O)CC4)C(=C1)Cl)Cl MTXFAXYPMZARDU-UHFFFAOYSA-N 0.000 description 1
- JMPOZTKILSDOHC-UHFFFAOYSA-N NC1=CC(=C(OC=2C=C3CCC(N(C3=CC=2)C)=O)C(=C1)Cl)Cl Chemical compound NC1=CC(=C(OC=2C=C3CCC(N(C3=CC=2)C)=O)C(=C1)Cl)Cl JMPOZTKILSDOHC-UHFFFAOYSA-N 0.000 description 1
- KVKOUEKTKYGZJU-UHFFFAOYSA-N NC1=CC(=C(OC=2C=CC3=C(CCCC(N3)=O)C2)C(=C1)Br)Br Chemical compound NC1=CC(=C(OC=2C=CC3=C(CCCC(N3)=O)C2)C(=C1)Br)Br KVKOUEKTKYGZJU-UHFFFAOYSA-N 0.000 description 1
- IKHGIYMZEKGLTH-UHFFFAOYSA-N NC1=CC(=C(OC=2C=CC3=C(CCCC(N3)=O)C2)C(=C1)Cl)Cl Chemical compound NC1=CC(=C(OC=2C=CC3=C(CCCC(N3)=O)C2)C(=C1)Cl)Cl IKHGIYMZEKGLTH-UHFFFAOYSA-N 0.000 description 1
- UDDHXJWOGAKLCB-UHFFFAOYSA-N NC1=CC(=C(OC=2C=CC3=C(CCCC(N3C)=O)C2)C(=C1)Cl)Cl Chemical compound NC1=CC(=C(OC=2C=CC3=C(CCCC(N3C)=O)C2)C(=C1)Cl)Cl UDDHXJWOGAKLCB-UHFFFAOYSA-N 0.000 description 1
- YUUUIOLCILXQMJ-UHFFFAOYSA-N NC1=CC(=C(OC=2C=CC3=C(OCC(N3)=O)C=2)C(=C1)Cl)Cl Chemical compound NC1=CC(=C(OC=2C=CC3=C(OCC(N3)=O)C=2)C(=C1)Cl)Cl YUUUIOLCILXQMJ-UHFFFAOYSA-N 0.000 description 1
- ZNSPHKJFQDEABI-NZQKXSOJSA-N Nc1nc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)cc(n1)N1CCC2(CN[C@@H](C2)C(O)=O)CC1 Chemical compound Nc1nc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)cc(n1)N1CCC2(CN[C@@H](C2)C(O)=O)CC1 ZNSPHKJFQDEABI-NZQKXSOJSA-N 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- ZYXXDHUHSLJKKX-UHFFFAOYSA-N O=C1CCCC2=C(C=CC(OC3=C(Cl)C=C(C=C3Cl)N(=O)=O)=C2)N1C Chemical compound O=C1CCCC2=C(C=CC(OC3=C(Cl)C=C(C=C3Cl)N(=O)=O)=C2)N1C ZYXXDHUHSLJKKX-UHFFFAOYSA-N 0.000 description 1
- IAQNEOGILGOYNH-UHFFFAOYSA-N O=C1NN=C(C=N1)C#N Chemical compound O=C1NN=C(C=N1)C#N IAQNEOGILGOYNH-UHFFFAOYSA-N 0.000 description 1
- MVVVLHKHSUCVIM-UHFFFAOYSA-N OC=1C=C2CC3(C(NC2=CC=1)=O)CC3 Chemical compound OC=1C=C2CC3(C(NC2=CC=1)=O)CC3 MVVVLHKHSUCVIM-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- SCKXCAADGDQQCS-UHFFFAOYSA-N Performic acid Chemical compound OOC=O SCKXCAADGDQQCS-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229940125907 SJ995973 Drugs 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 229940121886 Thyroid hormone receptor agonist Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- KSQVGVMZECCPAT-AEFFLSMTSA-N [(1R)-4-phenyl-1-[[(2R)-2-(pyrazine-2-carbonylamino)pentanoyl]amino]butyl]boronic acid Chemical compound B([C@H](CCCC1=CC=CC=C1)NC(=O)[C@@H](CCC)NC(=O)C2=NC=CN=C2)(O)O KSQVGVMZECCPAT-AEFFLSMTSA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- NELWQUQCCZMRPB-UBPLGANQSA-N [(2r,3r,4r,5r)-4-acetyloxy-5-(4-amino-5-ethenyl-2-oxopyrimidin-1-yl)-2-methyloxolan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](C)O[C@H]1N1C(=O)N=C(N)C(C=C)=C1 NELWQUQCCZMRPB-UBPLGANQSA-N 0.000 description 1
- SZPWXAOBLNYOHY-UHFFFAOYSA-N [C]1=CC=NC2=CC=CC=C12 Chemical group [C]1=CC=NC2=CC=CC=C12 SZPWXAOBLNYOHY-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 208000020450 carbohydrate metabolism disease Diseases 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 231100000060 cardiovascular toxicity Toxicity 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- AEULIVPVIDOLIN-UHFFFAOYSA-N cep-11981 Chemical compound C1=C2C3=C4CNC(=O)C4=C4C5=CN(C)N=C5CCC4=C3N(CC(C)C)C2=CC=C1NC1=NC=CC=N1 AEULIVPVIDOLIN-UHFFFAOYSA-N 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940125876 compound 15a Drugs 0.000 description 1
- 229940125796 compound 3d Drugs 0.000 description 1
- 229940125872 compound 4d Drugs 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 125000004988 dibenzothienyl group Chemical group C1(=CC=CC=2SC3=C(C21)C=CC=C3)* 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000006001 difluoroethyl group Chemical group 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 125000005816 fluoropropyl group Chemical group [H]C([H])(F)C([H])([H])C([H])([H])* 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000017745 inborn carbohydrate metabolic disease Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 102000005861 leptin receptors Human genes 0.000 description 1
- 108010019813 leptin receptors Proteins 0.000 description 1
- 229950008325 levothyroxine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- QAPTWHXHEYAIKG-RCOXNQKVSA-N n-[(1r,2s,5r)-5-(tert-butylamino)-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 QAPTWHXHEYAIKG-RCOXNQKVSA-N 0.000 description 1
- PHVXTQIROLEEDB-UHFFFAOYSA-N n-[2-(2-chlorophenyl)ethyl]-4-[[3-(2-methylphenyl)piperidin-1-yl]methyl]-n-pyrrolidin-3-ylbenzamide Chemical compound CC1=CC=CC=C1C1CN(CC=2C=CC(=CC=2)C(=O)N(CCC=2C(=CC=CC=2)Cl)C2CNCC2)CCC1 PHVXTQIROLEEDB-UHFFFAOYSA-N 0.000 description 1
- XZMHJYWMCRQSSI-UHFFFAOYSA-N n-[5-[2-(3-acetylanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide Chemical compound CC(=O)C1=CC=CC(NC=2SC=C(N=2)C2=C(N=C(NC(=O)C=3C=CC=CC=3)S2)C)=C1 XZMHJYWMCRQSSI-UHFFFAOYSA-N 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- HBEDNENASUYMPO-LJQANCHMSA-N n-hydroxy-4-[[(2r)-3-oxo-2-(thiophen-2-ylmethyl)-2,4-dihydroquinoxalin-1-yl]methyl]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1CN1C2=CC=CC=C2NC(=O)[C@H]1CC1=CC=CS1 HBEDNENASUYMPO-LJQANCHMSA-N 0.000 description 1
- 125000003935 n-pentoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Substances [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005004 perfluoroethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- GJSGGHOYGKMUPT-UHFFFAOYSA-N phenoxathiine Chemical compound C1=CC=C2OC3=CC=CC=C3SC2=C1 GJSGGHOYGKMUPT-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000004262 preparative liquid chromatography Methods 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- OSFBJERFMQCEQY-UHFFFAOYSA-N propylidene Chemical compound [CH]CC OSFBJERFMQCEQY-UHFFFAOYSA-N 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- TZSZZENYCISATO-WIOPSUGQSA-N rodatristat Chemical compound CCOC(=O)[C@@H]1CC2(CN1)CCN(CC2)c1cc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)nc(N)n1 TZSZZENYCISATO-WIOPSUGQSA-N 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- DVWOYOSIEJRHKW-UIRZNSHLSA-M sodium (2S)-2-[[(2S)-2-[[(4,4-difluorocyclohexyl)-phenylmethoxy]carbonylamino]-4-methylpentanoyl]amino]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate Chemical compound FC1(CCC(CC1)C(OC(=O)N[C@H](C(=O)N[C@H](C(S(=O)(=O)[O-])O)C[C@H]1C(NCC1)=O)CC(C)C)C1=CC=CC=C1)F.[Na+] DVWOYOSIEJRHKW-UIRZNSHLSA-M 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- LBBWIBWOPGDMAJ-UHFFFAOYSA-N spiro[1h-indole-3,1'-cyclopropane]-2-one Chemical compound O=C1NC2=CC=CC=C2C11CC1 LBBWIBWOPGDMAJ-UHFFFAOYSA-N 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- JZBRFIUYUGTUGG-UHFFFAOYSA-J tetrapotassium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [K+].[K+].[K+].[K+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O JZBRFIUYUGTUGG-UHFFFAOYSA-J 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000006168 tricyclic group Chemical group 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000000725 trifluoropropyl group Chemical group [H]C([H])(*)C([H])([H])C(F)(F)F 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000009849 vacuum degassing Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention relates to a compound serving as a thyroid hormone beta receptor agonist and application thereof, and further relates to a pharmaceutical composition containing the compound. The compound or the pharmaceutical composition can be used for preparing medicaments for preventing, treating or relieving diseases modulated by thyroid hormone beta receptors, and particularly can be used for preparing medicaments for treating non-alcoholic fatty liver diseases.
Description
Technical Field
The invention belongs to the field of medicines, particularly relates to a compound serving as a thyroid hormone beta receptor agonist and application thereof, and further relates to a pharmaceutical composition containing the compound. The invention further relates to application of the compound and the pharmaceutical composition in preparing medicines for preventing, treating or alleviating diseases modulated by thyroid hormone beta receptors, in particular to application in preparing medicines for treating non-alcoholic fatty liver diseases.
Background
Thyroid Hormone (TH) has an extremely important role in growth, differentiation, development and maintenance of metabolic balance. Thyroid hormones are synthesized by the thyroid gland and secreted into the circulation in two major forms, triiodothyronine (T3) and tetraiodothyronine (T4). While T4 is the predominant form secreted by the thyroid, T3 is the more physiologically active form. T4 was converted to T3 by a tissue-specific deiodinase, which is present in all tissues but mainly in the liver and kidney.
The physiological effects of TH are mainly performed by thyroid hormone receptors (TR). TR, a member of the nuclear receptor superfamily, is a transcription factor induced by ligand T3 and is central in mediating the action of ligand T3. TR is mainly located in the nucleus, forms a heterodimer with retinoic acid X receptor (RXR) and other nuclear receptors, binds to a thyroid hormone response element (TRE) in the promoter region of a target gene, and thus regulates gene transcription. There are two subtypes of TR: TR α and TR β. TR α is further divided into TR α 1 and TR α 2, and TR β is further divided into TR β 1 and TR β 2. Of these, only TR α 1, TR β 1 and TR β 2 are capable of binding ligand T3. TR α primarily regulates heart rate, and TR β plays a key role in controlling hepatic cholesterol metabolism and inhibiting Thyroid Stimulating Hormone (TSH) release, which may be associated with high expression of TR β in the liver and pituitary.
Thyroid hormones have certain therapeutic benefits if side effects can be minimized or eliminated (Paul M. Yen et al. physiological Reviews, Vol.81(3): pp.1097-1126 (2001); Paul Webb et al. expert Opin. investig. drugs, Vol.13(5): pp.489-500 (2004)). For example, thyroid hormones can increase metabolic rate, oxygen consumption, and heat production, thereby reducing body weight. Reducing body weight will improve the co-morbidities associated with obesity with beneficial effects on obese patients, and may also have beneficial effects on glycemic control in obese patients with type 2 diabetes.
Thyroid hormones also lower serum Low Density Lipoprotein (LDL) (Eugene Morkin et al. journal of Molecular and Cellular diagnostics, Vol.37: pp.1137-1146 (2004)). Hyperthyroidism has been found to be associated with low total serum cholesterol, due to thyroid hormones increasing hepatic LDL receptor expression and stimulating cholesterol metabolism to bile acids (jj. abrams et al. j. lipid res., vol.22: pp.323-38 (1981)). Hypothyroidism is in turn associated with hypercholesterolemia and reduction of total cholesterol by thyroid hormone replacement therapy has been reported (M.Aviram et al. Clin. biochem., Vol.15: pp.62-66 (1982); JJ.Abrams et al. J.lipid Res., Vol.22: pp.323-38 (1981)). In animal models, thyroid hormones have been shown to have beneficial effects of increasing HDL cholesterol and increasing the conversion rate of LDL to HDL by increasing the expression of apo A-1, one of the major apoproteins of HDL (Gene C.Ness et al. biochemical Pharmacology, Vol.56: pp.121-129 (1998); GJ.Grover et al. Endocrinology, Vol.145: pp.1656-1661 (2004); GJ.Grover et al. Proc.Natl.Acad.Sci.USA, Vol.100: pp.10067-10072 (2003)). The incidence of atherosclerotic vascular disease is directly related to LDL cholesterol levels, and by modulating LDL and HDL, thyroid hormones may also reduce the risk of atherosclerosis and other cardiovascular diseases. In addition, there is evidence that the thyroid hormone reduces lipoprotein (a), an important risk factor, which is elevated in patients with atherosclerosis (Paul Webb et al. expert Opin. investig. drugs, Vol.13(5): pp.489-500 (2004); de Bruin et al. J. Clin. endo. Metab. Vol.76: pp.121-126 (1993)).
In addition, nonalcoholic fatty liver disease (NAFLD) is also closely related to thyroid hormone. On one hand, patients with NAFLD have influence on the functions of thyroid hormone such as transformation, inactivation and the like, and can cause the reduction of serum thyroid hormone level; on the other hand, the decrease of thyroid hormone level further causes lipid metabolism disorder and carbohydrate metabolism disorder, and is involved in the occurrence of NAFLD. It has been shown that the induction of fatty liver formation in rats by a choline-methionine deficient diet, followed by feeding T3, is observed in the reversal of fatty liver (Perra A, et al. Faseeb, 2008,22(8): 2981).
However, endogenous thyroid hormones are non-selective and present side effects, such as hyperthyroidism, in particular side effects associated with cardiovascular toxicity. Thus, the development of thyroid hormone analogs (e.g., thyroid hormone beta receptor agonists) that avoid the adverse effects of hyperthyroidism while maintaining the beneficial effects of thyroid hormone will open new avenues for treating patients with the following disorders: such as obesity, hyperlipidemia, hypercholesterolemia, diabetes, hepatic steatosis, non-alcoholic fatty liver disease, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer, thyroid diseases, and related conditions and diseases.
Disclosure of Invention
The invention provides a compound with better agonistic activity to a thyroid hormone beta receptor, and the compound and a composition thereof can be used for preparing medicaments for preventing, treating or relieving non-alcoholic fatty liver disease, atherosclerosis, coronary heart disease, hypertension, hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, dyslipidemia, obesity, diabetes, metabolic disorder, lipid metabolism disorder, 1A type glycogen storage disease, hypothyroidism or thyroid cancer of patients.
In one aspect, the invention relates to a compound that is a compound of formula (I) or a stereoisomer, geometric isomer, tautomer, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt of a compound of formula (I), or prodrug thereof,
wherein,
y is-O-, -NH-, -CH2-、-CH=CH-、-C(=O)-、-CH(OH)-、-CH(CH3)-、-C(CH3)2-or-S-;
R3a、R3b、R3cand R3dEach independently is H, deuterium, F, Cl, Br, I, -CN, -NO2、-COOH、-OH、-NH2、-SH、C1-6Alkyl radical, C1-6Alkoxy radical, C1-6Alkylthio radical, C1-6Alkylamino radical, C1-6Haloalkyl, C1-6Haloalkoxy, hydroxy C1-6Alkyl, amino C1-6Alkyl or cyano C1-6An alkyl group;
R1is H, deuterium, F, Cl, Br, I, -CN, -NO2、-COOH、-OH、-NH2、-SH、C1-6Alkyl radical, C2-6Alkenyl radical, C2-6Alkynyl, -C (═ O) -C1-6Alkoxy radical、-C(=O)-C1-6Alkyl, -C (═ O) -C1-6Alkylamino, -C (═ O) NH2、-S(=O)2-C1-6Alkyl, -S (═ O)2-C1-6Alkylamino, -S (═ O)2NH2、C1-6Alkylamino radical, C1-6Alkoxy radical, C1-6Haloalkyl, C1-6Haloalkoxy, hydroxy C1-6Alkyl, amino C1-6Alkyl, carboxyl C1-6Alkyl or cyano C1-6An alkyl group;
R2is H, deuterium, C1-6Alkyl radical, C2-6Alkenyl radical, C2-6Alkynyl, C3-6Cycloalkyl, heterocyclic radical of 5-6 atoms, C6-10Aryl or heteroaryl of 5 to 6 atoms;
X is N or CH;
E1is- (CR)aRb)q-、-C(=O)-、-O-、-C(=CRjRk)-、-S-、-S(=O)-、-S(=O)2-or-NRg-; q is 0,1, 2 or 3;
E2is-CRcRd-、-C(=O)-、-C(=CRhRi)-、-O-、-S-、-S(=O)-、-S(=O)2-or-NRg-;
E3is-CReRf-、-C(=O)-、-C(=CRmRn)-、-O-、-S-、-S(=O)-、-S(=O)2-or-NRg-;
Each Ra、Rb、Rc、Rd、Re、Rf、Rh、Ri、Rj、Rk、RmAnd RnIndependently H, deuterium, F, Cl, Br, I, -CN, -NO2、-COOH、-OH、-NH2、-SH、C1-6Alkyl radical, C2-6Alkenyl radical, C2-6Alkynyl, C1-6Alkoxy radical, C1-6Alkylamino radical, C1-6Haloalkyl, C1-6Haloalkoxy, C3-6Cycloalkyl radical, C3-6cycloalkyl-C1-4Alkylene, heterocyclic group consisting of 5 to 6 atoms, (heterocyclic group consisting of 5 to 6 atoms) -C1-4Alkylene radical, C6-10Aryl radical, C6-10aryl-C1-4Alkylene, heteroaryl of 5 to 6 atoms or (heteroaryl of 5 to 6 atoms) -C1-4Alkylene, wherein said C1-6Alkyl radical, C2-6Alkenyl radical, C2-6Alkynyl, C1-6Alkoxy radical, C1-6Alkylamino radical, C1-6Haloalkyl, C1-6Haloalkoxy, C3-6Cycloalkyl radical, C3-6cycloalkyl-C1-4Alkylene, heterocyclic group consisting of 5 to 6 atoms, (heterocyclic group consisting of 5 to 6 atoms) -C1-4Alkylene radical, C6-10Aryl radical, C6-10aryl-C1-4Alkylene, heteroaryl of 5 to 6 atoms and (heteroaryl of 5 to 6 atoms) -C1-4Alkylene is each independently unsubstituted or substituted by 1,2 or 3Ry1Substituted;
or Ra、RbTogether with the carbon atom to which they are attached form C3-8Carbocyclic ring or heterocyclic ring of 5 to 6 atoms, or Rc、RdTogether with the carbon atom to which they are attached form C3-8Carbocyclic ring or heterocyclic ring of 5 to 6 atoms, or Re、RfTogether with the carbon atom to which they are attached form C3-8A carbocyclic ring or a heterocyclic ring of 5 to 6 atoms in which said C3-8The carbocycle and the heterocycle of 5 to 6 atoms are each independently unsubstituted or substituted by 1,2 or 3Ry1Substituted;
each R4And RgIndependently of one another H, deuterium, C1-6Alkyl radical, C2-6Alkenyl radical, C2-6Alkynyl, C1-6Haloalkyl, C3-6Cycloalkyl radical, C3-6cycloalkyl-C1-4Alkylene, heterocyclic group consisting of 5 to 6 atoms, (heterocyclic group consisting of 5 to 6 atoms) -C1-4Alkylene radical, C6-10Aryl radical, C6-10aryl-C1-4Alkylene, heteroaryl of 5 to 6 atoms or (heteroaryl of 5 to 6 atoms) -C1-4Alkylene, wherein said C1-6Alkyl radical, C2-6Alkenyl radical, C2-6Alkynyl, C1-6Haloalkyl, C3-6Cycloalkyl radical, C3-6cycloalkyl-C1-4Alkylene, heterocyclic group consisting of 5 to 6 atoms, (heterocyclic group consisting of 5 to 6 atoms) -C1-4Alkylene radical, C6-10Aryl radical, C6-10aryl-C1-4Alkylene, heteroaryl of 5 to 6 atoms and (heteroaryl of 5 to 6 atoms) -C1-4Alkylene is each independently unsubstituted or substituted by 1,2 or 3Ry1Substituted;
or Ra、RcAnd together with the carbon atom to which they are each attached form-C ═ C-;
or Rc、ReAnd together with the carbon atom to which they are each attached form-C ═ C-;
or R4、ReAnd together with the atom to which they are each attached form-N ═ C-;
each RyIndependently H, deuterium, F, Cl, Br, I, -CN, -OH, -NH2、C1-6Alkyl radical, C1-6Haloalkyl, C1-6Haloalkoxy, C1-6Alkoxy or C1-6An alkylamino group;
each Ry1Independently deuterium, F, Cl, Br, I, -CN, -OH, -NH2、C1-6Alkyl radical, C1-6Haloalkyl, C1-6Haloalkoxy, C1-6Alkoxy or C1-6An alkylamino group.
In some embodiments, R3a、R3b、R3cAnd R3dEach independently is H, deuterium, F, Cl, Br, I, -CN, -NO2、-COOH、-OH、-NH2-SH, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, methylthio, methylamino, -CF3、-CHF2、-CH2F、-CH2CF3、-CH2CHF2Trifluoromethoxy, difluoromethoxy, hydroxymethyl, aminomethyl or cyanomethyl.
In some embodiments, R1Is H, deuterium, F, Cl, Br, I, -CN, -NO2、-COOH、-OH、-NH2-SH, methyl, ethyl, n-propyl, isopropyl, -CH ═ CH2、-CH2CH=CH2、-CH=CHCH3、-C≡CH、-C(=O)-OCH3、-C(=O)-OCH2CH3、-C(=O)-OCH(CH3)2、-C(=O)-OCH2CH2CH3、-C(=O)-O(CH2)3CH3、-C(=O)-OCH2CH(CH3)2、-C(=O)-CH3、-C(=O)-CH2CH3、-C(=O)-NHCH3、-C(=O)-N(CH3)2、-C(=O)NH2、-S(=O)2-CH3、-S(=O)2-CH2CH3、-S(=O)2-NHCH3、-S(=O)2NH2Methylamino, ethylamino, methoxy, ethoxy, -CF3、-CHF2、-CH2F、-CH2CF3、-CH2CHF2Trifluoromethoxy, difluoromethoxy, hydroxymethyl, aminomethyl, carboxymethyl or cyanomethyl.
In some embodiments, R2Is H, deuterium, methyl, ethyl, n-propyl, isopropyl, tert-butyl, -CH ═ CH2、-CH2CH=CH2、-CH=CHCH3C ≡ CH, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclyl with 5-6 atoms, phenyl, naphthyl or heteroaryl with 5-6 atoms.
In some embodiments, each R isa、Rb、Rc、Rd、Re、Rf、Rh、Ri、Rj、Rk、RmAnd RnIndependently H, deuterium, F, Cl, Br, I, -CN, -NO2、-COOH、-OH、-NH2、-SH、C1-4Alkyl radical, C2-4Alkenyl radical, C2-4Alkynyl, C1-4Alkoxy radical, C1-4Alkylamino radical, C1-4Haloalkyl, C1-4Haloalkoxy, C3-6Cycloalkyl radical, C3-6cycloalkyl-C1-2Alkylene, heterocyclic group consisting of 5 to 6 atoms, (heterocyclic group consisting of 5 to 6 atoms) -C1-2Alkylene radical, C6-10Aryl radical, C6-10aryl-C1-2Alkylene, heteroaryl of 5 to 6 atoms or (heteroaryl of 5 to 6 atoms) -C1-2Alkylene, wherein said C1-4Alkyl radical, C2-4Alkenyl radical, C2-4Alkynyl, C1-4Alkoxy radical, C1-4Alkylamino radical, C1-4Haloalkyl, C1-4Haloalkoxy, C3-6Cycloalkyl radical, C3-6cycloalkyl-C1-2Alkylene, heterocyclic group consisting of 5 to 6 atoms, (heterocyclic group consisting of 5 to 6 atoms) -C1-2Alkylene radical, C6-10Aryl radical, C6-10aryl-C1-2Alkylene, heteroaryl of 5 to 6 atoms and (heteroaryl of 5 to 6 atoms) -C1-2Alkylene is each independently unsubstituted or substituted by 1,2 or 3Ry1Substituted;
or Ra、RbTogether with the carbon atom to which they are attached form C3-8Carbocyclic ring or heterocyclic ring of 5 to 6 atoms, or Rc、RdTogether with the carbon atom to which they are attached form C3-8Carbocyclic ring or heterocyclic ring of 5 to 6 atoms, or Re、RfTogether with the carbon atom to which they are attached form C3-8A carbocyclic ring or a heterocyclic ring of 5 to 6 atoms in which said C3-8The carbocycle and the heterocycle of 5 to 6 atoms are each independently unsubstituted or substituted by 1,2 or 3Ry1And (4) substituting.
In some embodiments, each R isa、Rb、Rc、Rd、Re、Rf、Rh、Ri、Rj、Rk、RmAnd RnIndependently H, deuterium, F, Cl, Br, I, -CN, -NO2、-COOH、-OH、-NH2-SH, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, -CH ═ CH2、-CH2CH=CH2、-CH=CHCH3-C.ident.CH, methoxy, ethoxy, methylamino, -CF3、-CHF2、-CH2F、-CH2CF3、-CH2CHF2Trifluoromethoxy, difluoromethoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyl-CH2-, pyrrolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, (heterocyclyl consisting of 5 to 6 atoms) -C1-2Alkylene, phenyl-CH2-, phenyl-CH2CH2-, furyl, thienyl, imidazolyl, pyrimidinyl, pyridyl, pyrrolyl, pyrazinyl, thiazolyl, oxazolyl, furyl-CH2-, thienyl-CH2-, imidazolyl-CH2-, pyrimidinyl-CH2-, pyridinyl-CH2-or pyrrolyl-CH2-, wherein said methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, -CH ═ CH2、-CH2CH=CH2、-CH=CHCH3-C.ident.CH, methoxy, ethoxy, methylamino, -CHF2、-CH2F、-CH2CF3、-CH2CHF2Difluoromethoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyl-CH2-, pyrrolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, (heterocyclyl consisting of 5 to 6 atoms) -C1-2Alkylene, phenyl-CH2-, phenyl-CH2CH2-, furyl, thienyl, imidazolyl, pyrimidinyl, pyridyl, pyrrolyl, pyrazinyl, thiazolyl, oxazolyl, furyl-CH2-, thienyl-CH2-, imidazolyl-CH2-, pyrimidinyl-CH2-, pyridinyl-CH2-and pyrrolyl-CH2Each independently unsubstituted or substituted by 1,2 or 3Ry1Substituted;
or Ra、RbTogether with the carbon atom to which they are attached form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or a heterocyclic ring of 5 to 6 atoms, or Rc、RdTogether with the carbon atom to which they are attached form cyclopropyl, cyclobutyl, cyclopentyl, cyclohexylRadicals, cycloheptyl or heterocyclic rings of 5 to 6 atoms, or Re、RfTogether with the carbon atoms to which they are attached form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or a 5-6 atom heterocycle wherein the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and 5-6 atom heterocycle are each independently unsubstituted or substituted with 1,2, or 3Ry1And (4) substituting.
In some embodiments, each R is4And RgEach independently is H, deuterium, methyl, ethyl, n-propyl, isopropyl, -CH ═ CH2、-CH2CH=CH2、-CH=CHCH3、-C≡CH、-CF3、-CHF2、-CH2F、-CH2CHF2、-CH2CF3Cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C3-6cycloalkyl-C1-2Alkylene, heterocyclic group consisting of 5 to 6 atoms, (heterocyclic group consisting of 5 to 6 atoms) -C1-2Alkylene, phenyl-C1-2Alkylene, heteroaryl of 5 to 6 atoms or (heteroaryl of 5 to 6 atoms) -C1-2Alkylene, wherein the methyl, ethyl, n-propyl, isopropyl, -CH ═ CH2、-CH2CH=CH2、-CH=CHCH3、-C≡CH、-CHF2、-CH2F、-CH2CHF2、-CH2CF3Cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C3-6cycloalkyl-C1-2Alkylene, heterocyclic group consisting of 5 to 6 atoms, (heterocyclic group consisting of 5 to 6 atoms) -C1-2Alkylene, phenyl-C1-2Alkylene, heteroaryl of 5 to 6 atoms and (heteroaryl of 5 to 6 atoms) -C1-2Alkylene is each independently unsubstituted or substituted by 1,2 or 3Ry1And (4) substituting.
In some embodiments, each R isyIndependently H, deuterium, F, Cl, Br, I, -CN, -OH, -NH2Methyl, ethyl, n-propyl, isopropyl, -CF3、-CHF2Trifluoromethoxy, difluoromethoxy, methoxy, ethoxy or methylamino.
In some embodiments, each R isy1Independently deuterium, F, Cl, Br, I, -CN, -OH, -NH2Methyl, ethyl, n-propyl, isopropyl, -CF3、-CHF2Trifluoromethoxy, difluoromethoxy, methoxy, ethoxy or methylamino. In another aspect, the present invention relates to a pharmaceutical composition comprising a compound of the present invention, optionally further comprising any one of a pharmaceutically acceptable carrier, excipient, adjuvant, vehicle, or any combination thereof.
In another aspect, the invention relates to the use of a compound according to the invention or a pharmaceutical composition according to the invention for the preparation of a medicament for agonizing a thyroid hormone receptor; or for the prevention, treatment or alleviation of diseases modulated by thyroid hormone receptors.
In some embodiments, the thyroid hormone receptor of the present invention is the thyroid hormone beta receptor.
In some embodiments, the disease modulated by a thyroid hormone receptor of the present invention is non-alcoholic fatty liver disease, atherosclerosis, coronary heart disease, hypertension, hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, dyslipidemia, obesity, diabetes, a metabolic disorder, a lipid metabolism disorder, glycogen storage disease type 1A, hypothyroidism, or thyroid cancer.
In some embodiments, the non-alcoholic fatty liver disease of the present invention is non-alcoholic simple fatty liver, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease-associated cryptogenic cirrhosis, or primary liver cancer.
The foregoing merely summarizes certain aspects of the invention, but is not limited to such aspects. These and other aspects will be more fully described below.
Detailed Description
The invention provides a compound with better agonistic activity to a thyroid hormone beta receptor, a preparation method thereof, a pharmaceutical composition thereof and application thereof. Those skilled in the art can modify the process parameters appropriately to achieve the desired results with reference to the disclosure herein. It is expressly intended that all such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the scope of the invention.
Definitions and general terms
Reference will now be made in detail to certain embodiments of the invention, examples of which are illustrated by the accompanying structural and chemical formulas. The invention is intended to cover alternatives, modifications and equivalents, which may be included within the scope of the invention. Those skilled in the art will recognize that many methods and materials similar or equivalent to those described herein can be used in the practice of the present invention. The present invention is in no way limited to the methods and materials described herein, and in cases where one or more of the incorporated documents, patents, and similar materials is different from or contradictory to the present application (including but not limited to defined terms, application of terms, described techniques, and the like), the present application shall control.
It will be further appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All patents and publications referred to herein are incorporated by reference in their entirety.
The following definitions as used herein should be applied unless otherwise indicated. For the purposes of the present invention, the chemical elements are in accordance with the CAS version of the periodic Table of the elements, and the handbook of chemistry and Physics, 75 th edition, 1994. In addition, general principles of Organic Chemistry can be referred to as described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausaltito: 1999, and "March's Advanced Organic Chemistry" by Michael B.Smith and Jerry March, John Wiley & Sons, New York:2007, the entire contents of which are incorporated herein by reference.
The articles "a," "an," and "the" as used herein are intended to include "at least one" or "one or more" unless otherwise indicated or clearly contradicted by context. Thus, as used herein, the articles refer to articles of one or more than one (i.e., at least one) object. For example, "a component" refers to one or more components, i.e., there may be more than one component contemplated for use or use in embodiments of the described embodiments.
Unless otherwise indicated, the terms used in the specification and claims have the following definitions.
The term "comprising" is open-ended, i.e. includes the elements indicated in the present invention, but does not exclude other elements.
The compounds of the invention may be optionally substituted with one or more substituents, as described herein, in compounds of the general formula above, or as specifically exemplified, sub-classes, and classes of compounds encompassed by the invention. It is understood that the term "optionally substituted" is used interchangeably with the term "unsubstituted or … … substituted". The terms "optionally," "optional" or "optionally" mean that the subsequently described event or circumstance may, but need not, occur, and that the description includes instances where the event or circumstance occurs and instances where it does not. Generally, an optional substituent group may be substituted at each substitutable position of the group, unless otherwise indicated. When more than one position in a given formula can be substituted with one or more substituents selected from a particular group, the substituents may be substituted at each position, identically or differently. Wherein said substituent may be, but is not limited to, H, deuterium, F, Cl, Br, I, -CN, -NO2、-COOH、-OH、-NH2SH, alkyl, alkoxy, alkylthio, alkylamino, haloalkyl, haloalkoxy, hydroxyalkyl, aminoalkyl, cyanoalkyl, carboxyalkyl, alkenyl, alkynyl, cycloalkyl-alkylene, heterocyclyl-alkylene, carbocyclyl, heterocyclyl, aryl-alkylene, heteroarylAlkyl-alkylene, and the like.
In addition, unless otherwise explicitly indicated, the descriptions of the terms "… … independently" and "… … independently" and "… … independently" used in the present invention are interchangeable and should be understood in a broad sense to mean that the specific items expressed between the same symbols do not affect each other in different groups or that the specific items expressed between the same symbols in the same groups do not affect each other.
In the various parts of this specification, substituents of the disclosed compounds are disclosed in terms of group type or range. It is specifically intended that the invention includes each and every independent subcombination of the various members of these groups and ranges. For example, the term "C1-6Alkyl "in particular denotes independently disclosed C1Alkyl (methyl), C2Alkyl (ethyl), C3Alkyl radical, C4Alkyl radical, C5Alkyl and C6An alkyl group; "C3-8Cycloalkyl "especially refers to independently disclosed C3Cycloalkyl radical, C4Cycloalkyl radical, C5Cycloalkyl radical, C6Cycloalkyl radical, C7Cycloalkyl and C8A cycloalkyl group; "heterocyclic group consisting of 3 to 6 atoms" means a heterocyclic group consisting of 3 atoms, a heterocyclic group consisting of 4 atoms, a heterocyclic group consisting of 5 atoms and a heterocyclic group consisting of 6 ring atoms.
In the various parts of this specification, linking substituents are described. Where the structure clearly requires a linking group, the markush variables listed for that group are understood to be linking groups. For example, if the structure requires a linking group and the markush group definition for that variable recites "alkyl" or "aryl," it is understood that the "alkyl" or "aryl" represents an attached alkylene group or arylene group, respectively.
The term "alkylene" refers to a saturated divalent hydrocarbon radical resulting from the removal of two hydrogen atoms from a saturated straight or branched chain hydrocarbon radical. Unless otherwise specified, the alkylene group contains 1 to 12 carbon atoms. In some embodiments, the alkylene group contains 1 to 8A carbon atom; in other embodiments, the alkylene group contains 1 to 6 carbon atoms, i.e., C1-6An alkylene group; in some embodiments, the alkylene group contains 1 to 4 carbon atoms, i.e., C1-4An alkylene group; in some embodiments, the alkylene group contains 1 to 3 carbon atoms, i.e., C1-3An alkylene group; in some embodiments, the alkylene group contains 1-2 carbon atoms, i.e., C1-2An alkylene group. Examples include, but are not limited to, methylene (-CH)2-, ethylene (including-CH)2CH2-or-CH (CH)3) -, isopropylidene (including-CH (CH)3)CH2-or-C (CH)3)2-), n-propylidene (including-CH)2CH2CH2-、-CH(CH2CH3) -or-CH2CH(CH3) -) n-butylene (including-CH)2(CH2)2CH2-、-CH(CH2CH2CH3)-、-CH2CH(CH2CH3)-、-CH2CH2CH(CH3) -or-CH (CH)3)CH(CH3) -), tert-butylidene (including-CH (CH)3)2)-、-CH2CH(CH3)CH2-or-CH2C(CH3)2-), pentylene (e.g., -CH)2(CH2)3CH2-), hexylene (e.g. -CH2(CH2)4CH2-) and the like. Wherein said alkylene may be optionally substituted with one or more substituents as described herein.
The term "alkyl" or "alkyl group" refers to a saturated, straight or branched chain, monovalent hydrocarbon group containing 1 to 20 carbon atoms, wherein the alkyl group may be optionally substituted with one or more substituents described herein. In some embodiments, the alkyl group contains 1 to 10 carbon atoms; in some embodiments, the alkyl group contains 1-8 carbon atoms, i.e., C1-8An alkyl group; in some embodiments, the alkyl group contains 1-6 carbon atoms, i.e., C1-6An alkyl group; in some embodiments, the alkyl group contains 1-4 carbon atoms, i.e., C1-4An alkyl group; in some embodiments, the alkyl group contains 1-2 carbon atoms, i.e., C1-2An alkyl group.
Examples of alkyl groups include, but are not limited to, methyl (Me, -CH)3) Ethyl group (Et, -CH)2CH3) N-propyl (n-Pr, -CH)2CH2CH3) Isopropyl group (i-Pr, -CH (CH)3)2) N-butyl (n-Bu, -CH)2CH2CH2CH3) Isobutyl (i-Bu, -CH)2CH(CH3)2) Sec-butyl (s-Bu, -CH (CH)3)CH2CH3) Tert-butyl (t-Bu, -C (CH)3)3) N-pentyl (-CH)2CH2CH2CH2CH3) 2-pentyl (-CH (CH)3)CH2CH2CH3) 3-pentyl (-CH (CH)2CH3)2) 2-methyl-2-butyl (-C (CH)3)2CH2CH3) 3-methyl-2-butyl (-CH (CH)3)CH(CH3)2) 3-methyl-1-butyl (-CH)2CH2CH(CH3)2) 2-methyl-1-butyl (-CH)2CH(CH3)CH2CH3) N-hexyl (-CH)2CH2CH2CH2CH2CH3) 2-hexyl (-CH (CH)3)CH2CH2CH2CH3) 3-hexyl (-CH (CH)2CH3)(CH2CH2CH3) 2-methyl-2-pentyl (-C (CH))3)2CH2CH2CH3) 3-methyl-2-pentyl (-CH (CH)3)CH(CH3)CH2CH3) 4-methyl-2-pentyl (-CH (CH)3)CH2CH(CH3)2) 3-methyl-3-pentyl (-C (CH)3)(CH2CH3)2) 2-methyl-3-pentyl (-CH (CH)2CH3)CH(CH3)2)2, 3-dimethyl-2-butyl (-C (CH)3)2CH(CH3)2) 3, 3-dimethyl-2-butyl (-CH (CH)3)C(CH3)3) N-heptyl, n-heptylOctyl, and the like.
The term "alkenyl" denotes a straight or branched chain monovalent hydrocarbon radical containing 2 to 12 carbon atoms, wherein at least one site of unsaturation is a carbon-carbon sp2A double bond, wherein the alkenyl group may be optionally substituted with one or more substituents described herein, including the positioning of "cis" and "trans", or the positioning of "E" and "Z". In some embodiments, alkenyl groups contain 2 to 8 carbon atoms; in some embodiments, the alkenyl group contains 2 to 6 carbon atoms, i.e., C2-6An alkenyl group; in some embodiments, the alkenyl group contains 2 to 4 carbon atoms, i.e., C2-4An alkenyl group.
Examples of alkenyl groups include, but are not limited to, vinyl (-CH ═ CH)2) Allyl (-CH)2CH=CH2) Propenyl (-CH ═ CHCH)3) Butenyl (-CH ═ CHCH)2CH3、-CH2CH=CHCH3、-CH2CH2CH=CH2、-CH=C(CH3)2、-CH=C(CH3)2、-CH2C(CH3)=CH2) Pentenyl (-CH)2CH2CH2CH=CH2、-CH2CH2CH=CHCH3、-CH2CH2CH=CHCH3、-CH2CH=CHCH2CH3、-CH=CHCH2CH2CH3、-CH2CH2C(CH3)=CH2、-CH2CH=C(CH3)2、-CH=CHCH(CH3)2、-C(CH2CH3)=CHCH3、-CH(CH2CH3)CH=CH2) And so on.
The term "alkynyl" denotes a straight or branched chain monovalent hydrocarbon radical containing 2 to 12 carbon atoms wherein at least one site of unsaturation is a carbon-carbon sp triple bond, wherein the alkynyl radical may be optionally substituted with one or more substituents as described herein. In some embodiments, alkynyl groups contain 2-8 carbon atoms; in some embodiments, alkynyl groups contain 2-6Carbon atoms, i.e. C2-6An alkynyl group; in some embodiments, alkynyl groups contain 2-4 carbon atoms, i.e., C2-4Alkynyl. Examples of alkynyl groups include, but are not limited to, ethynyl (-C.ident.CH), 1-propynyl (-C.ident.CH-CH)3) Propargyl (-CH)2C.ident.CH), 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl, 3-methyl-1-butynyl, 1-hexynyl, 1-heptynyl, 1-octynyl, and the like.
The term "alkoxy" means an alkyl group attached to the rest of the molecule through an oxygen atom, i.e., -O-alkyl, wherein the alkyl group has the meaning as described herein, wherein the alkoxy group may be optionally substituted with one or more substituents as described herein. In some embodiments, alkoxy groups contain 1 to 20 carbon atoms; in some embodiments, alkoxy groups contain 1 to 10 carbon atoms; in some embodiments, alkoxy groups contain 1 to 8 carbon atoms; in some embodiments, the alkoxy group contains 1 to 6 carbon atoms, i.e., C1-6An alkoxy group; in some embodiments, the alkoxy group contains 1 to 4 carbon atoms, i.e., C1-4An alkoxy group; in some embodiments, the alkoxy group contains 1-3 carbon atoms, i.e., C1-3An alkoxy group.
Examples of alkoxy groups include, but are not limited to, methoxy (MeO, -OCH)3) Ethoxy (EtO, -OCH)2CH3) N-propyloxy (n-PrO, n-propoxy, -OCH)2CH2CH3) i-Propyloxy (i-PrO, i-propoxy, -OCH (CH)3)2) 1-butoxy (n-BuO, n-butoxy, -OCH)2CH2CH2CH3) 2-methyl-l-propoxy (i-BuO, i-butoxy, -OCH)2CH(CH3)2) 2-butoxy (s-BuO, s-butoxy, -OCH (CH)3)CH2CH3) 2-methyl-isopropyloxy (t-BuO, t-butoxy, -OC (CH)3)3) 1-pentyloxy (n-pentyloxy, -OCH)2CH2CH2CH2CH3) 2-pentyloxy (-OCH (CH)3)CH2CH2CH3) 3-pentyloxy (-OCH (CH))2CH3)2) 2-methyl-2-butoxy (-OC (CH))3)2CH2CH3) 3-methyl-2-butoxy (-OCH (CH)3)CH(CH3)2) 3-methyl-l-butoxy (-OCH)2CH2CH(CH3)2) 2-methyl-l-butoxy (-OCH)2CH(CH3)CH2CH3) And so on.
The term "alkylamino" includes "N-alkylamino" and "N, N-dialkylamino", meaning that the amino groups are each independently substituted with one or two alkyl groups having the definitions described herein. Wherein the alkylamino group may be optionally substituted with one or more substituents described herein. In some embodiments, alkylamino is one or two C1-6Alkylamino radicals in which the alkyl radical is bound to the nitrogen atom, i.e. C1-6An alkylamino group; in some embodiments, alkylamino is one or two C1-4Alkylamino radicals in which the alkyl radical is bound to the nitrogen atom, i.e. C1-4An alkylamino group; in some embodiments, alkylamino is one or two C1-2Alkylamino radicals in which the alkyl radical is bound to the nitrogen atom, i.e. C1-2An alkylamino group. Examples of alkylamino groups include, but are not limited to, methylamino (N-methylamino), ethylamino (N-ethylamino), dimethylamino (N, N-dimethylamino), diethylamino (N, N-diethylamino), N-propylamino (N-N-propylamino), isopropylamino (N-isopropylamino), tert-butylamino (N-tert-butylamino), and the like.
The term "alkylthio" means an alkyl group attached to the rest of the molecule through a sulfur atom, i.e., -S-alkyl, wherein the alkyl group has the meaning as described herein, wherein the alkylthio group may be optionally substituted with one or more substituents as described herein. In some embodiments, the alkylthio group contains 1 to 20 carbon atoms; in some embodiments, the alkylthio group contains 1 to 10 carbon atoms; in some embodiments, the alkylthio group contains 1 to 8 carbon atoms; in some embodiments, the alkylthio group contains 1-6 carbon atoms, i.e., C1-6An alkylthio group; in some embodiments of the present invention, the substrate is,the alkylthio radical having 1 to 4 carbon atoms, i.e. C1-4An alkylthio group; in some embodiments, the alkylthio group contains 1-3 carbon atoms, i.e., C1-3An alkylthio group. Examples of alkylthio groups include, but are not limited to, methylthio, ethylthio, and the like.
The term "haloalkyl" refers to an alkyl group having one or more halo substituents, wherein the haloalkyl group may be optionally substituted with one or more substituents described herein. In some embodiments, haloalkyl groups contain 1 to 10 carbon atoms; in some embodiments, haloalkyl groups contain 1 to 8 carbon atoms; in some embodiments, the haloalkyl group contains 1 to 6 carbon atoms, i.e., C1-6A haloalkyl group; in some embodiments, the haloalkyl group contains 1 to 4 carbon atoms, i.e., C1-4A haloalkyl group; in some embodiments, the haloalkyl group contains 1 to 3 carbon atoms, i.e., C1-3A haloalkyl group; in some embodiments, the haloalkyl group contains 1-2 carbon atoms, i.e., C1-2A haloalkyl group. Examples of haloalkyl groups include, but are not limited to, fluoromethyl (-CH)2F) Difluoromethyl (-CHF)2) Trifluoromethyl (-CF)3) Fluoroethyl (-CHFCH)3,-CH2CH2F) Difluoroethyl (-CF)2CH3,-CFHCFH2,-CH2CHF2) Perfluoroethyl, fluoropropyl (-CHFCH)2CH3,-CH2CHFCH3,-CH2CH2CH2F) Difluoropropyl (-CF)2CH2CH3,-CFHCFHCH3,-CH2CH2CHF2,-CH2CF2CH3,-CH2CHFCH2F) Trifluoropropyl, 1-dichloroethyl, 1, 2-dichloropropyl, and the like.
The term "haloalkoxy" refers to an alkoxy group substituted with one or more halogen substituents, wherein the haloalkoxy group may be optionally substituted with one or more substituents described herein. In some embodiments, haloalkoxy groups contain 1 to 10 carbon atoms; in some implementationsIn this embodiment, the haloalkoxy group contains 1 to 8 carbon atoms; in some embodiments, the haloalkoxy group contains 1-6 carbon atoms, i.e., C1-6A haloalkoxy group; in some embodiments, the haloalkoxy group contains 1-4 carbon atoms, i.e., C1-4A haloalkoxy group; in some embodiments, the haloalkoxy group contains 1-3 carbon atoms, i.e., C1-3A haloalkoxy group; in some embodiments, the haloalkyl group contains 1-2 carbon atoms, i.e., C1-2A haloalkoxy group. Examples of haloalkoxy include, but are not limited to, trifluoromethoxy, difluoromethoxy, and the like.
The term "hydroxyalkyl" refers to an alkyl group substituted with one or more hydroxyl groups (-OH), the alkyl group having the meaning described herein, wherein the hydroxyalkyl group may be optionally substituted with one or more substituents described herein. In some embodiments, a hydroxyalkyl group as described herein refers to C substituted with one or more hydroxyl (-OH) groups1-6Alkyl, i.e. hydroxy C1-6An alkyl group; in some embodiments, a hydroxyalkyl group refers to C substituted with one or more hydroxyl (-OH) groups1-4Alkyl, i.e. hydroxy C1-4An alkyl group; in some embodiments, a hydroxyalkyl group refers to C substituted with one or more hydroxyl (-OH) groups1-2Alkyl, i.e. hydroxy C1-2An alkyl group. Examples of hydroxyalkyl groups include, but are not limited to, hydroxymethyl (e.g., -CH)2OH), hydroxyethyl (e.g., 2-hydroxyethyl), hydroxy-n-propyl (e.g., -CH)2CH2CH2OH), and the like.
The term "aminoalkyl" refers to a substituted amino group (-NH)2) Substituted alkyl having the meaning described herein, wherein the aminoalkyl may be optionally substituted with one or more substituents described herein. In some embodiments, an aminoalkyl group, as described herein, is defined as being substituted with one or more amino (-NH) groups2) Substituted C1-6Alkyl radicals, i.e. amino radicals C1-6An alkyl group; in some embodiments, an aminoalkyl group is referred to as being mono-substitutedOne or more amino groups (-NH)2) Substituted C1-4Alkyl radicals, i.e. amino radicals C1-4An alkyl group; in some embodiments, an aminoalkyl group is defined as being substituted with one or more amino (-NH) groups2) Substituted C1-2Alkyl radicals, i.e. amino radicals C1-2An alkyl group. Examples of aminoalkyl groups include, but are not limited to, aminomethyl (-CH)2NH2) Diamino methyl (-CH (NH)2)2) Aminoethyl (e.g., -2-aminoethyl), amino-n-propyl (e.g., -CH)2CH2CH2NH2) And so on.
The term "cyanoalkyl" refers to an alkyl group substituted with one or more cyano groups (-CN), the alkyl group having the meaning described herein, wherein the cyanoalkyl group may be optionally substituted with one or more substituents described herein. In some embodiments, a cyanoalkyl group as described herein refers to C substituted with one or more cyano (-CN) groups1-6Alkyl, i.e. cyano C1-6An alkyl group; in some embodiments, cyanoalkyl refers to C substituted with one or more cyano (-CN) groups1-4Alkyl, i.e. cyano C1-4An alkyl group; in some embodiments, cyanoalkyl refers to C substituted with one or more cyano (-CN) groups1-2Alkyl, i.e. cyano C1-2An alkyl group. Examples of cyanoalkyl groups include, but are not limited to, cyanomethyl (e.g., -CH)2CN), cyanoethyl (e.g., 2-cyanoethyl), and the like.
The term "carboxyalkyl" refers to an alkyl group substituted with one or more carboxy groups (-COOH), said alkyl group having the meaning described herein, wherein said carboxyalkyl group may be optionally substituted with one or more substituents described herein. In some embodiments, a carboxyalkyl group as described herein refers to C substituted with one or more carboxyl groups (-COOH)1-6Alkyl, i.e. carboxyl C1-6An alkyl group; in some embodiments, a carboxyalkyl group refers to C substituted with one or more carboxyl groups (-COOH)1-4Alkyl, i.e. carboxyl C1-4An alkyl group; in some embodimentsWherein carboxyalkyl refers to C substituted with one or more carboxyl groups (-COOH)1-2Alkyl, i.e. carboxyl C1-2An alkyl group. Examples of carboxyalkyl groups include, but are not limited to, carboxymethyl, carboxyethyl (e.g., 2-carboxyethyl), and the like.
The term "cycloalkyl" refers to a saturated, monocyclic, bicyclic, or tricyclic ring system containing 3 to 12 ring carbon atoms having one or more points of attachment to the rest of the molecule, wherein the cycloalkyl group is optionally substituted with the substituents described herein. In some embodiments, cycloalkyl is a ring system containing 3 to 10 ring carbon atoms, i.e., C3-10A cycloalkyl group; in some embodiments, cycloalkyl is a ring system containing 3 to 8 ring carbon atoms, i.e., C3-8A cycloalkyl group; in some embodiments, cycloalkyl is a ring system containing 3 to 6 ring carbon atoms, i.e., C3-6A cycloalkyl group. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like.
The term "heterocyclyl" refers to a saturated or partially unsaturated, non-aromatic, monocyclic, bicyclic, or tricyclic ring system containing 3 to 12 atoms, wherein at least one ring atom is selected from the group consisting of nitrogen, sulfur, oxygen, and phosphorus, wherein the heterocyclyl is non-aromatic and does not contain any aromatic rings, and wherein the ring system has one or more attachment points to the rest of the molecule. Wherein said heterocyclyl group may be optionally substituted by one or more substituents as described herein. The term "heterocyclyl" includes monocyclic, bicyclic or polycyclic fused, spiro or bridged heterocyclic ring systems. Bicyclic heterocyclic groups include bridged bicyclic heterocyclic groups, fused bicyclic heterocyclic groups, and spiro bicyclic heterocyclic groups. The terms "heterocyclyl" and "heterocycle" are used interchangeably herein. Unless otherwise specified, heterocyclyl may be carbon-or nitrogen-based, and-CH2The-group may optionally be replaced by-C (═ O) -. The sulfur atom of the ring may optionally be oxidized to the S-oxide. The nitrogen atom of the ring may optionally be oxidized to an N-oxygen compound. The phosphorus atom of the ring may optionally be oxidized to a P-oxygen compound. In some embodiments, heterocyclyl is 3-10 atomsA ring system of components; in some embodiments, heterocyclyl is a ring system of 5-10 atoms; in some embodiments, heterocyclyl is a ring system of 5-8 atoms; in some embodiments, heterocyclyl is a ring system of 6-8 atoms; in some embodiments, heterocyclyl is a 5-6 atom ring system, i.e., 5-6 atom heterocyclyl; in some embodiments, heterocyclyl is a ring system of 3-6 atoms, i.e., heterocyclyl of 3-6 atoms; in some embodiments, heterocyclyl is a system of 3 ring atoms; in some embodiments, heterocyclyl is a ring system of 4 atoms; in other embodiments, heterocyclyl is a 5 atom ring system; in other embodiments, heterocyclyl is a 6 atom ring system.
Examples of heterocyclyl groups include, but are not limited to: oxiranyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, tetrahydrofuryl, dihydrofuranyl, tetrahydrothienyl, dihydrothienyl, 1, 3-dioxolanyl, dithiocyclopentyl, tetrahydropyranyl, dihydropyranyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, dioxanyl, dithianyl, thiaxanyl, homopiperazinyl, homopiperidinyl, oxepanyl, thiepanyl, tetrahydropyrrolyl, dihydropyrrolyl, tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydropyrazinyl, tetrahydropyridazinyl, etc. In heterocyclic radicals of-CH2Examples of-groups substituted by-C (═ O) -include, but are not limited to, 2-oxopyrrolidinyl, oxo-1, 3-thiazolidinyl, 2-piperidinonyl, 3, 5-dioxopiperidinyl, pyrimidinedione. Examples of heterocyclic sulfur atoms that are oxidized include, but are not limited to, sulfolane and 1, 1-dioxothiomorpholinyl. Bridging heterocyclyl groups include, but are not limited to, 2-oxabicyclo [2.2.2]Octyl, 1-azabicyclo [2.2.2]Octyl, 3-azabicyclo [3.2.1]Octyl, and the like.
The term "m-atomic" where m is an integer typically describes the number of ring-forming atoms in the molecule, which is m. For example, piperidinyl is a heterocyclyl group of 6 atoms, and furanyl is a heteroaryl group of 5 atoms. As another example, "heterocyclyl consisting of 3 to 6 atoms" refers to a heterocyclyl group consisting of 3,4,5, or 6 atoms.
The term "aryl" denotes monocyclic, bicyclic and tricyclic aromatic carbocyclic ring systems containing 6 to 14 ring atoms, or 6 to 12 ring atoms, or 6 to 10 ring atoms, wherein each ring contains 3 to 7 ring atoms and has one or more attachment points to the rest of the molecule. Wherein said aryl group may be optionally substituted with one or more substituents as described herein. The term "aryl" may be used interchangeably with the terms "aromatic ring" or "aromatic ring", and examples of aryl groups include, but are not limited to, phenyl, indenyl, naphthyl, and anthryl, and the like.
The term "heteroaryl" denotes monocyclic, bicyclic and tricyclic aromatic systems containing 5 to 10 ring atoms, wherein at least one ring contains one or more heteroatoms, wherein each ring contains 5 to 7 ring atoms, wherein at least one ring system is aromatic, and wherein the heteroaryl has one or more attachment points to the rest of the molecule. Wherein said heteroaryl group may be optionally substituted with one or more substituents as described herein. Unless otherwise indicated, the heteroaryl group may be attached to the rest of the molecule (e.g., the main structure in the general formula) via any reasonable site (which may be C in CH, or N in NH). When a heteroaryl group is present-CH2When said radical is-CH2-the group may optionally be replaced by-C (═ O) -. The term "heteroaryl" may be used interchangeably with the terms "heteroaromatic ring" or "heteroaromatic compound". In some embodiments, heteroaryl is a heteroaryl consisting of 5 to 8 atoms containing 1,2,3, or 4 heteroatoms independently selected from O, S, and N; in some embodiments, heteroaryl is a heteroaryl consisting of 5-7 atoms containing 1,2,3, or 4 heteroatoms independently selected from O, S, and N; in some embodiments, heteroaryl is 5-6 containing 1,2,3, or 4 heteroatoms independently selected from O, S, and NAn atomic heteroaryl group; in some embodiments, heteroaryl is a heteroaryl consisting of 5 atoms comprising 1,2,3, or 4 heteroatoms independently selected from O, S, and N; in some embodiments, heteroaryl is a heteroaryl consisting of 6 atoms comprising 1,2,3, or 4 heteroatoms independently selected from O, S, and N.
Examples of heteroaryl groups include, but are not limited to, the following monocyclic groups: furyl (2-furyl, 3-furyl), imidazolyl (N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl), isoxazolyl (3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl), oxazolyl (2-oxazolyl, 4-oxazolyl, 5-oxazolyl), pyrrolyl (N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl), pyridyl (2-pyridyl, 3-pyridyl, 4-pyridyl), pyrimidinyl (2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl), pyridazinyl (e.g. 3-pyridazinyl), thiazolyl (2-thiazolyl, 4-thiazolyl, 5-thiazolyl), tetrazolyl (e.g. 5H-tetrazolyl), 2H-tetrazolyl), triazolyl (e.g., 2-triazolyl, 5-triazolyl, 4H-1,2, 4-triazolyl, 1,2, 3-triazolyl), thienyl (2-thienyl, 3-thienyl), pyrazolyl (e.g., 2-pyrazolyl and 3-pyrazolyl), isothiazolyl, 1,2, 3-oxadiazolyl, 1,2, 5-oxadiazolyl, 1,2, 4-oxadiazolyl, 1,3, 4-oxadiazolyl, 1,2, 3-thiadiazolyl, 1,3, 4-thiadiazolyl, 1,2, 5-thiadiazolyl, pyrazinyl, 1,3, 5-triazinyl; the following bicyclic or tricyclic groups are also included, but in no way limited to these groups: indolinyl, 1,2,3, 4-tetrahydroisoquinolinyl, benzimidazolyl, benzofuranyl, benzothienyl, indolyl (e.g., 2-indolyl), purinyl, quinolinyl (e.g., 2-quinolinyl, 3-quinolinyl, 4-quinolinyl), isoquinolinyl (e.g., 1-isoquinolinyl, 3-isoquinolinyl, or 4-isoquinolinyl), phenoxathiin, dibenzoimidazolyl, dibenzofuranyl, dibenzothienyl.
The term "carbocyclyl" refers to a non-aromatic carbocyclic ring system of 3 to 14 ring carbon atoms that is saturated or contains one or more units of unsaturation. The terms "carbocycle", "carbocyclyl" or "carbocyclic" are used interchangeably herein. In some embodiments, the number of carbon ring carbon atoms of the carbocyclic ring is from 3 to 12; in other embodimentsIn which the number of carbon ring carbon atoms is 3 to 10; in other embodiments, the number of carbon ring carbon atoms of the carbocyclic ring is from 3 to 8; in other embodiments, the number of carbon ring carbon atoms of the carbocyclic ring is 3 to 6, i.e., C3-6A carbocyclic group; in other embodiments, the number of carbon ring carbon atoms of the carbocyclic ring is from 5 to 6, i.e., C5-6A carbocyclic group; in other embodiments, the number of carbon ring carbon atoms in a carbocyclic ring is from 5 to 8. In other embodiments, the number of carbon ring carbon atoms in a carbocyclic ring is from 6 to 8. "carbocyclyl" includes monocyclic, bicyclic or polycyclic fused, spiro or bridged carbocyclic ring systems, and also includes polycyclic ring systems in which the carbocyclic rings may be fused to one or more non-aromatic carbocyclic rings or one or more aromatic rings or combinations thereof. Bicyclic carbocyclyl includes bridged bicyclic carbocyclyl, fused bicyclic carbocyclyl and spirobicyclic carbocyclyl, and a "fused" bicyclic ring system comprises two rings that share 2 adjacent ring atoms. The bridged bicyclic group includes two rings that share 3 or 4 adjacent ring atoms. Spiro ring systems share 1 ring atom. Suitable carbocyclic groups include, but are not limited to, cycloalkyl, cycloalkenyl, and cycloalkynyl. Examples of carbocyclic groups further include, but are in no way limited to, cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopentyl-1-alkenyl, 1-cyclopentyl-2-alkenyl, 1-cyclopentyl-3-alkenyl, cyclohexyl, 1-cyclohexyl-1-alkenyl, 1-cyclohexyl-2-alkenyl, 1-cyclohexyl-3-alkenyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, and the like. Bridged carbocyclyl groups include, but are not limited to, bicyclo [2.2.2]Octyl, bicyclo [2.2.1]Heptyl, bicyclo [3.3.1]Nonyl, bicyclo [3.2.3]Nonyl, and the like.
The term "cycloalkyl-alkylene" means that the cycloalkyl group is attached to the rest of the molecule through an alkylene group, wherein cycloalkyl and alkylene have the meaning described herein. The cycloalkyl-alkylene groups may be optionally substituted with one or more substituents as described herein. The term "C" in the present invention3-6cycloalkyl-C1-4Alkylene "represents C3-6Cycloalkyl radicals through C1-4The alkylene group is attached to the rest of the molecule. The term "C" in the present invention3-6cycloalkyl-C1-2Alkylene "represents C3-6Cycloalkyl radicals through C1-2The alkylene group is attached to the rest of the molecule. Examples include, but are not limited to, cyclopropyl-CH2-, cyclopropyl-CH2CH2-, cyclobutyl-CH2-, cyclobutyl-CH2CH2-, cyclopentyl-CH2-, cyclopentyl-CH2CH2-, cyclohexyl-CH2-, cyclohexyl-CH2CH2-and the like.
The term "heterocyclyl-alkylene" means that the heterocyclyl group is attached to the rest of the molecule through an alkylene group, wherein heterocyclyl and alkylene have the meaning described herein. The heterocyclyl-alkylene group may be optionally substituted with one or more substituents as described herein. (heterocyclic group consisting of 5 to 6 atoms) -C described in the present invention1-4Alkylene "denotes a heterocyclic radical of 5 to 6 atoms bonded via C1-4The alkylene group is attached to the rest of the molecule. (heterocyclic group consisting of 5 to 6 atoms) -C described in the present invention1-2Alkylene "denotes a heterocyclic radical of 5 to 6 atoms bonded via C1-2The alkylene group is attached to the rest of the molecule. Examples include, but are not limited to, tetrahydropyranyl-CH2-, tetrahydropyranyl-CH2CH2-, tetrahydrofuryl-CH2-, tetrahydrofuryl-CH2CH2-, pyrrolidinyl-CH2-, piperidinyl-CH2-, piperidinyl-CH2CH2-, morpholinyl-CH2-, morpholinyl-CH2CH2-and so on.
The term "aryl-alkylene" means that the aryl group is attached to the rest of the molecule through an alkylene group, wherein aryl and alkylene have the meaning described herein. The aryl-alkylene groups may be optionally substituted with one or more substituents as described herein. For example, "C" according to the invention6-10aryl-C1-4Alkylene "represents C6-10Aryl radicals through C1-4The alkylene group is attached to the rest of the molecule. "C" according to the invention6-10aryl-C1-2Alkylene "represents C6-10Aryl radicals through C1-2The alkylene group is attached to the rest of the molecule. Examples include, but are not limited to, phenyl-CH2-, phenyl-CH2CH2-, naphthyl-CH2-and the like.
The term "heteroaryl-alkylene" means that the heteroaryl group is attached to the rest of the molecule through an alkylene group, wherein heteroaryl and alkylene have the meaning described herein. The heteroaryl-alkylene group may be optionally substituted with one or more substituents described herein. (5-6-atom-constituting heteroaryl) -C as defined in the invention1-4Alkylene "denotes a heteroaryl group of 5 to 6 atoms bonded via C1-4The alkylene group is attached to the rest of the molecule. (5-6-atom-constituting heteroaryl) -C as defined in the invention1-2Alkylene "denotes a heteroaryl group of 5 to 6 atoms bonded via C1-2The alkylene group is attached to the rest of the molecule. Examples include, but are not limited to, pyridyl-CH2-, pyrrolyl-CH2CH2-, quinolyl-CH2-, thienyl-CH2-, furyl-CH2-, pyrimidinyl-CH2-, pyridinyl-CH2-and the like.
The term "heteroatom" refers to O, S, N, P and any oxidation state form of Si, including S, N, and P; primary, secondary, tertiary amines and quaternary ammonium salt forms; or hydrogen on nitrogen atoms in the heterocycle substituted, e.g. N (like N in 3, 4-dihydro-2H-pyrrolyl), NH (like NH in pyrrolidinyl) or NRT(like NR in N-substituted pyrrolidinylT,RTAs a substituent on N).
The term "halogen" refers to F, Cl, Br or I.
The term "nitro" means-NO2。
The term "mercapto" refers to-SH.
The term "hydroxy" refers to-OH.
The term "amino" refers to the group-NH2。
The term "cyano" refers to — CN.
The term "carboxylic acid" or "carboxyl" refers to-C (═ O) OH or-COOH.
The term "carbonyl", whether used alone or in combination with other terms such as "aminocarbonyl" or "acyloxy", denotes — (C ═ O) -.
The term "deuterium" means deuterated, i.e.2H。
As described herein, the ring system formed by a ring with a substituent R bonded to the center represents that the substituent R may be substituted at any substitutable or any reasonable position on the ring to which it is attached. For example, formula a represents that substituent R may be substituted at any possible substituted position on the C ring as shown in formulas a-1 to a-4:
the term "protecting group" or "PG" refers to a substituent group that blocks or protects a particular functionality when other functional groups in a compound are reacted. For example, "amino protecting group" means a substituent attached to an amino group to block or protect the functionality of the amino group in a compound, and suitable amino protecting groups include acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC ), benzyloxycarbonyl (CBZ ) and 9-fluorenylmethoxycarbonyl (Fmoc). Similarly, "hydroxy protecting group" refers to the functionality of a substituent of a hydroxy group to block or protect the hydroxy group, and suitable protecting groups include, but are not limited to, acetyl, benzoyl, benzyl, p-methoxybenzyl, silyl, and the like. "carboxy protecting group" refers to the functionality of a substituent of a carboxy group to block or protect the carboxy group, and typical carboxy protecting groups include-CH2CH2SO2Ph, cyanoethyl, 2- (trimethylsilyl) ethyl, 2- (trimethylsilyl) ethoxymethyl, 2- (p-toluenesulfonyl) ethyl, 2- (p-nitrobenzenesulfonyl) ethyl, 2- (diphenylphosphino) ethyl, nitroethyl, and the like. General descriptions of protecting groups can be found in the literature: greene, Protective Groups in Organic Synthesis, John Wiley&Sons,New York,1991;and P.J.Kocienski,Protecting Groups,Thieme,Stuttgart,2005.
The term "leaving group" or "LG" refers to an atom or functional group that is removed from a larger molecule in a chemical reaction, a term used in nucleophilic substitution reactions and elimination reactions. In nucleophilic substitution reactions, the reactant attacked by the nucleophile is called the substrate, and the atom or group of atoms cleaved away from the substrate molecule with a pair of electrons is called the leaving group. Common leaving groups are, for example, but not limited to, halogen atoms, ester groups, sulfonate groups, nitro groups, azide groups, hydroxyl groups, or the like.
The term "pharmaceutically acceptable" means that the substance or composition must be chemically and/or toxicologically compatible with the other ingredients comprising the formulation and/or the mammal being treated therewith. Preferably, the term "pharmaceutically acceptable" as used herein refers to those approved by a federal regulatory agency or a state government or listed in the U.S. pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
The term "carrier" includes any solvent, dispersion medium, coating, surfactant, antioxidant, preservative (e.g., antibacterial, antifungal), isotonic agent, salt, Pharmaceutical stabilizer, binder, excipient, dispersant, lubricant, sweetener, flavoring agent, coloring agent, or combination thereof, known to those skilled in the art (e.g., Remington's Pharmaceutical Sciences,18th Ed. Mack Printing Company,1990, pp. 1289-1329). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in therapeutic or pharmaceutical compositions is contemplated.
The term "pharmaceutical composition" means a mixture of one or more compounds described herein or physiologically/pharmaceutically acceptable salts or prodrugs thereof with other chemical components such as physiologically/pharmaceutically acceptable carriers, excipients, diluents, binders, fillers and like excipients, and additional therapeutic agents such as anti-diabetic agents, anti-hyperglycemic agents, anti-obesity agents, anti-hypertensive agents, anti-platelet agents, anti-atherosclerotic agents or lipid-lowering agents. The purpose of the pharmaceutical composition is to facilitate the administration of the compound to an organism.
The term "prodrug", as used herein, represents a compound that is converted in vivo to a compound of formula (I). Such conversion is effected by hydrolysis of the prodrug in the blood or by enzymatic conversion to the parent structure in the blood or tissue. The prodrug compound of the invention can be ester, and in the prior invention, the ester can be used as the prodrug and comprises phenyl ester and aliphatic (C)1-24) Esters, acyloxymethyl esters, carbonates, carbamates and amino acid esters. For example, a compound of the present invention contains a hydroxy group, i.e., it can be acylated to provide the compound in prodrug form. Other prodrug forms include phosphate esters, such as those obtained by phosphorylation of a hydroxyl group on the parent. For a complete discussion of prodrugs, reference may be made to the following: higuchi et al, Pro-drugs as Novel Delivery Systems, vol.14, a.c.s.symposium Series; roche et al, Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987; rautio et al, primers: Design and Clinical Applications, Nature Reviews Discovery,2008,7, 255-.
The term "metabolite" refers to the product of the metabolism of a particular compound or salt thereof in vivo. Metabolites of a compound can be identified by techniques well known in the art, and its activity can be characterized by assay methods as described herein. Such products may be obtained by administering the compound by oxidation, reduction, hydrolysis, amidation, deamidation, esterification, defatting, enzymatic cleavage, and the like. Accordingly, the present invention includes metabolites of compounds, including metabolites produced by contacting a compound of the present invention with a mammal for a sufficient period of time.
The term "pharmaceutically acceptable salts" refers to both organic and inorganic salts of the compounds of the present invention. Pharmaceutically acceptable salts are well known in the art, as are: berge et al, describe the description of the descriptive pharmaceutical acceptable salts in detail in J. Pharmacol Sci,1997,66, 1-19.
The term "solvate" refers to an association of one or more solvent molecules with a compound of the invention. Solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, dimethyl sulfoxide, ethyl acetate, acetic acid, aminoethanol. The term "hydrate" refers to an association of solvent molecules that is water.
The term "nitroxide" means that when a compound contains several amine functional groups, 1 or more than 1 nitrogen atom can be oxidized to form an N-oxide. Specific examples of N-oxides are N-oxides of tertiary amines or N-oxides of nitrogen-containing heterocyclic nitrogen atoms. The corresponding amines can be treated with an oxidizing agent such as hydrogen peroxide or a peracid (e.g., peroxycarboxylic acid) to form the N-oxide (see Advanced Organic Chemistry, Wiley Interscience, 4 th edition, Jerry March, pages). In particular, the N-oxide may be prepared by the method of L.W.Deady (Syn.Comm.1977,7,509-514) in which an amine compound is reacted with m-chloroperbenzoic acid (MCPBA), for example, in an inert solvent such as dichloromethane.
Any asymmetric atom (e.g., carbon, etc.) of a compound of the invention can exist in racemic or enantiomerically enriched forms, such as the (R) -, (S) -or (R, S) -configuration. In certain embodiments, each asymmetric atom has at least 50% enantiomeric excess, at least 60% enantiomeric excess, at least 70% enantiomeric excess, at least 80% enantiomeric excess, at least 90% enantiomeric excess, at least 95% enantiomeric excess, or at least 99% enantiomeric excess in the (R) -or (S) -configuration. Substituents on atoms having unsaturated double bonds may, if possible, be present in cis- (Z) -or trans- (E) -form.
Thus, as described herein, the compounds of the present invention may exist in one of the possible isomers, rotamers, atropisomers, tautomers, or mixtures thereof, for example, as substantially pure geometric (cis or trans) isomers, diastereomers, optical isomers (enantiomers), racemates, or mixtures thereof.
Any resulting mixture of isomers may be separated into pure or substantially pure geometric or optical isomers, diastereomers, racemates on the basis of the physicochemical differences of the components, for example, by chromatography and/or fractional crystallization.
The racemates of any of the resulting end products or intermediates can be resolved into the optical enantiomers by known methods using methods familiar to those skilled in the art, e.g., by separation of the diastereomeric salts obtained. Racemic products can also be separated by chiral chromatography, e.g., High Pressure Liquid Chromatography (HPLC) using a chiral adsorbent. In particular, Enantiomers can be prepared by Asymmetric Synthesis (e.g., Jacques, et al, Enantiomers, racemes and solutions (Wiley Interscience, New York, 1981); Principles of Asymmetric Synthesis (2)nd Ed.Robert E.Gawley,Jeffrey Aubé,Elsevier,Oxford,UK,2012);Eliel,E.L.Stereochemistry of Carbon Compounds(McGraw-Hill,NY,1962);and Wilen,S.H.Tables of Resolving Agents and Optical Resolutions p.268(E.L.Eliel,Ed.,Univ.of Notre Dame Press,Notre Dame,IN 1972))。
The present invention also includes isotopically-labelled compounds of the present invention which are identical to those recited herein, except for the fact that: one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Exemplary isotopes that can also be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, such as2H,3H,13C,14C,15N,16O,17O,31P,32P,36S,18F and37Cl。
compounds of the present invention that contain the aforementioned isotopes and/or other isotopes of other atoms, as well as pharmaceutically acceptable salts of such compounds, are included within the scope of the present invention. Isotopically-labelled compounds of the invention, e.g. radioisotopes, e.g.3H and14incorporation of C into the compounds of the invention can be used in drug and/or substrate tissue distribution assays. Tritiated, i.e.,3h, and carbon-14, i.e14C, an isotope is particularly preferred. Furthermore, with isotopes having a larger mass number, e.g. deuterium, i.e. with2H substitution may provide some of the therapeutic advantages of greater metabolic stability, such as increased in vivo half-life or reduced dosage requirements. Thus, it may be preferable in some situations.
The stereochemical definitions and conventions used in the present invention are generally in accordance with S.P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; definitions and conventions described by and Eliel, e.and Wilen, s., "Stereochemistry of Organic Compounds", John Wiley & Sons, inc., New York, 1994. The compounds of the invention may contain asymmetric or chiral centers and thus exist in different stereoisomeric forms. It is contemplated that all stereoisomeric forms of the compounds of the present invention, including but not limited to diastereomers, enantiomers, and atropisomers (atropisomers) and mixtures thereof, such as racemic mixtures, are also included within the scope of the present invention. Many organic compounds exist in an optically active form, i.e., they have the ability to rotate the plane of plane polarized light. When describing optically active compounds, the prefixes D and L or R and S are used to denote the absolute configuration of the molecule with respect to the chiral center (or centers) in the molecule. The prefixes d and l or (+) and (-) are the symbols used to specify the rotation of plane polarized light by the compound, where (-) or l indicates that the compound is left-handed. Compounds prefixed with (+) or d are dextrorotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of each other. A particular stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often referred to as a mixture of enantiomers. A 50:50 mixture of enantiomers is referred to as a racemic mixture or racemate, which may occur when there is no stereoselectivity or stereospecificity in the chemical reaction or process.
Depending on the choice of starting materials and process, the compounds according to the invention may be present as one of the possible isomers or as a mixture thereof, for example as the pure optical isomer, or as a mixture of isomers, for example as a mixture of racemic and non-corresponding isomers, depending on the number of asymmetric carbon atoms. Optically active (R) -or (S) -isomers can be prepared using chiral synthons or chiral preparations, or resolved using conventional techniques. If the compound contains a double bond, the substituents may be in the E or Z configuration; if the compound contains a disubstituted cycloalkyl group, the substituents of the cycloalkyl group may be in the cis or trans (cis-or trans-) configuration.
Unless otherwise indicated, the structures described herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, atropisomer, and geometric (or conformational)) forms of the structure; for example, the R and S configurations of each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Thus, individual stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) isomeric mixtures of the compounds of the present invention are within the scope of the invention.
The term "tautomer" or "tautomeric form" refers to structural isomers having different energies that can interconvert by a low energy barrier (low energy barrier). If tautomerism is possible (e.g., in solution), then the chemical equilibrium of the tautomer can be reached. For example, proton tautomers (also known as proton transfer tautomers) include interconversions by proton migration, such as keto-enol isomerization and imine-enamine isomerization. Valence tautomers (valenctautomers) include interconversion by recombination of some of the bonding electrons. A specific example of keto-enol tautomerism is the tautomerism of the pentan-2, 4-dione and 4-hydroxypent-3-en-2-one tautomers. Another example of tautomerism is phenol-ketone tautomerism. One specific example of phenol-ketone tautomerism is the tautomerism of pyridin-4-ol and pyridin-4 (1H) -one tautomers. Unless otherwise indicated, all tautomeric forms of the compounds of the invention are within the scope of the invention.
The term "geometric isomer," also known as "cis-trans isomer," is an isomer resulting from the inability of double bonds (including olefinic double bonds, C ═ N double bonds, and N ═ N double bonds) or single bonds of ring carbon atoms to rotate freely.
The term "subject" as used herein refers to an animal. Typically the animal is a mammal. Subjects also refer to primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds, and the like. In certain embodiments, the subject is a primate. In still other embodiments, the subject is a human.
The terms "subject" and "patient" as used herein are used interchangeably. The terms "subject" and "patient" refer to animals (e.g., birds or mammals such as chickens, quails or turkeys), particularly "mammals" including non-primates (e.g., cows, pigs, horses, sheep, rabbits, guinea pigs, rats, cats, dogs, and mice) and primates (e.g., monkeys, chimpanzees, and humans), and more particularly humans. In one embodiment, the subject is a non-human animal, such as a farm animal (e.g., a horse, cow, pig, or sheep) or a pet (e.g., a dog, cat, guinea pig, or rabbit). In other embodiments, the "patient" refers to a human.
In addition, unless otherwise indicated, the structural formulae of the compounds described herein include isotopically enriched concentrations of one or more different atoms.
The term "treating" or "treatment" as used herein refers, in some embodiments, to ameliorating a disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one clinical symptom thereof). In other embodiments, "treating" or "treatment" refers to moderating or improving at least one physical parameter, including physical parameters that may not be perceived by the patient. In other embodiments, "treating" or "treatment" refers to modulating the disease or disorder, either physically (e.g., stabilizing a perceptible symptom) or physiologically (e.g., stabilizing a parameter of the body), or both. In other embodiments, "treating" or "treatment" refers to preventing or delaying the onset, occurrence, or worsening of a disease or disorder.
Description of the Compounds of the invention
The invention provides a compound with better agonistic activity on thyroid hormone beta receptor, which is used for preparing medicaments for treating non-alcoholic fatty liver disease, atherosclerosis, coronary heart disease, hypertension, hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, dyslipidemia, obesity, diabetes, metabolic disorder, lipid metabolism disorder, 1A type glycogen storage disease, hypothyroidism or thyroid cancer. The invention also provides processes for preparing these compounds, pharmaceutical compositions comprising these compounds and methods of using these compounds and pharmaceutical compositions in the manufacture of medicaments for the treatment of the above-mentioned diseases in mammals, especially humans. Compared with the existing similar compounds, the compound of the invention not only has good pharmacological activity and selectivity, but also has excellent in vivo metabolic kinetics property and in vivo pharmacodynamics property. The preparation method of the compound is simple and feasible, has stable process method, and is suitable for industrial production. Therefore, compared with the existing similar compounds, the compound provided by the invention has better drugability.
Specifically, the method comprises the following steps:
in one aspect, the invention relates to a compound that is a compound of formula (I) or a stereoisomer, geometric isomer, tautomer, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt of a compound of formula (I), or prodrug thereof,
wherein, ring A, Y, R1、R2、R3a、R3b、R3cAnd R3dHaving the definitions as described in the present invention.
In some embodiments, Y is-O-, -NH-, -CH2-、-CH=CH-、-C(=O)-、-CH(OH)-、-CH(CH3)-、-C(CH3)2-or-S-.
In some embodiments, R3a、R3b、R3cAnd R3dEach independently is H, deuterium, F, Cl, Br, I, -CN, -NO2、-COOH、-OH、-NH2、-SH、C1-6Alkyl radical, C1-6Alkoxy radical, C1-6Alkylthio radical, C1-6Alkylamino radical, C1-6Haloalkyl, C1-6Haloalkoxy, hydroxy C1-6Alkyl, amino C1-6Alkyl or cyano C1-6An alkyl group.
In some embodiments, R1Is H, deuterium, F, Cl, Br, I, -CN, -NO2、-COOH、-OH、-NH2、-SH、C1-6Alkyl radical, C2-6Alkenyl radical, C2-6Alkynyl, -C (═ O) -C1-6Alkoxy, -C (═ O) -C1-6Alkyl, -C (═ O) -C1-6Alkylamino, -C (═ O) NH2、-S(=O)2-C1-6Alkyl, -S (═ O)2-C1-6Alkylamino, -S (═ O)2NH2、C1-6Alkylamino radical, C1-6Alkoxy radical, C1-6Haloalkyl, C1-6Haloalkoxy, hydroxy C1-6Alkyl, amino C1-6Alkyl, carboxyl C1-6Alkyl or cyano C1-6An alkyl group.
In some embodiments, R2Is H, deuterium, C1-6Alkyl radical, C2-6Alkenyl radical, C2-6Alkynyl, C3-6Cycloalkyl, heterocyclic radical of 5-6 atoms, C6-10Aryl or heteroaryl of 5 to 6 atoms.
In some embodiments, ring a isSaid E1、E2、E3、R4X and RyHaving the definitions set out in the present invention.
In some embodiments, X is N or CH.
In some embodiments, E1Is- (CR)aRb)q-、-C(=O)-、-O-、-C(=CRjRk)-、-S-、-S(=O)-、-S(=O)2-or-NRg-; the R isa、Rb、Rj、Rk、RgAnd q has the definitions stated in the present invention.
In some embodiments, E2is-CRcRd-、-C(=O)-、-C(=CRhRi)-、-O-、-S-、-S(=O)-、-S(=O)2-or-NRg-, said Rc、Rd、Rh、RiAnd RgHaving the definitions set out in the present invention.
In some embodiments, E3is-CReRf-、-C(=O)-、-C(=CRmRn)-、-O-、-S-、-S(=O)-、-S(=O)2-or-NRg-, said Re、Rf、Rm、RnAnd RgHaving the definitions set out in the present invention.
In some embodiments, each R isa、Rb、Rc、Rd、Re、Rf、Rh、Ri、Rj、Rk、RmAnd RnIndependently H, deuterium, F, Cl, Br, I, -CN, -NO2、-COOH、-OH、-NH2、-SH、C1-6Alkyl radical, C2-6Alkenyl radical, C2-6Alkynyl, C1-6Alkoxy radical, C1-6Alkylamino radical, C1-6Haloalkyl, C1-6Haloalkoxy, C3-6Cycloalkyl radical, C3-6cycloalkyl-C1-4Alkylene, heterocyclic group consisting of 5 to 6 atoms, (heterocyclic group consisting of 5 to 6 atoms) -C1-4Alkylene radical, C6-10Aryl radical, C6-10aryl-C1-4Alkylene, heteroaryl of 5 to 6 atoms or (heteroaryl of 5 to 6 atoms) -C1-4Alkylene, wherein said C1-6Alkyl radical, C2-6Alkenyl radical, C2-6Alkynyl, C1-6Alkoxy radical, C1-6Alkylamino radical, C1-6Haloalkyl, C1-6Haloalkoxy, C3-6Cycloalkyl radical, C3-6cycloalkyl-C1-4Alkylene, heterocyclic group consisting of 5 to 6 atoms, (heterocyclic group consisting of 5 to 6 atoms) -C1-4Alkylene radical, C6-10Aryl radical, C6-10aryl-C1-4Alkylene, heteroaryl of 5 to 6 atoms and (heteroaryl of 5 to 6 atoms) -C1-4Alkylene is each independently unsubstituted or substituted by 1,2 or 3Ry1Substituted, said Ry1Having the definitions set out in the present invention.
In some embodiments, any two R area、Rb、Rc、Rd、Re、RfTogether with the carbon atom to which they are attached form C3-8A carbocyclic ring or a heterocyclic ring of 5 to 6 atoms in which said C3-8The carbocycle and the heterocycle of 5 to 6 atoms are each independently unsubstituted or substituted by 1,2 or 3Ry1Substituted, said Ry1Having the definitions set out in the present invention.
In some embodiments, Ra、RbTogether with the carbon atom to which they are attached form C3-8A carbocyclic ring or a heterocyclic ring of 5 to 6 atoms in which said C3-8The carbocycle and the heterocycle of 5 to 6 atoms are each independently unsubstituted or substituted by 1,2 or 3Ry1Substituted, said Ry1Having the definitions set out in the present invention.
In some embodiments, Rc、RdTogether with the carbon atom to which they are attached form C3-8A carbocyclic ring or a heterocyclic ring of 5 to 6 atoms in which said C3-8The carbocycle and the heterocycle of 5 to 6 atoms are each independently unsubstituted or substituted by 1,2 or 3Ry1Substituted, said Ry1Having the definitions set out in the present invention.
In some embodiments, Re、RfTogether with the carbon atom to which they are attached form C3-8A carbocyclic ring or a heterocyclic ring of 5 to 6 atoms in which said C3-8The carbocycle and the heterocycle of 5 to 6 atoms are each independently unsubstituted or substituted by 1,2 or 3Ry1Substituted, said Ry1Having the definitions set out in the present invention.
In some embodiments, each R is4And RgIndependently of one another H, deuterium, C1-6Alkyl radical, C2-6Alkenyl radical, C2-6Alkynyl radical、C1-6Haloalkyl, C3-6Cycloalkyl radical, C3-6cycloalkyl-C1-4Alkylene, heterocyclic group consisting of 5 to 6 atoms, (heterocyclic group consisting of 5 to 6 atoms) -C1-4Alkylene radical, C6-10Aryl radical, C6-10aryl-C1-4Alkylene, heteroaryl of 5 to 6 atoms or (heteroaryl of 5 to 6 atoms) -C1-4Alkylene, wherein said C1-6Alkyl radical, C2-6Alkenyl radical, C2-6Alkynyl, C1-6Haloalkyl, C3-6Cycloalkyl radical, C3-6cycloalkyl-C1-4Alkylene, heterocyclic group consisting of 5 to 6 atoms, (heterocyclic group consisting of 5 to 6 atoms) -C1-4Alkylene radical, C6-10Aryl radical, C6-10aryl-C1-4Alkylene, heteroaryl of 5 to 6 atoms and (heteroaryl of 5 to 6 atoms) -C1-4Alkylene is each independently unsubstituted or substituted by 1,2 or 3Ry1Substituted, said Ry1Having the definitions set out in the present invention.
In some embodiments, Ra、RcAnd together with the carbon atom to which they are each attached form-C ═ C-.
In some embodiments, Rc、ReAnd together with the carbon atom to which they are each attached form-C ═ C-.
In some embodiments, R4、ReAnd together with the atom to which they are each attached form-N ═ C-.
In some embodiments, q is 0,1, 2, or 3.
In some embodiments, each R isyIndependently H, deuterium, F, Cl, Br, I, -CN, -OH, -NH2、C1-6Alkyl radical, C1-6Haloalkyl, C1-6Haloalkoxy, C1-6Alkoxy or C1-6An alkylamino group.
In some embodiments, each R isy1Independently deuterium, F, Cl, Br, I, -CN, -OH, -NH2、C1-6Alkyl radical, C1-6Haloalkyl, C1-6Haloalkoxy, C1-6Alkoxy or C1-6Alkyl ammoniaAnd (4) a base.
In some embodiments, R3a、R3b、R3cAnd R3dEach independently is H, deuterium, F, Cl, Br, I, -CN, -NO2、-COOH、-OH、-NH2、-SH、C1-4Alkyl radical, C1-4Alkoxy radical, C1-4Alkylthio radical, C1-4Alkylamino radical, C1-4Haloalkyl, C1-4Haloalkoxy, hydroxy C1-4Alkyl, amino C1-4Alkyl or cyano C1-4An alkyl group.
In some embodiments, R3a、R3b、R3cAnd R3dEach independently is H, deuterium, F, Cl, Br, I, -CN, -NO2、-COOH、-OH、-NH2-SH, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, methylthio, methylamino, -CF3、-CHF2、-CH2F、-CH2CF3、-CH2CHF2Trifluoromethoxy, difluoromethoxy, hydroxymethyl, aminomethyl or cyanomethyl.
In some embodiments, R1Is H, deuterium, F, Cl, Br, I, -CN, -NO2、-COOH、-OH、-NH2、-SH、C1-4Alkyl radical, C2-4Alkenyl radical, C2-4Alkynyl, -C (═ O) -C1-4Alkoxy, -C (═ O) -C1-4Alkyl, -C (═ O) -C1-4Alkylamino, -C (═ O) NH2、-S(=O)2-C1-4Alkyl, -S (═ O)2-C1-4Alkylamino, -S (═ O)2NH2、C1-4Alkylamino radical, C1-4Alkoxy radical, C1-4Haloalkyl, C1-4Haloalkoxy, hydroxy C1-4Alkyl, amino C1-4Alkyl, carboxyl C1-4Alkyl or cyano C1-4An alkyl group.
In some embodiments, R1Is H, deuterium, F, Cl, Br, I, -CN, -NO2、-COOH、-OH、-NH2-SH, methyl, ethyl, n-propyl, isopropyl, -CH ═ CH2、-CH2CH=CH2、-CH=CHCH3、-C≡CH、-C(=O)-OCH3、-C(=O)-OCH2CH3、-C(=O)-OCH(CH3)2、-C(=O)-OCH2CH2CH3、-C(=O)-O(CH2)3CH3、-C(=O)-OCH2CH(CH3)2、-C(=O)-CH3、-C(=O)-CH2CH3、-C(=O)-NHCH3、-C(=O)-N(CH3)2、-C(=O)NH2、-S(=O)2-CH3、-S(=O)2-CH2CH3、-S(=O)2-NHCH3、-S(=O)2NH2Methylamino, ethylamino, methoxy, ethoxy, -CF3、-CHF2、-CH2F、-CH2CF3、-CH2CHF2Trifluoromethoxy, difluoromethoxy, hydroxymethyl, aminomethyl, carboxymethyl or cyanomethyl.
In some embodiments, R2Is H, deuterium, C1-4Alkyl radical, C2-4Alkenyl radical, C2-4Alkynyl, C3-6Cycloalkyl, heterocyclic radical of 5-6 atoms, C6-10Aryl or heteroaryl of 5 to 6 atoms.
In some embodiments, R2Is H, deuterium, methyl, ethyl, n-propyl, isopropyl, tert-butyl, -CH ═ CH2、-CH2CH=CH2、-CH=CHCH3C ≡ CH, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclyl with 5-6 atoms, phenyl, naphthyl or heteroaryl with 5-6 atoms.
In some embodiments, each R isa、Rb、Rc、Rd、Re、Rf、Rh、Ri、Rj、Rk、RmAnd RnIndependently H, deuterium, F, Cl, Br, I, -CN, -NO2、-COOH、-OH、-NH2、-SH、C1-4Alkyl radical, C2-4Alkenyl radical, C2-4Alkynyl, C1-4Alkoxy radical, C1-4Alkylamino radical, C1-4Alkyl halidesBase, C1-4Haloalkoxy, C3-6Cycloalkyl radical, C3-6cycloalkyl-C1-2Alkylene, heterocyclic group consisting of 5 to 6 atoms, (heterocyclic group consisting of 5 to 6 atoms) -C1-2Alkylene radical, C6-10Aryl radical, C6-10aryl-C1-2Alkylene, heteroaryl of 5 to 6 atoms or (heteroaryl of 5 to 6 atoms) -C1-2Alkylene, wherein said C1-4Alkyl radical, C2-4Alkenyl radical, C2-4Alkynyl, C1-4Alkoxy radical, C1-4Alkylamino radical, C1-4Haloalkyl, C1-4Haloalkoxy, C3-6Cycloalkyl radical, C3-6cycloalkyl-C1-2Alkylene, heterocyclic group consisting of 5 to 6 atoms, (heterocyclic group consisting of 5 to 6 atoms) -C1-2Alkylene radical, C6-10Aryl radical, C6-10aryl-C1-2Alkylene, heteroaryl of 5 to 6 atoms and (heteroaryl of 5 to 6 atoms) -C1-2Alkylene is each independently unsubstituted or substituted by 1,2 or 3Ry1Substituted, said Ry1Having the definitions set out in the present invention.
In some embodiments, each R isa、Rb、Rc、Rd、Re、Rf、Rh、Ri、Rj、Rk、RmAnd RnIndependently H, deuterium, F, Cl, Br, I, -CN, -NO2、-COOH、-OH、-NH2-SH, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, -CH ═ CH2、-CH2CH=CH2、-CH=CHCH3-C.ident.CH, methoxy, ethoxy, methylamino, -CF3、-CHF2、-CH2F、-CH2CF3、-CH2CHF2Trifluoromethoxy, difluoromethoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyl-CH2-, pyrrolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, (heterocyclyl consisting of 5 to 6 atoms) -C1-2Alkylene, phenyl-CH2-, phenyl-CH2CH2-, furyl, thienyl, imidazolyl, pyrimidinyl, pyridyl, pyrrolyl, pyrazinyl, thiazolyl, oxazolyl, furyl-CH2-, thienyl-CH2-, imidazolyl-CH2-, pyrimidinyl-CH2-, pyridinyl-CH2-or pyrrolyl-CH2-, wherein said methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, -CH ═ CH2、-CH2CH=CH2、-CH=CHCH3-C.ident.CH, methoxy, ethoxy, methylamino, -CHF2、-CH2F、-CH2CF3、-CH2CHF2Difluoromethoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyl-CH2-, pyrrolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, (heterocyclyl consisting of 5 to 6 atoms) -C1-2Alkylene, phenyl-CH2-, phenyl-CH2CH2-, furyl, thienyl, imidazolyl, pyrimidinyl, pyridyl, pyrrolyl, pyrazinyl, thiazolyl, oxazolyl, furyl-CH2-, thienyl-CH2-, imidazolyl-CH2-, pyrimidinyl-CH2-, pyridinyl-CH2-and pyrrolyl-CH2Each independently unsubstituted or substituted by 1,2 or 3Ry1Substituted, said Ry1Having the definitions set out in the present invention.
In some embodiments, any two R area、Rb、Rc、Rd、Re、RfTogether with the carbon atom to which they are attached form C3-6Carbocyclic ring or heterocyclic ring of 5 to 6 atoms in which the ring forms C3-6The carbocycle and the heterocycle of 5 to 6 atoms are each independently unsubstituted or substituted by 1,2 or 3Ry1Substituted, said Ry1Having the definitions set out in the present invention.
In some embodiments, any two R area、Rb、Rc、Rd、Re、RfTogether with the carbon atoms to which they are attached form a cyclopropyl, cyclobutyl, ringPentyl, cyclohexyl, cycloheptyl or a 5-6 atom heterocycle wherein said cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and 5-6 atom heterocycle are each independently unsubstituted or substituted with 1,2 or 3Ry1Substituted, said Ry1Having the definitions set out in the present invention.
In some embodiments, Ra、RbTogether with the carbon atom to which they are attached form C3-6A carbocyclic ring or a heterocyclic ring of 5 to 6 atoms in which said C3-6The carbocycle and the heterocycle of 5 to 6 atoms are each independently unsubstituted or substituted by 1,2 or 3Ry1Substituted, said Ry1Having the definitions set out in the present invention.
In some embodiments, Ra、RbTogether with the carbon atoms to which they are attached form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or a 5-6 atom heterocycle wherein the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and 5-6 atom heterocycle are each independently unsubstituted or substituted with 1,2, or 3Ry1Substituted, said Ry1Having the definitions set out in the present invention.
In some embodiments, Rc、RdTogether with the carbon atom to which they are attached form C3-6A carbocyclic ring or a heterocyclic ring of 5 to 6 atoms in which said C3-6The carbocycle and the heterocycle of 5 to 6 atoms are each independently unsubstituted or substituted by 1,2 or 3Ry1Substituted, said Ry1Having the definitions set out in the present invention.
In some embodiments, Rc、RdTogether with the carbon atoms to which they are attached form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or a 5-6 atom heterocycle wherein the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and 5-6 atom heterocycle are each independently unsubstituted or substituted with 1,2, or 3Ry1Substituted, said Ry1Having the definitions set out in the present invention.
In some embodiments, Re、RfTogether with the carbon atom to which they are attached formC3-6A carbocyclic ring or a heterocyclic ring of 5 to 6 atoms in which said C3-6The carbocycle and the heterocycle of 5 to 6 atoms are each independently unsubstituted or substituted by 1,2 or 3Ry1Substituted, said Ry1Having the definitions set out in the present invention.
In some embodiments, Re、RfTogether with the carbon atoms to which they are attached form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or a 5-6 atom heterocycle wherein the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and 5-6 atom heterocycle are each independently unsubstituted or substituted with 1,2, or 3Ry1Substituted, said Ry1Having the definitions set out in the present invention.
In some embodiments, each R is4And RgIndependently of one another H, deuterium, C1-4Alkyl radical, C2-4Alkenyl radical, C2-4Alkynyl, C1-4Haloalkyl, C3-6Cycloalkyl radical, C3-6cycloalkyl-C1-2Alkylene, heterocyclic group consisting of 5 to 6 atoms, (heterocyclic group consisting of 5 to 6 atoms) -C1-2Alkylene radical, C6-10Aryl radical, C6-10aryl-C1-2Alkylene, heteroaryl of 5 to 6 atoms or (heteroaryl of 5 to 6 atoms) -C1-2Alkylene, wherein said C1-4Alkyl radical, C2-4Alkenyl radical, C2-4Alkynyl, C1-4Haloalkyl, C3-6Cycloalkyl radical, C3-6cycloalkyl-C1-2Alkylene, heterocyclic group consisting of 5 to 6 atoms, (heterocyclic group consisting of 5 to 6 atoms) -C1-2Alkylene radical, C6-10Aryl radical, C6-10aryl-C1-2Alkylene, heteroaryl of 5 to 6 atoms and (heteroaryl of 5 to 6 atoms) -C1-2Alkylene is each independently unsubstituted or substituted by 1,2 or 3Ry1Substituted, said Ry1Having the definitions set out in the present invention.
In some embodiments, each R is4And RgEach independently is H, deuterium, methyl, ethyl, n-propyl, isopropyl, -CH ═ CH2、-CH2CH=CH2、-CH=CHCH3、-C≡CH、-CF3、-CHF2、-CH2F、-CH2CHF2、-CH2CF3Cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C3-6cycloalkyl-C1-2Alkylene, heterocyclic group consisting of 5 to 6 atoms, (heterocyclic group consisting of 5 to 6 atoms) -C1-2Alkylene, phenyl-C1-2Alkylene, heteroaryl of 5 to 6 atoms or (heteroaryl of 5 to 6 atoms) -C1-2Alkylene, wherein the methyl, ethyl, n-propyl, isopropyl, -CH ═ CH2、-CH2CH=CH2、-CH=CHCH3、-C≡CH、-CHF2、-CH2F、-CH2CHF2、-CH2CF3Cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C3-6cycloalkyl-C1-2Alkylene, heterocyclic group consisting of 5 to 6 atoms, (heterocyclic group consisting of 5 to 6 atoms) -C1-2Alkylene, phenyl-C1-2Alkylene, heteroaryl of 5 to 6 atoms and (heteroaryl of 5 to 6 atoms) -C1-2Alkylene is each independently unsubstituted or substituted by 1,2 or 3Ry1Substituted, said Ry1Having the definitions set out in the present invention.
In some embodiments, each R isyIndependently H, deuterium, F, Cl, Br, I, CN, OH, NH2、C1-4Alkyl radical, C1-4Haloalkyl, C1-4Haloalkoxy, C1-4Alkoxy or C1-4An alkylamino group.
In some embodiments, each R isy1Independently deuterium, F, Cl, Br, I, CN, OH, NH2、C1-4Alkyl radical, C1-4Haloalkyl, C1-4Haloalkoxy, C1-4Alkoxy or C1-4An alkylamino group.
In some embodiments, each R isyIndependently H, deuterium, F, Cl, Br, I, CN, OH, NH2Methyl, ethyl, n-propyl, isopropyl, -CF3、-CHF2Trifluoromethoxy, difluoromethoxy, methoxy, ethoxy or methylamino.
In some embodiments, each R isy1Independently deuterium, F, Cl, Br, I, CN, OH, NH2Methyl, ethyl, n-propyl, isopropyl, -CF3、-CHF2Trifluoromethoxy, difluoromethoxy, methoxy, ethoxy or methylamino.
In another aspect, the invention relates to a structure of one of the following, or a stereoisomer, geometric isomer, tautomer, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof,
in another aspect, the invention relates to a pharmaceutical composition comprising a compound of the invention.
In some embodiments, the pharmaceutical composition of the present invention, optionally, further comprises any one of a pharmaceutically acceptable carrier, excipient, adjuvant, vehicle, or any combination thereof.
In another aspect, the invention relates to the use of a compound according to the invention or a pharmaceutical composition according to the invention for the preparation of a medicament for agonizing a thyroid hormone receptor; or for the prevention, treatment or alleviation of diseases modulated by thyroid hormone receptors.
In another aspect, the invention relates to a method of agonizing a thyroid hormone receptor, or a method for preventing, treating or ameliorating a disease modulated by a thyroid hormone receptor, using a compound or a pharmaceutical composition of the invention, by administering a therapeutically effective amount of the compound or the pharmaceutical composition to a subject in need thereof. Also, the present invention provides the above-mentioned compounds or pharmaceutical compositions thereof can be co-administered with other therapies or therapeutic agents. The administration may be simultaneous, sequential or at intervals.
In another aspect, the invention relates to the use of a compound or pharmaceutical composition according to the invention for agonizing a thyroid hormone receptor, or for the prevention, treatment or alleviation of a disease modulated by a thyroid hormone receptor.
In some embodiments, the thyroid hormone receptor of the present invention is the thyroid hormone beta receptor.
In some embodiments, the disease modulated by a thyroid hormone receptor agonist according to the invention is non-alcoholic fatty liver disease, atherosclerosis, coronary heart disease, hypertension, hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, dyslipidemia, obesity, diabetes, a metabolic disorder, a lipid metabolism disorder, glycogen storage disease type 1A, hypothyroidism, or thyroid cancer.
In some embodiments, the non-alcoholic fatty liver disease of the present invention is non-alcoholic simple fatty liver, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease-associated cryptogenic cirrhosis, or primary liver cancer.
The dosage of a compound or pharmaceutical composition required to effect a therapeutic, prophylactic or delay-acting effect, etc., will generally depend on the particular compound being administered, the patient, the particular disease or condition and its severity, route and frequency of administration, etc., and will need to be determined on a case-by-case basis by the attending physician. For example, when a compound or pharmaceutical composition provided by the present invention is administered by intravenous route, administration may be performed once per week or at even longer intervals.
In some embodiments, the salt refers to a pharmaceutically acceptable salt. The term "pharmaceutically acceptable" means that the substance or composition must be chemically and/or toxicologically compatible with the other ingredients comprising the formulation and/or the mammal being treated therewith.
The compounds of the present invention also include other salts of such compounds, which are not necessarily pharmaceutically acceptable salts, and which may be useful as intermediates for the preparation and/or purification of the compounds of the present invention and/or for the isolation of enantiomers of the compounds of the present invention.
Furthermore, the compounds of the present invention, including salts thereof, may also be obtained in the form of their hydrates or include other solvents used for their crystallization. The compounds of the present invention may form solvates, either inherently or by design, with pharmaceutically acceptable solvents (including water); thus, the present invention is intended to include both solvated and unsolvated forms.
Pharmaceutical compositions, formulations and administration of the compounds of the invention
The invention relates to a pharmaceutical composition which comprises a compound of the invention or a compound of the structure shown in the examples, or a stereoisomer, a geometric isomer, a tautomer, a nitrogen oxide, a solvate, a metabolite and a pharmaceutically acceptable salt thereof or a prodrug thereof. The pharmaceutical composition further comprises at least one pharmaceutically acceptable carrier, excipient, adjuvant, vehicle, or combination thereof, and optionally, other therapeutic and/or prophylactic ingredients. In some embodiments, the pharmaceutical compositions comprise an effective amount of a compound of the present invention and at least one pharmaceutically acceptable carrier, excipient, adjuvant, or vehicle. The amount of compound in the pharmaceutical composition of the invention is effective to detectably agonize thyroid hormone beta receptors in a biological sample or patient.
Pharmaceutically acceptable carriers may contain inert ingredients that do not unduly inhibit the biological activity of the compound. The pharmaceutically acceptable carrier should be biocompatible, e.g., non-toxic, non-inflammatory, non-immunogenic, or free of other adverse or side effects once administered to a patient. Standard pharmaceutical techniques may be employed.
The pharmaceutical composition or pharmaceutically acceptable composition of the present invention further comprises a pharmaceutically acceptable carrier, excipient, adjuvant or vehicle, as described herein, including any solvent, diluent, liquid excipient, dispersant, suspending agent, surfactant, isotonic agent, thickener, emulsifier, preservative, solid binder or lubricant, and the like, as appropriate for the particular intended dosage form, as used herein. The Science and Practice of Pharmacy,21st edition,2005, ed.D.B.Troy, Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, eds.J.Swarbrick and J.C.Boylan, 1988. Annu 1999, Marcel Dekker, New York disclose various carriers for use in formulating pharmaceutically acceptable compositions and methods for their preparation. In addition to conventional carrier vehicles which are incompatible with the compounds of the present invention, e.g., may produce undesirable biological effects or may deleteriously interact with any other component of the pharmaceutically acceptable composition, any other conventional carrier vehicle and its use are contemplated by the present invention.
Some examples of substances that may be used as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins (e.g., human serum albumin), buffer substances (e.g., tween 80, phosphate, glycine, sorbic acid, or potassium sorbate), partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes (e.g., protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, or zinc salts), silica gel, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block copolymers, methylcellulose, hydroxypropylmethylcellulose, lanolin, sugars (e.g., lactose, glucose, and sucrose), starches (e.g., corn starch and potato starch), celluloses and derivatives thereof (e.g., sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate), Powdered tragacanth, malt, gelatin, talc, excipients (such as cocoa butter and suppository waxes), oils (such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil), glycols (such as propylene glycol or polyethylene glycol), esters (such as ethyl oleate and ethyl dodecanoate), agar, buffers (such as magnesium hydroxide and aluminum hydroxide), alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethanol and phosphate buffers, as well as other non-toxic compatible lubricants (such as sodium lauryl sulfate and magnesium stearate), as well as coloring agents, detackifiers, coating agents, sweetening and flavoring agents, preservatives and antioxidants, according to the judgment of the formulator, may also be present in the composition.
The pharmaceutical compositions of the present invention may be administered directly or in the form of pharmaceutical compositions or medicaments, together with suitable carriers or excipients, as is well known in the art. The methods of treatment of the present invention may comprise administering to a subject in need thereof an effective compound of the present invention. In some embodiments, the subject is a mammalian subject, and in other embodiments, the subject is a human subject.
Effective amounts of the compounds, pharmaceutical compositions or medicaments of the present invention can be readily determined by routine method tests, as can the most effective and convenient route of administration and the most appropriate formulation.
The compounds or compositions of the present invention may be administered by any suitable means, and the above-described compounds and pharmaceutically acceptable compositions may be administered to humans or other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments or drops), or by nasal spray, etc., depending on the severity of the disease.
Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1, 3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. In addition to inert diluents, oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
Injectable preparations may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents, for example sterile injectable aqueous or oily suspensions. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1, 3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, ringer's solution, and isotonic sodium chloride solution. In addition, sterile fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono-or diglycerides. In addition, fatty acids, such as octadecenoic acid, are used in the preparation of injections.
For example, injectable formulations can be sterilized by filtration through a bacteria retaining filter or by the addition of a sterilizing agent in the form of a sterile solid composition which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
To prolong the effect of the compounds or compositions of the present invention, it is often desirable to slow the absorption of the compounds from subcutaneous or intramuscular injection. This can be achieved by using a liquid suspension of crystalline or amorphous material which is poorly water soluble. The rate of absorption of the compound then depends on its rate of dissolution, which in turn depends on crystal size and crystal form. Alternatively, delayed absorption of the parenterally administered compound is achieved by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming a microcapsule matrix of the compound in a biodegradable polymer such as polylactide-polyglycolic acid. Depending on the ratio of compound to polymer and the nature of the particular polymer employed, the rate of release of the compound can be controlled. Examples of other biodegradable polymers include polyorthoesters and polyanhydrides. Depot injectable formulations can also be prepared by entrapping the compound in liposomes or microemulsions which are compatible with body tissues.
Compositions for rectal or vaginal administration are in particular suppositories which can be prepared by mixing the compounds of the invention with suitable non-irritating excipients or carriers, for example cocoa butter, polyethylene glycol or a suppository wax, which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
Oral solid dosage forms include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or bulking agents such as starches, lactose, sucrose, glucose, mannitol and silicic acid; b) binders such as carboxymethyl cellulose, alginate, gelatin, polyvinyl pyrrolidone, sucrose and acacia; c) humectants, such as glycerol; d) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; e) solution retarding agents, such as paraffin; f) absorption accelerators, such as quaternary ammonium compounds; g) wetting agents, such as cetyl alcohol and glyceryl monostearate; h) absorbents such as kaolin and bentonite clay; and i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
Solid compositions of a similar type may also be employed as fillers in soft and hard gelatin capsules using excipients such as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. Solid dosage forms of tablets, dragees, capsules, pills and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical art. They may optionally contain opacifying agents and may also have the properties of a composition such that the active ingredient is released only, optionally in a delayed manner, or preferably, in a certain part of the intestinal tract. Examples of embedding compositions that can be used include polymers and waxes.
The active compound may also be in the form of a microencapsulated form with one or more of the above-mentioned excipients. In such solid dosage forms, the active compound may be mixed with at least one inert diluent, for example sucrose, lactose or starch. In general, such dosage forms may also contain additional substances in addition to the inert diluents, such as tableting lubricants and other tableting aids, for example magnesium stearate and microcrystalline cellulose. They may optionally contain opacifying agents and may also have the properties of a composition such that the active ingredient is released only, optionally in a delayed manner, or preferably, in a certain part of the intestinal tract. Examples of embedding compositions that can be used include polymers and waxes.
Formulations for topical or transdermal administration of the compounds of the present invention include ointments, salves, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. Under sterile conditions, the active compound is combined with a pharmaceutically acceptable carrier and any required preservatives or buffers that may be required. Ophthalmic formulations, ear drops and eye drops are also contemplated within the scope of the present invention. In addition, the present invention contemplates the use of a dermal patch that has the added advantage of providing controlled delivery of the compound to the body. Such dosage forms may be made by dissolving or dispersing the compound in the appropriate medium. Absorption enhancers may also be used to increase the flux of the compound through the skin. The rate can be controlled by providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
The compositions of the present invention may also be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted kit. The term "parenteral" as used herein includes, but is not limited to, subcutaneous, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. In particular, the compositions are administered orally, intraperitoneally, or intravenously.
The sterile injectable form of the composition of the invention may be an aqueous or oily suspension. These suspensions may be prepared using suitable dispersing or wetting agents and suspending agents following techniques known in the art. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1, 3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono-or diglycerides. In addition, as natural pharmaceutically acceptable oils, such as olive oil or castor oil, especially in polyoxyethylated form, fatty acids, such as octadecenoic acid and its glyceride derivatives are used for the preparation of injections. These oil solutions or suspensions may also contain a long chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents commonly used in formulating pharmaceutically acceptable dosage forms, including emulsions and suspensions. Other commonly used surfactants such as Tweens, Spans, and other emulsifiers or bioavailability enhancers commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for formulation purposes.
The pharmaceutical compositions of the present invention may be administered orally in any orally acceptable dosage form, including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral administration, carriers that are commonly used include, but are not limited to, lactose and starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are required for oral administration, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
Alternatively, the pharmaceutical compositions of the present invention may be administered in the form of suppositories for rectal use. These pharmaceutical compositions may be prepared by mixing the agents and non-irritating excipients, such materials including, but not limited to, cocoa butter, beeswax and polyethylene glycols.
The pharmaceutical compositions of the present invention may also be administered topically, particularly when the target of treatment includes topical application to an easily accessible area or organ, including the eye, skin, or lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
Local instillation to the lower intestinal tract may be achieved with rectal suppository formulations (see above) or suitable enema formulations. Topical skin patches may also be used.
For topical application, the pharmaceutical compositions may be formulated as a suitable ointment containing the active ingredient suspended or dissolved in one or more carriers. Suitable carriers for topical application of the compounds of the present invention include, but are not limited to, mineral oil, petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical compositions may be formulated as a suitable lotion or cream containing the active ingredient suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
For ophthalmic use, the pharmaceutical compositions may be formulated as micronized suspensions in isotonic pH adjusted sterile saline, or solutions in isotonic pH adjusted sterile saline in particular, with or without preservatives such as benzalkonium chloride. Alternatively, for ophthalmic use, the pharmaceutical composition may be formulated as an ointment, such as petrolatum.
The pharmaceutical compositions may also be administered by nasal aerosol spray or inhalation. Such compositions are prepared according to techniques well known in the pharmaceutical art and are prepared as solutions in saline using benzyl alcohol and other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons and/or other conventional solubilizing or dispersing agents.
Application of compound and pharmaceutical composition of the invention
The compound or the pharmaceutical composition provided by the invention can be used for preparing a medicament for exciting thyroid hormone receptors or preparing a medicament for preventing, treating or alleviating diseases modulated by the thyroid hormone receptors.
The compounds or pharmaceutical compositions provided by the present invention are useful for agonizing thyroid hormone receptors or for preventing, treating or ameliorating diseases modulated by thyroid hormone receptors.
The present invention provides a method for agonizing thyroid hormone receptors or for preventing, treating or alleviating disorders modulated by thyroid hormone receptors, which comprises administering a therapeutically effective amount of the above-mentioned compound or a pharmaceutical composition thereof to a patient in need of treatment. Also, the present invention provides the above-mentioned compounds or pharmaceutical compositions thereof can be co-administered with other therapies or therapeutic agents. The administration may be simultaneous, sequential or at intervals.
The thyroid hormone receptor is a thyroid hormone beta receptor.
The diseases are non-alcoholic fatty liver disease, atherosclerosis, coronary heart disease, hypertension, hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, dyslipidemia, obesity, diabetes, metabolic disorder, lipid metabolism disorder, 1A type glycogen storage disease, hypothyroidism or thyroid cancer, wherein the non-alcoholic fatty liver disease is non-alcoholic simple fatty liver, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease-related cryptogenic liver cirrhosis or primary liver cancer.
In addition to being beneficial for human therapy, the compounds of the present invention may also find use in veterinary therapy for pets, animals of the introduced species and animals in farms, including mammals, rodents, and the like. Examples of other animals include horses, dogs, and cats. Herein, the compound of the present invention includes pharmaceutically acceptable derivatives thereof.
An "effective amount," "therapeutically effective amount," or "effective dose" of a compound of the invention or a pharmaceutically acceptable pharmaceutical composition refers to an effective amount to treat or reduce the severity of one or more of the conditions referred to herein. The compounds or pharmaceutically acceptable pharmaceutical compositions of the present invention are effective over a relatively wide dosage range. For example, the daily dosage may be in the range of about 0.1mg to about 1000mg per person, divided into one or more administrations. The methods, compounds and pharmaceutical compositions according to the present invention can be of any amount administered and any route of administration effective to treat or reduce the severity of the disease. The exact amount necessary will vary depending on the patient, depending on the race, age, general condition of the patient, severity of infection, particular factors, mode of administration, and the like. The compounds or pharmaceutical compositions of the present invention may be administered in combination with one or more other therapeutic agents, as discussed herein.
General Synthesis and detection methods
To illustrate the invention, the following examples are set forth. It is to be understood that the invention is not limited to these embodiments, but is provided as a means of practicing the invention.
In this specification, a structure is dominant if there is any difference between the chemical name and the chemical structure.
In general, the compounds of the present invention may be prepared by the methods described herein, wherein the substituents are as defined in formula (I), unless otherwise indicated. The following reaction schemes and examples serve to further illustrate the context of the invention.
Those skilled in the art will recognize that: the chemical reactions described herein may be used to suitably prepare a number of other compounds of the invention, and other methods for preparing the compounds of the invention are considered to be within the scope of the invention. For example, the synthesis of those non-exemplified compounds according to the present invention can be successfully accomplished by those skilled in the art by modification, such as appropriate protection of interfering groups, by the use of other known drugs other than those described herein, or by some routine modification of reaction conditions. In addition, the reactions disclosed herein or known reaction conditions are also recognized as being applicable to the preparation of other compounds of the present invention.
The structure of the compound is determined by nuclear magnetic resonance1H-NMR、13C-NMR or/and19F-NMR).1H-NMR、13C-NMR、19F-NMR chemical shifts (δ) are given in parts per million (ppm).1H-NMR、13C-NMR、19F-NMR was measured using a Bruker Ultrashield-400 NMR spectrometer and a Bruker Avance III HD 600 NMR spectrometer in deuterated chloroform (CDCl)3) Deuterated methanol (CD)3OD or MeOH-d4) Or deuterated dimethyl sulfoxide (DMSO-d)6). TMS (0ppm) or chloroform (7.25ppm) was used as reference standard. When multiple peaks occur, the following abbreviations will be used: s (singlets, singlet), d (doublets ), t (triplets, triplets), m (multiplets ), br (broadcasters, broad), dd (doublets of doublets), dt (doublets of triplets, doublets), td (triplets of doublets, triplet), brs (broad singlets). Coupling constant J, in Hertz (Hz).
Preparative purification or preparative resolution generally uses a Novasep pump 250 high performance liquid chromatograph.
The LC-MS was determined using an Agilen-6120Quadrupole LC/MS mass spectrometer.
The column chromatography generally uses 300-400 mesh silica gel in Qingdao ocean chemical industry as a carrier.
The starting materials of the present invention are known and commercially available, are available from Shanghai Accela Company, Annage Company, Bailingwei Company (J & K), Tianjin Afaha Angsa Company (Alfa Company), etc., or may be synthesized using or according to methods known in the art.
In the examples, the reaction was carried out in a nitrogen atmosphere unless otherwise specified;
the nitrogen atmosphere refers to that a reaction bottle is connected with a nitrogen balloon or a steel kettle with the volume of about 1L;
the hydrogen atmosphere refers to that a reaction bottle is connected with a hydrogen balloon with the volume of about 1L or a stainless steel high-pressure reaction kettle with the volume of about 1L;
in the examples, unless otherwise specified, the solution means an aqueous solution;
in the examples, the reaction temperature is room temperature unless otherwise specified;
in the examples, the room temperature is 20 ℃ to 40 ℃ unless otherwise specified.
The progress of the reaction in the examples was monitored by Thin Layer Chromatography (TLC) using a developing solvent system of: dichloromethane and methanol system, dichloromethane and ethyl acetate system, petroleum ether and ethyl acetate system, and the volume ratio of the solvent is adjusted according to the polarity of the compound.
The system of eluent for column chromatography comprises: a: petroleum ether and ethyl acetate system, B: dichloromethane and ethyl acetate system, C: dichloromethane and methanol system. The volume ratio of the solvent is adjusted according to the polarity of the compound, and a small amount of ammonia water, acetic acid and the like can be added for adjustment.
HPLC refers to high performance liquid chromatography;
HPLC was carried out using an Agilent 1260 high pressure liquid chromatograph (column: Agilent ZORBAX Eclipse Plus C184.6 mm. times.150 mm,3.5 μm);
HPLC test conditions: operating time: 25min column temperature: detection wavelength at 35 ℃: 210 nm; 245 nm;
mobile phase: phase A: 0.05% phosphoric acid solution phase B: acetonitrile; flow rate: 1.0 ml/min;
mobile phase gradients are shown in table a:
TABLE A
Time | Gradient of mobile phase A | Gradient of mobile phase B |
0min | 90% | 10% |
15min | 10% | 90% |
20min | 10% | 90% |
25min | 90% | 10% |
The analytical LC/MS/MS system in the biological test experiment includes Agilent 1200 series vacuum degassing furnace, binary injection pump, orifice plate automatic sampler, column thermostat, Agilent G6430 three-stage quadrupole mass spectrometer with Electric Spray Ionization (ESI) source. The quantitative analysis was performed in MRM mode, with the parameters of the MRM transition as shown in table B:
TABLE B
Full scan | 50~1400 |
Fragmentation voltage | 230V |
Capillary voltage | 55V |
Dryer temperature | 350℃ |
Atomizer | 0.28MPa |
Flow rate of dryer | 10L/min |
Analysis 5. mu.L of sample was injected using an Agilent XDB-C18, 2.1X 30mm,3.5 μm column. Analysis conditions were as follows: the mobile phase was 0.1% aqueous formic acid (A) and 0.1% methanolic formic acid (B). The flow rate was 0.4 mL/min. Mobile phase gradients are shown in table C:
watch C
Time | Gradient of mobile phase B |
0.5min | 5% |
1.0min | 95% |
2.2min | 95% |
2.3min | 5% |
5.0min | Terminate |
The test conditions for low resolution Mass Spectrometry (MS) data were: agilent 6120Quadrupole HPLC-MS (column model: Zorbax SB-C18, 2.1X 30mm,3.5 μm,6min, flow rate 0.6mL/min, mobile phase 5% -95% (CH with 0.1% formic acid)3CN) in (H containing 0.1% formic acid)2O) at 210nm/254nm with UV detection, using electrospray ionization mode (ESI).
The following acronyms are used throughout the invention:
DMSO-d6: | deuterated dimethyl sulfoxide; | Boc: | a tert-butoxycarbonyl group; |
DCC: | dicyclohexylcarbodiimide; | DMSO: | dimethyl sulfoxide; |
CDCl3: | deuterated chloroform; | %wt,mass%: | weight percentage; |
CD3OD: | deuterated methanol; | mL,ml: | ml; |
μL,μl: | microliter; | mol/L,mol/l: | moles per liter; |
mol: | molar ratio; | mmol/L,mmol/l,mM: | millimoles per liter; |
μmol/L,μmol/l,μM: | micromole/liter; | nmol/L,nmol/l,nM: | nanomole/liter; |
g: | g; | h: | hours; |
mg: | mg; | μg: | microgram; |
ng: | nanogram; | nm: | nano; |
μm: | micron size; | mm: | millimeter; |
H2: | hydrogen gas; | N2: | nitrogen gas; |
min: | the method comprises the following steps of (1) taking minutes; | MPa: | megapascals; |
Me: | a methyl group; | ACN: | acetonitrile; |
TFA: | trifluoroacetic acid; | H2O: | and (3) water. |
General synthetic methods
Typical synthetic procedures for preparing the disclosed compounds of the invention are shown in the following synthetic schemes. Unless otherwise stated, each E1、E2、E3、R3a、R3dAnd R1Having the definition as described in the present invention, X is halogen.
Synthesis scheme 1:
compounds having a structure as shown in general formula (I-A) can be prepared by general synthetic methods as described in FIG. 1. Firstly, reacting a compound (I-a) with a compound (I-b) under the action of a base (such as potassium carbonate and sodium hydride) to obtain a compound (I-c); reducing the nitro group of the compound (I-c) to obtain a compound (I-d); diazotizing the amino group of the compound (I-d) and reacting with the compound (I-e) to obtain a compound (I-f); and (3) closing the ring of the compound (I-f) under the action of alkali (such as potassium acetate) to obtain the target compound shown in the general formula (I-A).
Preparation examples
EXAMPLE 12- [3, 5-dichloro-4- [ (2-oxo-3, 4-dihydro-1H-quinolin-6-yl) oxy ] phenyl ] -3, 5-dioxo-1, 2, 4-triazine-6-carbonitrile (Compound 1)
Step 1)6- (2, 6-dichloro-4-nitro-phenoxy) -3, 4-dihydro-1H-quinolin-2-one 1b
6-hydroxy-3, 4-dihydro-1H-quinolin-2-one 1a (2.0g,12.3mmol) was dissolved in N, N-dimethylacetamide (5mL), and potassium carbonate (2.57g, 18.4mmol) and 1, 3-dichloro-2-iodo-5-nitrobenzene (3.90g,12.3mmol) were added and reacted at 120 ℃ for 5.5 hours under nitrogen substitution. The reaction was cooled to room temperature, water (30mL) was added, stirred for 5 minutes, filtered, and the filter cake was collected and dried under vacuum to give the title compound 1b (4.0g, 93% yield) as an off-white solid.
1HNMR(400MHz,CDCl3)δ(ppm)8.43(s,1H),8.31(s,2H),6.73(d,J=8.5Hz,1H),6.67(s,1H),6.63(dd,J=8.5,2.6Hz,1H),2.93(t,J=7.5Hz,2H),2.67-2.58(m,2H)。
Step 2)6- (4-amino-2, 6-dichloro-phenoxy) -3, 4-dihydroquinolin-2-one 1c
Reacting 6- (2, 6-dichloro-4-nitro-phenoxy) -3, 4-diHydrogenQuinolin-2-one 1b (1.7g,4.81mmol) was dissolved in ethanol (10mL), and sodium sulfide (3.79g,48.1mmol) was added to the solution, followed by reaction at 80 ℃ for 4 hours. The reaction was cooled to room temperature, poured into water (30mL), stirred for 15 minutes, filtered, and the collected cake was dried under vacuum to give the title compound 1c (1.20g, 77% yield) as a yellow solid.
MS(ESI,pos.ion)m/z:323.2[M+H]+;
1HNMR(400MHz,DMSO-d6)δ(ppm)9.94(s,1H),6.77(d,J=8.6Hz,1H),6.69(s,2H),6.62(d,J=2.4Hz,1H),6.54(dd,J=8.6,2.7Hz,1H),5.60(s,2H),2.81(t,J=7.5Hz,2H),2.42-2.37(m,2H)。
Step 3) N- [ 2-cyano-2- [ [3, 5-dichloro-4- [ (2-oxo-3, 4-dihydro-1H-quinolin-6-yl) oxy]Benzene and its derivatives
Base of]Hydrazine fork]Acetyl group]Urethane 1d
6- (4-amino-2, 6-dichloro-phenoxy) -3, 4-dihydro-1H-quinolin-2-one 1c (0.80g,2.5mmol), N-cyanoacetylurethane (0.43g,2.7mmol) and concentrated hydrochloric acid (0.63mL) were added to acetic acid (5mL), and an aqueous solution (2mL) of sodium nitrite (0.19g,2.7mmol) was added dropwise at 3 deg.C, followed by continuing the reaction for 7 hours. The reaction solution was concentrated, and the resulting residue was purified by silica gel column chromatography [ petroleum ether/ethyl acetate (v/v) ═ 3/1] to give the title compound 1d (0.40g, yield 33%) as a yellow solid.
MS(ESI,pos.ion)m/z:491.1[M+H]+。
Step 4)2- [3, 5-dichloro-4- [ (2-oxo-3, 4-dihydro-1H-quinolin-6-yl) oxy]Phenyl radical]-3, 5-bis
Oxo-1, 2, 4-triazine-6-carbonitrile 1
Reacting N- [ 2-cyano-2- [ [3, 5-dichloro-4- [ (2-oxo-3, 4-dihydro-1H-quinolin-6-yl) oxy]Phenyl radical]Hydrazine fork]Acetyl group]Ethyl carbamate 1d (0.40g,0.82mmol) was dissolved in N, N-dimethylacetamide (1mL), and potassium acetate (0.32g,3.3mmol) was added to react at 120 ℃ for 12 hours. Cooling the reaction solution to room temperature, filtering, and separating and purifying the filtrate by preparation and purification [ 50% ACN/50% H ]2O (0.1% TFA), Philomena ACE specification C1810 μm X50 mm X250 mm, flow rate 100mL/min]To obtain the title compound 1(88mg, yield 24%, HPLC purity: 99.86%) as a white solid.
MS(ESI,neg.ion)m/z:442.0[M-H]-;
1HNMR(400MHz,DMSO-d6)δ(ppm)10.01(s,1H),7.80(s,2H),6.82(d,J=8.7Hz,1H),6.75(d,J=2.5Hz,1H),6.64(dd,J=8.6,2.7Hz,1H),2.84(t,J=7.4Hz,2H),2.44-2.37(m,2H)。
Example 22- [3, 5-dichloro-4- [ (4, 4-dimethyl-2-oxo-1, 3-dihydroquinolin-6-yl) oxy ] phenyl ] -3, 5-dioxo-1, 2, 4-triazine-6-carbonitrile (Compound 2)
Step 1) N- (4-methoxyphenyl) -3-methyl-but-2-enamide 2b
P-methoxyaniline 2a (4.00g,32.5mmol), 3-methyl-but-2-ene-oic acid (3.69g,35.8mmol), triethylamine (6.8mL,49mmol) and 2- (7-azobenzotrifluorazole) -N, N, N ', N' -tetramethyluronium hexafluorophosphate (15.6g,39.0mmol) were dissolved in N, N-dimethylformamide (10mL) and reacted at room temperature for 30 minutes. Water (100mL) was added to the reaction, stirred for 10min, filtered, the filter cake was washed with ethanol (10mL), collected and dried under vacuum to give the title compound 2b (4.6g, 69% yield) as a white solid.
Step 2) N- (4-hydroxyphenyl) -3-methyl-but-2-enamide 2c
N- (4-methoxyphenyl) -3-methyl-but-2-enamide 2b (4.6g,22.4mmol) was dissolved in dichloromethane (15mL), and boron tribromide (4.2mL,44mmol) was added dropwise at 5 ℃ to react for 2.5 hours. The reaction was poured into an ice-water mixture (30g), saturated sodium bicarbonate solution (30mL) was added, stirred for 10 minutes, extracted with dichloromethane (10mL × 2), and the combined organic phases were dried over anhydrous sodium sulfate, concentrated by suction filtration to give the title compound 2c (4.0g, yield 93%) as a white solid.
MS(ESI,pos.ion)m/z:192.3[M+H]+;
1HNMR(400MHz,DMSO-d6)δ(ppm)9.54(s,1H),9.13(s,1H),7.39(d,J=8.7Hz,2H),6.67(d,J=8.8Hz,2H),5.81(s,1H),2.12(s,3H),1.83(s,3H)。
Step 3) 6-hydroxy-4, 4-dimethyl-1, 3-dihydroquinolin-2-one 2d
N- (4-hydroxyphenyl) -3-methyl-but-2-enamide 2c (4.0g,20.9mmol) was dissolved in chlorobenzene (10mL), and aluminum trichloride (5.58g,41.8mmol) was added and reacted at 120 ℃ for 22 hours. The reaction solution was poured into ice water (40mL), extracted with ethyl acetate (20mL × 2), the combined organic phases were dried over anhydrous sodium sulfate, concentrated by suction filtration, and the resulting residue was purified by silica gel column chromatography [ petroleum ether/ethyl acetate (v/v) ═ 1/1] to give the title compound 2d (1.4g, yield 35%) as a pale gray solid.
MS(ESI,pos.ion)m/z:192.3[M+H]+;
1HNMR(400MHz,DMSO-d6)δ(ppm)9.84(s,1H),9.03(s,1H),6.67(d,J=8.3Hz,2H),6.53(dd,J=8.4,2.5Hz,1H),2.26(s,2H),1.17(s,6H)。
Step 4)6- (2, 6-dichloro-4-nitro-phenoxy) -4, 4-dimethyl-1, 3-dihydroquinolin-2-one 2e
6-hydroxy-4, 4-dimethyl-1, 3-dihydroquinolin-2-one 2d (0.80g, 4.2mmol) was dissolved in N, N-dimethylacetamide (5mL), and potassium carbonate (1.5g, 10mmol) and 1, 3-dichloro-2-iodo-5-nitrobenzene (1.3g,4.2mmol) were added and reacted at 120 ℃ for 5.5 hours under nitrogen substitution. The reaction was cooled to room temperature, water (30mL) was added, stirred for 5 minutes, filtered, and the filter cake was collected and dried under vacuum to give the title compound 2e (1.2g, 75% yield) as a gray solid.
MS(ESI,pos.ion)m/z:381.0[M+H]+。
Step 5)6- (4-amino-2, 6-dichloro-phenoxy) -4, 4-dimethyl-1, 3-dihydroquinolin-2-one 2f
6- (2, 6-dichloro-4-nitro-phenoxy) -4, 4-dimethyl-1, 3-dihydroquinolin-2-one 2e (1.2g,3.15mmol) was dissolved in ethanol (5mL), and sodium sulfide (2.48g,31.5mmol) was added and reacted at 80 ℃ for 12 hours. The reaction solution was cooled to room temperature, poured into water (30mL), stirred for 15 minutes, filtered, and purified by silica gel column chromatography [ petroleum ether/ethyl acetate (v/v) ═ 1/1] collecting the cake to give the title compound 2f (0.50g, yield 45%) as an off-white solid.
1HNMR(400MHz,DMSO-d6)δ(ppm)10.02(s,1H),6.81(d,J=2.7Hz,1H),6.77(d,J=8.6Hz,1H),6.70(s,2H),6.43(dd,J=8.6,2.7Hz,1H),5.61(s,2H),2.32(s,2H),1.17(s,6H)。
Step 6) N- [ 2-cyano-2 [ [3, 5-dichloro-4- [ (4, 4-methyl-2-oxo-1, 3-dihydroquinolin-6-yl) oxy
Base of]Phenyl radical]Hydrazine fork]Acetyl group]2g of urethane
6- (4-amino-2, 6-dichloro-phenoxy) -4, 4-dimethyl-1, 3-dihydroquinolin-2-one 2f (0.45g,1.3mmol), N-cyanoacetylurethane (0.22g,1.4mmol) and concentrated hydrochloric acid (0.33mL) were added to acetic acid (4mL), and an aqueous solution (2mL) of sodium nitrite (0.098g,1.4mmol) was added dropwise at 3 ℃ followed by reaction for 6 hours. The reaction solution was concentrated, and the obtained residue was purified by silica gel column chromatography [ petroleum ether/ethyl acetate (v/v) ═ 3/1] to give 2g (0.2g, yield 30%) of the title compound as a yellow solid.
MS(ESI,pos.ion)m/z:518.1[M+H]+。
Step 7)2- [3, 5-dichloro-4- [ (4, 4-dimethyl-2-oxo-1, 3-dihydroquinolin-6-yl) oxy]Phenyl radical]-
3, 5-dioxo-1, 2, 4-triazine-6-carbonitrile 2
Reacting N- [ 2-cyano-2 [ [3, 5-dichloro-4- [ (4, 4-methyl-2-oxo-1, 3-dihydroquinolin-6-yl) oxy]Phenyl radical]Hydrazine fork]Acetyl group]Ethyl carbamate (2 g, 0.20g,0.39mmol) was dissolved in N, N-dimethylacetamide (1mL), and potassium acetate (0.15g,1.5mmol) was added to react at 120 ℃ for 24 hours. Cooling the reaction solution to room temperature, filtering, separating and purifying the filtrate [ 50% ACN/50%H2O (0.1% TFA), Philomena ACE specification C1810 μm X50 mm X250 mm, flow rate 100mL/min]To obtain the title compound 2(8mg, yield 4%, HPLC purity: 98.92%) as a white solid.
MS(ESI,pos.ion)m/z:472.0[M+H]+;
1HNMR(400MHz,DMSO-d6)δ(ppm)9.01(s,1H),7.63(s,2H),7.03(d,J=2.4Hz,1H),6.70(d,J=8.6Hz,1H),6.44(dd,J=8.6,2.5Hz,1H),2.05(s,6H)。
Example 32- [3, 5-dichloro-4- [ (2-oxo-1, 4-dihydro-3, 1-benzoxazin-6-yl) oxy ] phenyl ] -3, 5-dioxo-1, 2, 4-triazine-6-carbonitrile (Compound 3)
Step 1)6- (2, 6-dichloro-4-nitro-phenoxy) -1, 4-dihydro-3, 1-benzoxazine-2-one 3b
Under the protection of nitrogen, 6-hydroxy-1, 4-dihydro-3, 1-benzoxazine-2-one 3a (1.0g,6.1mmol) was dissolved in N, N-dimethylacetamide (7mL), and potassium carbonate (1.24g,8.97mmol) and 1, 3-dichloro-2-iodo-5-nitrobenzene (1.9g,6.0mmol) were added in this order to react at 100 ℃ for 4.5 hours. The reaction solution was cooled to room temperature, water (30mL) was added, the mixture was stirred for 5 minutes, and the mixture was filtered, collected and purified by silica gel column chromatography [ petroleum ether/ethyl acetate (v/v) ═ 3/1] to give the title compound 3b (1.33g, yield 62%) as a brown solid.
MS(ESI,neg.ion)m/z:353.0[M-H]-。
1HNMR(400MHz,CDCl3)δ(ppm)8.73(s,1H),8.31(s,2H),6.82(d,J=12.0Hz,1H),6.73(d,J=12.0Hz,1H),6.64(d,J=4.0Hz,1H),5.27(s,2H)。
Step 2)6- (4-amino-2, 6-dichloro-phenoxy) -1, 4-dihydro-3, 1-benzoxazine-2-one 3c
6- (2, 6-dichloro-4-nitro-phenoxy) -1, 4-dihydro-3, 1-benzoxazin-2-one 3b (1.2g,3.4mmol) was added to ethanol (20mL), sodium sulfide nonahydrate (8.29g,33.9mmol) was added, and the reaction was carried out at room temperature for 12 hours. The reaction was quenched by addition of water (40mL), extracted with ethyl acetate (50 × 3), the combined organic phases were washed with saturated sodium chloride solution (50mL), dried over anhydrous sodium sulfate, concentrated by suction filtration, and the resulting residue was purified by silica gel column chromatography [ petroleum ether/ethyl acetate (v/v) ═ 5/1] to give the title compound 3c (0.20g, yield 18%) as a yellow solid.
MS(ESI,pos.ion)m/z:325.0[M+H]+;
1HNMR(400MHz,DMSO-d6)δ(ppm)6.77(s,2H),6.59(s,J=4.0Hz,1H),6.54(d,J=8.0Hz,1H),6.43-6.40(m,1H),5.54(s,2H),4.56(s,2H)。
Step 3) N- [ 2-cyano-2- [ [3, 5-dichloro-4- [ (2-oxo-1, 4-dihydro-3, 1-benzoxazin-6-yl) oxy
Base of]Phenyl radical]Hydrazine fork]Acetyl group]Urethane 3d
6- (4-amino-2, 6-dichloro-phenoxy) -1, 4-dihydro-3, 1-benzoxazin-2-one 3c (0.16g,0.49mmol) was dissolved in water (6mL) and concentrated hydrochloric acid (1mL), an aqueous solution (1mL) of sodium nitrite (40mg,0.57mmol) was added dropwise at 0 ℃, the reaction solution was then rapidly filtered, and the filtrate was added dropwise to a mixed solution of N-cyanoacetylurethane (84mg,0.54mmol) at 0 ℃ in pyridine (3mL) and water (9mL) and allowed to react at 0 ℃ for 30 minutes. The reaction was filtered, the collected filter cake was dissolved in dichloromethane (20mL), the organic phase was washed successively with water (10mL) and saturated sodium chloride solution (10mL), dried over anhydrous sodium sulfate, and concentrated by suction filtration to give the title compound 3d (0.15g, 61% yield) as a red solid.
MS(ESI,neg.ion)m/z:489.9[M-H]-。
Step 4)2- [3, 5-dichloro-4- [ (2-oxo-1, 4-dihydro-3, 1-benzoxazin-6-yl) oxy]Phenyl radical]-3,
5-dioxo-1, 2, 4-triazine-6-carbonitrile 3
Reacting N- [ 2-cyano-2- [ [3, 5-dichloro-4- [ (2-oxo-1, 4-dihydro-3, 1-benzoxazin-6-yl) oxy group]Phenyl radical]Hydrazine fork]Acetyl group]Ethyl carbamate 3d (0.15g,0.30mmol) and sodium acetate (25mg,0.30mmol) were added to acetic acid (2.5mL) and reacted at 120 ℃ for 3.5 hours. The reaction mixture was cooled to room temperature, then concentrated under reduced pressure, and water (7mL) was added dropwise to the residue to obtain a red solidSeparating out, filtering, collecting filter cake, separating and purifying [ 40% ACN/60% H ]2O (0.1% TFA), Kromasil: C1810. mu. m.times.50 mm.times.250 mm, flow rate: 100mL/min]To obtain the title compound 3(17mg, yield 13%, HPLC purity: 95.95%) as a yellow solid.
MS(ESI,pos.ion)m/z:446.0[M+H]+;
1H NMR(400MHz,CD3OD)δ(ppm)7.81(s,2H),7.37(d,J=8.0Hz,1H),7.09(d,J=4.0Hz,1H),6.92-9.89(m,1H),4.53(s,2H)。
Example 42- [3, 5-dichloro-4- [ (3-oxo-4H-1, 4-benzoxazin-7-yl) oxy ] phenyl ] -3, 5-dioxo-1, 2, 4-triazine-6-carbonitrile (Compound 4)
Step 1)7- (2, 6-dichloro-4-nitro-phenoxy) -4H-1, 4-benzoxazine-3-one 4b
7-hydroxy-4H-1, 4-benzoxazin-3-one 4a (3.6g,22mmol) was dissolved in N, N-dimethylacetamide (10mL), and potassium carbonate (4.56g,33mmol) and 1, 3-dichloro-2-iodo-5-nitrobenzene (6.99g,22mmol) were added in this order to react at 120 ℃ for 12 hours. The reaction was cooled to room temperature, quenched by the addition of water (30mL), stirred for 5 minutes, filtered, the filter cake washed with water (10mL), collected and dried under vacuum to give the title compound 4b (6.7g, 87% yield) as a brown solid.
MS(ESI,neg.ion)m/z:354.1[M-H]-。
1H NMR(400MHz,DMSO-d6)δ(ppm)10.66(s,1H),8.51(s,2H),6.84(d,J=8.0Hz,1H),6.58(d,J=4.0Hz,1H),6.50-6.47(m,1H),4.57(s,2H)。
Step 2)7- (4-amino-2, 6-dichloro-phenoxy) -4H-1, 4-benzoxazine-3-one 4c
7- (2, 6-dichloro-4-nitro-phenoxy) -4H-1, 4-benzoxazin-3-one 4b (3.0g,8.4mmol) and sodium sulfide nonahydrate (5.6g,23.3mmol) were added to ethanol (20mL) and reacted at 80 ℃ for 15 hours. The reaction was quenched by the addition of water (40mL), stirred for 5 minutes, filtered, and the filter cake collected and dried in vacuo to give the title compound 4c (1.84g, 67% yield) as a brown solid.
MS(ESI,pos.ion)m/z:325.0[M+H]+。
1HNMR(400MHz,CD3OD)δ(ppm)6.80(d,J=8.0Hz,1H),6.73(s.2H),6.41-6.36(m,2H),4.54(s,2H)。
Step 3) N- [ 2-cyano-2- [ [3, 5-dichloro-4- [ (3-oxo-4H-1, 4-benzoxazin-7-yl) oxy group]Benzene and its derivatives
Base of]Hydrazine fork]Acetyl group]Urethane 4d
7- (4-amino-2, 6-dichloro-phenoxy) -4H-1, 4-benzoxazin-3-one 4c (1.0g,3.08mmol) was added to water (36mL) and concentrated hydrochloric acid (6mL), an aqueous solution (1mL) of sodium nitrite (0.24g,3.39mmol) was added dropwise at-5 deg.C, the reaction was allowed to react for 15 minutes, and the reaction solution was rapidly filtered. To the filtrate was added a mixed solution of N-cyanoacetylurethane (0.53g,3.38mmol) in pyridine (18mL) and water (42mL) at-5 ℃ to react for 30 minutes. The reaction was filtered and the filter cake was collected to give the title compound 4d (0.60g, 40% yield) as an orange solid.
MS(ESI,neg.ion)m/z:488.5[M-H]-。
Step 4)2- [3, 5-dichloro-4- [ (3-oxo-4H-1, 4-benzoxazin-7-yl) oxy group]Phenyl radical]-3, 5-dioxo
Substituted-1, 2, 4-triazine-6-carbonitrile 4
Acetic acid (10mL) was added to N- [ 2-cyano-2- [ [3, 5-dichloro-4- [ (3-oxo-4H-1, 4-benzoxazin-7-yl) oxy ] group]Phenyl radical]Hydrazine fork]Acetyl group]Ethyl carbamate 4d (0.60g,1.22mmol) and sodium acetate (100mg,1.2073mmol) were reacted at 120 ℃ for 3 hours. The reaction mixture was cooled to room temperature, concentrated, and the residue was added with acetic acid (3mL) and water (15mL), stirred for 15 minutes, filtered, washed with water (5mL), and the filter cake was collected to isolate and purify [ 20% ACN/80% H ]2O (0.1% ammonia), Kromasil: C1810. mu. m.times.50 mm.times.250 mm, flow rate: 90mL/min]To obtain the title compound 4(61mg, yield 11%, HPLC purity: 97.95%) as a yellow solid.
MS(ESI,neg.ion)m/z:443.9[M-H]-;
1H NMR(400MHz,CD3OD)δ(ppm)7.76(s,2H),6.85(d,J=12.0Hz,1H),6.51(d,J=2.6Hz,1H),6.46(dd,J=8.6,2.7Hz,1H),4.57(s,2H)。
Example 52- [3, 5-dichloro-4- (3, 3-dimethyl-2-oxo-indolin-5-yl) oxy-phenyl ] -3, 5-dioxo-1, 2, 4-triazine-6-carbonitrile (Compound 5)
Step 1)5- (2, 6-dichloro-4-nitro-phenoxy) -3, 3-dimethyl-indolin-2-one 5b
5-hydroxy-3, 3-dimethyl-indolin-2-one 5a (0.48g,2.7mmol) was dissolved in N, N-dimethylacetamide (5mL), and potassium carbonate (0.56g,4.05mmol) and 1, 3-dichloro-2-iodo-5-nitrobenzene (0.86g,2.7mmol) were added and reacted at 120 ℃ for 18 hours. The reaction was cooled to room temperature, water (20mL) was added, stirred for 5 minutes, filtered, and the filter cake was collected and dried to give the title compound 5b (0.62g, yield 62%) as a yellow solid.
MS(ESI,pos.ion)m/z:367.0[M+H]+;
1H NMR(400MHz,DMSO-d6)δ(ppm)10.29(s,1H),8.51(s,2H),7.06(d,J=4.0Hz,1H),6.77(d,J=8.0Hz,1H),6.61(dd,J=8.4,2.6Hz,1H),1.23(s,6H)。
Step 2)5- (4-amino-2, 6-dichloro-phenoxy) -3, 3-dimethyl-indolin-2-one 5c
Reacting 5- (2, 6-dichloro-4-nitro-phenoxy) -3, 3-dimethyl-indoleQuinoline (III)-2-ketone 5b (0.62g,1.69mmol) was dissolved in ethanol (10mL), and sodium sulfide nonahydrate (1.20g,4.90mmol) was added and reacted at 80 ℃ for 11 hours. The reaction was cooled to room temperature, quenched by the addition of water (40mL), stirred for 5 minutes, filtered, and the filter cake was collected and dried to give the title compound 5c (0.33g, 57% yield) as a yellow solid.
MS(ESI,pos.ion)m/z:337.0[M+H]+。
Step 3) N- [ 2-cyano-2- [ [3, 5-dichloro-4- (3, 3-dimethyl-2-oxo-indolin-5-yl) oxy-benzene
Base of]Hydrazine fork]Acetyl group]Carbamic acid esterEthyl ester 5d
5- (4-amino-2, 6-dichloro-phenoxy) -3, 3-dimethyl-indolin-2-one 5c (0.15g,0.45mmol) was dissolved in water (5mL) and concentrated hydrochloric acid (2.3mL), an aqueous solution (1mL) of sodium nitrite (31mg,0.45mmol) was added dropwise at 0 ℃, followed by addition of a mixed solution of N-cyanoacetylurethane (78mg,0.50mmol) in pyridine (2.3mL) and water (5.4mL), and reacted at 0 ℃ for 30 minutes. The reaction was filtered, the filter cake was collected and dried to give the title compound 5d (0.13g, 56% yield) as a red solid.
MS(ESI,Pos.ion)m/z:504.0[M+H]+;
1H NMR(400MHz,CD3OD)δ(ppm)7.81(s,2H),6.84(dd,J=7.5,5.6Hz,2H),6.58(dd,J=8.4,2.5Hz,1H),4.28(q,J=7.0Hz,2H),1.36-1.32(m,9H)。
Step 4)2- [3, 5-dichloro-4- (3, 3-dimethyl-2-oxo-indolin-5-yl) oxy-phenyl]-3, 5-bis
Oxo-1, 2, 4-triazine-6-carbonitrile 5
Reacting N- [ 2-cyano-2- [ [3, 5-dichloro-4- (3, 3-dimethyl-2-oxo-indole)Quinoline (III)-5-yl) oxy-phenyl]Hydrazine fork]Acetyl group]Ethyl carbamate 5d (126mg,0.25mmol) was dissolved in acetic acid (3.5mL), and sodium acetate (20mg,0.24mmol) was added to react at 120 ℃ for 4 hours. Concentrating the reaction solution, adding water (30mL), filtering, collecting filter cake, drying, and separating and purifying by preparation method [ 47% ACN/53% H2O (0.1% TFA), Kromasil: C1810. mu. m.times.50 mm.times.250 mm, flow rate: 100mL/min]To obtain the title compound 5(52mg, yield 45%, HPLC purity: 98.82%) as a pale yellow solid.
MS(ESI,neg.ion)m/z:455.9[M-H]-;
1H NMR(600MHz,DMSO-d6)δ(ppm)10.29(s,1H),7.80(s,2H),7.07(s,1H),6.78(d,J=8.2Hz,1H),6.51(d,J=7.4Hz,1H),1.24(s,6H)。
EXAMPLE 62- [3, 5-dichloro-4- (2 '-oxospiro [ cyclopropane-1, 3' -indolin ] -5-yl) oxy-phenyl ] -3, 5-dioxo-1, 2, 4-triazine-6-carbonitrile (Compound 6)
Step 1)5'- (2, 6-dichloro-4-nitro-phenoxy) spiro [ cyclopropane-1, 3' -indoline]-2' -keto 6b
5' -Hydroxyspiro [ cyclopropane-1, 3' -indolin ] -2' -one 6a (0.55g,3.14mmol) was dissolved in N, N-dimethylacetamide (5mL), and potassium carbonate (0.65g,4.65mmol) and 3-dichloro-2-iodo-5-nitrobenzene (0.99g,3.1mmol) were added and reacted at 120 ℃ for 14 hours. The reaction was cooled to room temperature, water (40mL) was added, stirred for 5 minutes, filtered, and the filter cake was collected and dried under vacuum to give the title compound 6b (0.88g, 77% yield) as a black solid.
MS(ESI,neg.ion)m/z:363.0[M-H]-。
Step 2)5'- (4-amino-2, 6-dichloro-phenoxy) spiro [ cyclopropane-1, 3' -indoline]-2' -keto 6c
5- (2, 6-dichloro-4-nitro-phenoxy) spiro [ cyclopropane-1, 3' -indolin ] -2-one 6b (0.88g,2.3mmol) was dissolved in ethanol (12mL), and sodium sulfide nonahydrate (1.47g,6.00mmol) was added and reacted at 80 ℃ for 1 hour. The reaction was cooled to room temperature and quenched by the addition of water (40mL), stirred for 5 minutes, filtered, and the filter cake collected and dried in vacuo to give the title compound 6c (0.39g, 50% yield) as a brown solid.
MS(ESI,pos.ion)m/z:335.0[M+H]+。
Step 3) N- [ 2-cyano-2- [ [3, 5-dichloro-4- (2 '-oxospiro [ cyclopropane-1, 3' -indoline)]-5' -yl)
Oxy-phenyl]Hydrazine fork]Acetyl group]Urethane 6d
5' - (4-amino-2, 6-dichloro-phenoxy) spiro [ cyclopropane-1, 3' -indolin ] -2' -one 6c (0.39g,1.16mmol) was dissolved in water (12mL) and concentrated hydrochloric acid (6mL), an aqueous solution (2mL) of sodium nitrite (80mg,1.15mmol) was added dropwise at 0 ℃, and then the above reaction solution was rapidly filtered, and the filtrate was added dropwise to a mixed solution of N-cyanoacetylurethane (200mg,1.28mmol) at 0 ℃ in pyridine (6mL) and water (14mL) and kept at 0 ℃ for reaction for 30 minutes. The reaction was filtered, the filter cake collected and dried in vacuo to give the title compound 6d (0.112g, 19% yield) as a red solid.
MS(ESI,neg.ion)m/z:499.9[M-H]-。
Step 4)2- [3, 5-dichloro-4- (2 '-oxospiro [ cyclopropane-1, 3' -indoleQuinoline (III)]-5' -yl) oxy-phenyl]- 3, 5-dioxo-1, 2, 4-triazine-6-carbonitrile 6
To N- [ 2-cyano-2- [ [3, 5-dichloro-4- (2 '-oxospiro [ cyclopropane-1, 3' -indoline)]-5' -yl) oxy-phenyl]Hydrazine fork]Acetyl group]To ethyl carbamate 6d (112mg,0.223mmol) and sodium acetate (18.5mg,0.223mmol) was added acetic acid (3mL) and reacted at 120 ℃ for 4 hours. The reaction was cooled to room temperature, water (10mL) was added, stirred for 10min, filtered, the filter cake was collected and dried under vacuum to give a red solid which was purified by preparative separation [ 25% ACN/75% H2O (0.1% ammonia), Kromasil: C1810. mu. m.times.50 mm.times.250 mm, flow rate: 100mL/min]To obtain the title compound 6(22mg, yield 21%, HPLC purity: 97.98%) as a pale yellow solid.
MS(ESI,pos.ion)m/z:455.9[M+H]+;
1H NMR(400MHz,CD3OD)δ(ppm)7.75(s,2H),6.89(d,J=8.0Hz,1H),6.60(m,2H),1.65-1.56(m,4H)。
Example 72- [3, 5-dichloro-4- (2-oxospiro [1, 4-dihydroquinoline-3, 1' -cyclopropane)]-6-yl) oxy-benzene Base of]-3, 5-dioxo-1, 2, 4-triazine-6-carbonitrile(Compound 7)
Step 1)6- (2, 6-dichloro-4-nitro-phenoxy) spiro [1, 4-dihydroquinoline-3, 1' -cyclopropane]-2-one 7b
6-Hydroxyspiro [1, 4-dihydroquinolin-3, 1' -cyclopropane ] -2-one 7a (0.57g,3.01mmol) was dissolved in N, N-dimethylacetamide (3.5mL), and potassium carbonate (0.62g,4.49mmol) and 1, 3-dichloro-2-iodo-5-nitrobenzene (0.95g,2.7mmol) were added in this order to react at 120 ℃ for 6 hours. The reaction was cooled to room temperature, water (20mL) was added, stirred for 30 minutes, filtered, and a yellow filter cake was collected to give the title compound 7b (1.1g, 96% yield) as a yellow solid.
MS(ESI,pos.ion)m/z:379.0[M+H]+。
Step 2)6- (4-amino-2, 6-dichloro-phenoxy) spiro [1, 4-dihydroquinoline-3, 1' -cyclopropane]-2-one 7c
6- (2, 6-dichloro-4-nitro-phenoxy) spiro [1, 4-dihydroquinoline-3, 1' -cyclopropane ] -2-one 7b (1.1g,2.9mmol) was dissolved in ethanol (20mL), and sodium sulfide nonahydrate (2.3g,9.4mmol) was added and reacted at 80 ℃ for 10 hours. The reaction was cooled to room temperature, and water (40mL) was added to quench the reaction, stirred for 5 minutes, filtered, and collected to give the title compound 7c (0.68g, 67% yield) as a brown solid.
MS(ESI,pos.ion)m/z:349.1[M+H]+。
Step 3) N- [ 2-cyano-2- [ [3, 5-dichloro-4- (2-oxospiro [1, 4-dihydroquinoline-3, 1' -cyclopropane)]-6-
Yl) oxy-phenyl]Hydrazine fork]Acetyl group]Urethane 7d
6- (4-amino-2, 6-dichloro-phenoxy) spiro [1, 4-dihydroquinoline-3, 1' -cyclopropane ] -2-one 7c (0.68g,1.94mmol) was dissolved in water (20mL) and concentrated hydrochloric acid (10mL), an aqueous solution (3mL) of sodium nitrite (135mg,1.94mmol) was added dropwise at 0 ℃, the reaction solution was then rapidly filtered, and the filtrate was added dropwise to a mixed solution of N-cyanoacetylurethane (334mg,2.13mmol) at 0 ℃ in pyridine (10mL) and water (23mL) and reacted at 0 ℃ for 30 minutes. The reaction was filtered, the collected filter cake was dried under vacuum to give the title compound 7d (83mg, yield 8.3%) as a yellow solid.
MS(ESI,pos.ion)m/z:516.0[M+H]+。
Step 4)2- [3, 5-dichloro-4- (2-oxaspiro (1, 4-dihydroquinoline-3, 1' -cyclopropane)]-6-yl-) oxy-benzene
Base of]-3, 5-dioxo-1, 2, 4-triazine-6-carbonitrile 7
To N- [ 2-cyano-2- [ [3, 5-dichloro-4- (2-oxospiro [1, 4-dihydroquinoline-3, 1' -cyclopropane)]-6-yl) oxy-phenyl]Hydrazine fork]Acetyl group]To ethyl carbamate 7d (83.1mg,0.161mmol) and sodium acetate (13.3mg,0.161mmol) was added acetic acid (3mL) and the reaction was carried out at 120 ℃ for 4 hours. Cooling the reaction solution to room temperature, adding water (10mL), stirring for 10min, filtering, collecting filter cake, vacuum drying to obtain red solid, and separatingPurification [ 47% ACN/53% H2O (0.1% TFA), Kromasil: C1810. mu. m.times.50 mm.times.250 mm, flow rate: 100mL/min]To obtain the title compound 7(37mg, yield 49%, HPLC purity: 95.95%) as a pale yellow solid.
MS(ESI,neg.ion)m/z:470.0[M-H]-;
1H NMR(400MHz,DMSO-d6)δ(ppm)10.07(s,1H),7.78(s,2H),6.85(d,J=8.9Hz,1H),6.65(s,2H),2.81(s,2H),1.04(s,2H),0.69(s,2H)。
Example 82- [3, 5-dichloro-4- [ (2-oxo-1H-quinolin-6-yl) oxy ] phenyl ] -3, 5-dioxo-1, 2, 4-triazine-6-carbonitrile (Compound 8)
Step 1)6- (2, 6-dichloro-4-nitro-phenoxy) -1H-quinolin-2-one 8a
6- (2, 6-dichloro-4-nitro-phenoxy) -3, 4-dihydro-1H-quinolin-2-one 1b (0.74g,2.09mmol), 2, 3-dichloro-5, 6-dicyano-1, 4-benzoquinone (0.79g,3.14mmol) and N, O-bis (trimethylsilyl) trifluoroacetamide were dissolved in 1, 4-dioxane (15mL) and reacted at 100 ℃ for 21 hours. The reaction solution was cooled to room temperature, water (30mL) was poured into the reaction solution, extracted with ethyl acetate (10mL × 2), the combined organic phases were dried over anhydrous sodium sulfate, concentrated by suction filtration, and the resulting residue was purified by silica gel column chromatography [ petroleum ether/ethyl acetate (v/v) ═ 1/1] to give the title compound 8a (0.21g, yield 29%) as a yellow solid.
MS(ESI,neg.ion)m/z:348.9[M-H]-;
1H NMR(400MHz,CDCl3)δ(ppm)11.15(s,1H),8.34(s,2H),7.66(d,J=9.6Hz,1H),7.32(d,J=9.0Hz,1H),7.18(dd,J=8.9,2.7Hz,1H),6.86(d,J=2.7Hz,1H),6.71(d,J=9.6Hz,1H)。
Step 2)6- (4-amino-2, 6-dichloro-phenoxy) -1H-quinolin-2-one 8b
6- (2, 6-dichloro-4-nitro-phenoxy) -1H-quinolin-2-one 8a (0.21g, 0.60mmol) and sodium sulfide (0.24g,3.00mmol) were dissolved in ethanol (3mL) and reacted at 80 ℃ for 4 hours. The reaction solution was cooled to room temperature, water (30mL) was added, stirred for 15 minutes, filtered, and the filter cake was collected and dried under vacuum to give the title compound 8b (0.10g, 52% yield) as a yellow solid.
MS(ESI,pos.ion)m/z:321.0[M+H]+。
Step 3) N- [ 2-cyano-2- [ [3, 5-dichloro-4- (2-oxo-1H-quinolin-6-yl) oxy]Phenyl radical]Hydrazine fork]Second step
Acyl radical]Urethane 8c
6- (4-amino-2, 6-dichloro-phenoxy) -1H-quinolin-2-one 8b (0.10g, 0.31mmol), N-cyanoacetylurethane (0.05g,0.34mmol) and concentrated hydrochloric acid (0.08mL) were added to acetic acid (2mL), and an aqueous solution (2mL) of sodium nitrite (0.02g,0.34mmol) was added dropwise at 3 ℃ followed by reaction for 2 hours. The reaction was concentrated to give the title compound 8c (0.15g, yield 99%) as a yellow solid.
MS(ESI,pos.ion)m/z:488.0[M+H]+。
Step 4)2- [3, 5-dichloro-4- [ (2-oxo-1H-quinolin-6-yl) oxy]Phenyl radical]-3, 5-dioxo-1, 2,
4-triazine-6-carbonitrile 8
Reacting N- [ 2-cyano-2- [ [3, 5-dichloro-4- (2-oxo-1H-quinolin-6-yl) oxy]Phenyl radical]Hydrazine fork]Acetyl group]Ethyl carbamate 8c (0.15g,0.31mmol) was dissolved in N, N-dimethylacetamide (1mL), and potassium acetate (0.12g,1.2mmol) was added to react at 120 ℃ for 5 hours. Cooling the reaction solution to room temperature, filtering, concentrating the filtrate, and separating and purifying the residue [ 39% ACN/61% H ]2O (0.1% TFA), Philomena ACE specification C1810 μm X50 mm X250 mm, flow rate 100mL/min]To obtain the title compound 8(20mg, yield 15%, HPLC purity: 98.34%) as a white solid.
MS(ESI,neg.ion)m/z:440.3[M-H]-;
1H NMR(400MHz,DMSO-d6)δ(ppm)13.30(s,1H),11.75(s,1H),7.87(d,J=9.5Hz,1H),7.82(s,2H),7.34(d,J=8.8Hz,1H),7.26(d,J=9.6Hz,1H),7.09(s,1H),6.50(d,J=9.4Hz,1H)。
Example 92- [3, 5-dichloro-4- [ (4, 4-dimethyl-2-oxo-1, 3-dihydroquinolin-6-yl) oxy ] phenyl ] -3, 5-dioxo-1, 2, 4-triazine-6-carboxamide (Compound 9)
Compound 2(0.15g,0.32mmol) was dissolved in concentrated hydrochloric acid (3mL) and reacted at 75 ℃ for 3.5 hours. The reaction was cooled to room temperature, quenched with water (10mL), adjusted to pH 9 with saturated aqueous sodium bicarbonate solution, then extracted with ethyl acetate (15mL × 3), and the combined organic phases were washed with saturated sodium chloride solution (15mL × 3), dried over anhydrous sodium sulfate, concentrated by suction filtration to give the title compound 9(62mg, yield 40%, HPLC purity: 95.00%) as a brown solid.
MS(ESI,pos.ion)m/z:490.1[M+H]+;
1H NMR(400MHz,DMSO-d6)δ(ppm)13.00(s,1H),10.11(s,1H),9.56(d,J=3.7Hz,1H),7.87(d,J=2.5Hz,2H),7.67(d,J=3.6Hz,1H),7.00-6.91(m,1H),6.82(d,J=8.6Hz,1H),6.50(dd,J=8.5,2.7Hz,1H),2.35(s,2H),1.21(s,6H)。
Example 102- [3, 5-dichloro-4- [ (4, 4-dimethyl-2-oxo-1, 3-dihydroquinolin-6-yl) oxy ] phenyl ] -3, 5-dioxo-1, 2, 4-triazine-6-carboxylic acid (Compound 10)
Compound 2(0.15g,0.32mmol) was dissolved in concentrated hydrochloric acid (3mL) and reacted at 75 ℃ for 3.5 hours. The reaction was cooled to room temperature, quenched with water (10mL), adjusted to pH 9 with saturated aqueous sodium bicarbonate solution, and extracted with ethyl acetate (15mL × 3); the aqueous phase was adjusted to pH 3 with dilute hydrochloric acid (3mol/L,30mL), followed by extraction with ethyl acetate (15mL × 3), and the combined organic phases were washed with saturated sodium chloride solution (15mL × 2), dried over anhydrous sodium sulfate, and concentrated by suction filtration to give the title compound 10(50mg, yield 32%, HPLC purity: 99.26%) as a pale yellow solid. MS (ESI, neg. ion) M/z 488.9[ M-H [ ]]-;
1H NMR(400MHz,DMSO-d6)δ(ppm)12.72(s,1H),10.09(s,1H),7.84(s,2H),6.98(d,J=2.6Hz,1H),6.82(d,J=8.7Hz,1H),6.50(dd,J=8.6,2.7Hz,1H),2.35(s,2H),1.22(s,6H)。
EXAMPLE 112- [3, 5-dichloro-4- [ (1-methyl-2-oxo-3, 4-dihydroquinolin-6-yl) oxy ] phenyl ] -3, 5-dioxo-1, 2, 4-triazine-6-carbonitrile (Compound 11)
Step 1)6- (2, 6-dichloro-4-nitro-phenoxy) -1-methyl-3, 4-dihydroquinolin-2-one 11a
Sodium hydride (0.57g,14mmol,60 mass%) was added portionwise to a solution of 6- (2, 6-dichloro-4-nitro-phenoxy) -3, 4-dihydro-1H-quinolin-2-one 1b (2.00g,5.66mmol) in tetrahydrofuran (30mL) under nitrogen blanket in an ice-water bath, and iodomethane (0.47mL,7.4mmol) was added dropwise, followed by reaction at room temperature for 12 hours. The reaction solution was quenched by adding water (30mL) under an ice-water bath, extracted with ethyl acetate (30mL × 3), the combined organic phases were washed with a saturated sodium chloride solution (30mL × 3), dried over anhydrous sodium sulfate, concentrated by suction filtration, and the resulting residue was purified by silica gel column chromatography [ petroleum ether/ethyl acetate (v/v) ═ 3/1] to give the title compound 11a (1.15g, yield 55%) as a pale yellow solid.
MS(ESI,pos.ion)m/z:367.0[M+H]+。
Step 2)6- (4-amino-2, 6-dichloro-phenoxy) -1-methyl-3, 4-dihydroquinolin-2-one 11b
6- (2, 6-dichloro-4-nitro-phenoxy) -1-methyl-3, 4-dihydroquinolin-2-one 11a (0.70g,1.90mmol) was dissolved in acetic acid (15mL), and iron powder (0.43g,7.5mmol) was added and reacted at 60 ℃ for 4 hours. The reaction was cooled to room temperature, iron powder was removed, water (40mL) was added, stirring was carried out for 30 minutes, filtration was carried out, and the collected cake was dried under vacuum to give the title compound 11b (0.52g, yield 81%) as an off-white solid.
MS(ESI,pos.ion)m/z:337.1[M+H]+。
Step 3) [ 2-cyano-2- [ [3, 5-dichloro-4- [ (1-methyl-2-oxo-3, 4-dihydroquinolin-6-yl) oxy]
Phenyl radical]Hydrazine fork]Acetyl group]Urethane 11c
6- (4-amino-2, 6-dichloro-phenoxy) -1-methyl-3, 4-dihydroquinolin-2-one 11b (0.50g,1.48mmol) and N-cyanoacetylurethane (0.26g,1.63mmol) were dissolved in acetic acid (10mL), and an aqueous solution (1.5mL) of sodium nitrite (0.16g,2.23mmol) was added at 0 ℃ to react for 4.5 hours. Water (30mL) was added to the reaction, stirred for 30 min, filtered, and the filter cake was collected and dried under vacuum to give the title compound 11c (0.64g, 86% yield) as a yellow solid.
MS(ESI,neg.ion)m/z:502.1[M-H]-。
Step 4)2- [3, 5-dichloro-4- [ (1-methyl-2-oxo-3, 4-dihydroquinolin-6-yl) oxy]Phenyl radical]-3,5-
Dioxo-1, 2, 4-triazine-6-carbonitrile 11
Ethyl [ 2-cyano-2- [ [3, 5-dichloro-4- [ (1-methyl-2-oxo-3, 4-dihydroquinolin-6-yl) oxy ] phenyl ] hydrazono ] acetyl ] carbamate 11c (0.75g,1.49mmol) was dissolved in N, N-dimethylacetamide (10mL), and sodium acetate (0.62g,7.43mmol) was added and reacted at 120 ℃ for 4.5 hours. The reaction was cooled to room temperature, water (40mL) was added, the pH was adjusted to 7 with dilute hydrochloric acid (2mol/L), stirring was carried out for 30 minutes, filtration was carried out, the collected cake was dried in vacuo, and the resulting reddish brown solid was purified by silica gel column chromatography [ petroleum ether/ethyl acetate (v/v) ═ 1/2] to give the title compound 11(0.12g, yield 17%, HPLC purity: 98.14%) as a pale yellow solid.
MS(ESI,neg.ion)m/z:456.1[M-H]-;
1H NMR(400MHz,DMSO-d6)δ(ppm)13.28(s,1H),7.82(s,2H),7.05(d,J=8.9Hz,1H),6.85(d,J=1.8Hz,1H),6.75-6.69(m,1H),3.23(s,3H),2.85(t,J=7.0Hz,2H),2.52(t,J=7.0Hz,2H)。
Example 122- [3, 5-dichloro-4- [ (2-oxo-1, 3,4, 5-tetrahydro-1-benzazepin-7-yl) oxy ] phenyl ] -3, 5-dioxo-1, 2, 4-triazine-6-carbonitrile (Compound 12)
Step 1)7- (2, 6-dichloro-4-nitro-phenoxy) -1,3,4, 5-tetrahydro-1-benzazepin-2-one 12b
7-hydroxy-1, 3,4, 5-tetrahydro-1-benzazepin-2-one 12a (0.50g,2.8mmol), 1, 3-dichloro-2-iodo-5-nitro-benzene (0.99g,3.1mmol) were dissolved in N, N-dimethylformamide (8mL), and potassium carbonate (0.79g,5.7mmol) was added to react at 100 ℃ for 16 hours. The reaction was cooled to room temperature, water (15mL) was added, stirred for 15 minutes, filtered, the filter cake was collected, and the resulting yellow solid was recrystallized at 85 ℃ (ethanol/ethyl acetate/petroleum ether ═ 1/5/10,16mL), filtered, and the filter cake was dried to give the title compound 12b (0.70g, yield 68%) as a gray solid.
Step 2)7- (4-amino-2, 6-dichloro-phenoxy) -1,3,4, 5-tetrahydro-1-benzazepin-2-one 12c
7- (2, 6-dichloro-4-nitro-phenoxy) -1,3,4, 5-tetrahydro-1-benzazepin-2-one 12b (0.70g,1.9mmol) was dissolved in acetic acid (8mL), and iron powder (0.43g,7.7mmol) was added and reacted at 70 ℃ for 4 hours. The reaction was cooled to room temperature, water (30mL) was added, stirred for 10 minutes, filtered, rinsed with water (10mL), and the solid collected and dried under vacuum to give the title compound 12c (0.64g, 100% yield) as a brown solid. MS (ESI, pos.ion) M/z 337.0[ M + H ]]+。
Step 3) N- [ 2-cyano-2- [ [3, 5-dichloro-4- [ (2-oxo-1, 3,4, 5-tetrahydro-1-benzazepine-7-
Radical) oxy]Phenyl radical]Hydrazine fork]Acetyl group]Urethane 12d
7- (4-amino-2, 6-dichloro-phenoxy) -1,3,4, 5-tetrahydro-1-benzazepin-2-one 12c (0.20g,0.54mmol), N-cyanoacetylurethane (94mg,0.59mmol) was dissolved in acetic acid (4mL) and a solution of sodium nitrite (75mg,1.08mmol) in water (2mL) was added at 0 ℃. Water (10mL) was added to the reaction mixture at 0 ℃, stirred for 10 minutes, filtered, rinsed with water (2mL), the filter cake was collected and dried under vacuum to give the title compound 12d (0.27g, 100% yield) as a brown solid.
Step 4)2- [3, 5-dichloro-4- [ (2-oxo-1, 3,4, 5-tetrahydro-1-benzazepin-7-yl) oxy]Benzene and its derivatives
Base of]-3, 5-dioxo-1, 2, 4-triazine-6-carbonitrile 12
Ethyl N- [ 2-cyano-2- [ [3, 5-dichloro-4- [ (2-oxo-1, 3,4, 5-tetrahydro-1-benzazepin-7-yl) oxy ] phenyl ] hydrazono ] acetyl ] carbamate 12d (0.27g,0.54mmol) was dissolved in N, N-dimethylacetamide (3mL), and sodium acetate (48mg,0.59mmol) was added and reacted at 120 ℃ for 4 hours. The reaction solution was cooled to room temperature, water (20mL) was added, extraction was performed with ethyl acetate (20mL × 5), the combined organic phases were washed with a saturated sodium chloride solution (10mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated, and the resulting residue was purified by silica gel column chromatography (100% ethyl acetate), and the resulting red solid was recrystallized (ethanol/ethyl acetate/petroleum ether ═ 1/6/12,9.5mL) at 85 ℃ to give the title compound 12(36mg, yield 15%, HPLC purity: 85.61%) as a red brown solid.
MS(ESI,neg.ion)m/z:456.5[M-H]-;
1H NMR(400MHz,DMSO-d6)δ(ppm)13.29(s,1H),9.42(s,1H),7.81(s,2H),6.94(d,J=8.7Hz,1H),6.87(d,J=2.6Hz,1H),6.70(dd,J=8.6,2.8Hz,1H),2.67(t,J=6.4Hz,2H),2.11(dd,J=17.3,4.6Hz,4H)。
EXAMPLE 132- [3, 5-dichloro-4- [ (2-oxo-1, 3,4, 5-tetrahydro-1-benzazepin-7-yl) oxy ] phenyl ] -3, 5-dioxo-1, 2, 4-triazine-6-carboxylic acid methyl ester (Compound 13)
Hydrogen chloride is reacted withTo a solution of compound 12(0.10g,0.22mmol) in methanol (2mL) was added and reacted at 50 ℃ for 4.5 hours (2mL,4.5 mol/L). Cooling the reaction solution to room temperature, concentrating, and separating and purifying the residue [ 40% ACN/60% H ]2O (0.1% TFA), Philomena ACE specification C1810 μm X50 mm X250 mm, flow rate 100mL/min]To obtain the title compound 13(62mg, yield 58%, HPLC purity: 98.48%) as an off-white solid.
MS(ESI,neg.ion)m/z:490.0[M-H]-;
1H NMR(400MHz,DMSO-d6)δ(ppm)7.81(s,2H),7.05(d,J=7.9Hz,1H),6.77(s,1H),6.67(d,J=7.5Hz,1H),3.59(s,3H),2.54(d,J=4.2Hz,2H),2.41-2.29(m,2H),1.85-1.65(m,2H)。
EXAMPLE 142- [3, 5-dichloro-4- [ (1-methyl-2-oxo-4, 5-dihydro-3H-1-benzazepin-7-yl) oxy ] phenyl ] -3, 5-dioxo-1, 2, 4-triazine-6-carbonitrile (Compound 14)
Step 1)7- (2, 6-dichloro-4-nitro-phenoxy) -1-methyl-4, 5-dihydro-3H-1-benzazepin-2-one
14a
7- (2, 6-dichloro-4-nitro-phenoxy) -1,3,4, 5-tetrahydro-1-benzazepin-2-one 12b (0.80g,2.2mmol) was dissolved in tetrahydrofuran (15mL), and sodium hydride (0.17g,4.3mmol,60 mass%) was added at 0 ℃ to react for 10 minutes, followed by methyl iodide (0.20mL,3.2mmol) and reacted at room temperature for 1 hour. The reaction was quenched by the addition of water (10mL), extracted with ethyl acetate (50mL × 2), the combined organic phases were washed with saturated sodium chloride (20mL), dried over anhydrous sodium sulfate, concentrated with suction filtration, and the resulting yellow solid was recrystallized from 85 ℃ (petroleum ether/ethyl acetate ═ 3/2,15mL) to give the title compound 14a (0.60g, yield 72%) as a yellow solid.
Step 2)7- (4-amino-2, 6-dichloro-phenoxy) -1-methyl-4, 5-dihydro-3H-1-benzazepin-2-one
14b
7- (2, 6-dichloro-4-nitro-phenoxy) -1-methyl-4, 5-dihydro-3H-1-benzazepin-2-one 14a (0.72g,1.9mmol) was dissolved in acetic acid (8mL), and iron powder (0.21g,3.8mmol) was added and reacted at 60 ℃ for 2 hours. The reaction was cooled to room temperature, water (48mL) was added, stirred for 10min, filtered, rinsed with water (10mL), and the solid was collected and dried under vacuum to give 14b as a yellow solid (0.66g, 99% yield).
Step 3) N- [ 2-cyano-2- [ [3, 5-dichloro-4- [ (1-methyl-2-oxo-4, 5-dihydro-3H-1-benzazepine
Zepin-7-yl) oxy]Phenyl radical]Hydrazine fork]Acetyl group]Urethane 14c
7- (4-amino-2, 6-dichloro-phenoxy) -1-methyl-4, 5-dihydro-3H-1-benzazepin-2-one 14b (0.56g,1.6mmol) was dissolved in acetic acid (11mL), a solution of sodium nitrite (0.22g,3.2mmol) in water (5.6mL) was added at 0 ℃ and reacted for 1 hour, N-cyanoacetylurethane (0.33g,2.1mmol) was added and the reaction was continued for 3.5 hours. Water (10mL) was added to the reaction mixture at 0 ℃, stirred for 10 minutes, filtered, rinsed with water (10mL), the cake collected and dried under vacuum to give the title compound 14c (0.83g, 100% yield) as a yellow solid.
Step 4)2- [3, 5-dichloro-4- [ (1-methyl-2-oxo-4, 5-dihydro-3H-1-benzazepin-7-yl) oxy
Base of]Phenyl radical]-3, 5-dioxo-1, 2, 4-triazine-6-carbonitrile 14
Ethyl N- [ 2-cyano-2- [ [3, 5-dichloro-4- [ (1-methyl-2-oxo-4, 5-dihydro-3H-1-benzazepin-7-yl) oxy ] phenyl ] hydrazono ] acetyl ] carbamate 14c (0.86g,1.7mmol) was dissolved in N, N-dimethylformamide (8mL), and sodium acetate (0.20g,2.4mmol) was added and reacted at 120 ℃ for 4 hours. The reaction solution was cooled to room temperature, water (20mL) was added, stirred for 10 minutes, filtered, washed with water (10mL), and the collected solid was slurried with ethanol/ethyl acetate/petroleum ether (5/5/10,20mL) to give the title compound 14(0.41g, yield 52%, HPLC purity: 88.67%) as a yellow solid.
MS(ESI,neg.ion)m/z:469.9[M-H]-;
1H NMR(400MHz,DMSO-d6)δ(ppm)7.82(s,2H),7.30(d,J=8.8Hz,1H),6.88(d,J=2.8Hz,1H),6.79(dd,J=8.7,2.9Hz,1H),3.20(s,3H),2.64(t,J=6.8Hz,2H),2.13(t,J=6.6Hz,2H),2.02(t,J=11.5Hz,2H)。
Example 152- [3, 5-dimethyl-4- [ (2-oxo-1, 3,4, 5-tetrahydro-1-benzazepin-7-yl) oxy ] phenyl ] -3, 5-dioxo-1, 2, 4-triazine-6-carbonitrile (Compound 15)
Step 1)7- (2, 6-dimethyl-4-nitro-phenoxy) -1,3,4, 5-tetrahydro-1-benzazepin-2-one 15a
7-hydroxy-1, 3,4, 5-tetrahydro-1-benzazepin-2-one 12a (0.30g,1.7mmol), 2-fluoro-1, 3-dimethyl-5-nitro-benzene (0.32g,1.9mmol) were dissolved in N, N-dimethylformamide (2.4mL), and potassium carbonate (0.47g,3.4mmol) was added to react at 70 ℃ for 16 hours. After the reaction solution was cooled to room temperature, water (10mL) was added, stirred for 15 minutes, filtered, and the filter cake was collected and dried to give the title compound 15a (0.55g, yield 100%) as an off-white solid.
Step 2)7- (4-amino-2, 6-dimethyl-phenoxy) -1,3,4, 5-tetrahydro-1-benzazepin-2-one 15b
7- (2, 6-dimethyl-4-nitro-phenoxy) -1,3,4, 5-tetrahydro-1-benzazepin-2-one 15a (0.55g,1.7mmol) was dissolved in acetic acid (3.3mL), and iron powder (0.28g,5.0mmol) was added to the solution to react at 60 ℃ for 5 hours. The reaction was cooled to room temperature, water (10mL) was added, extraction was performed with ethyl acetate (20 mL. times.3), the combined organic phases were washed with saturated sodium chloride (10 mL. times.3), dried over anhydrous sodium sulfate, concentrated by suction filtration, slurried with petroleum ether/ethyl acetate (1/1,10mL), filtered, the cake was collected and dried to give the title compound 15b (0.50g, 100% yield) as an off-white solid.
Step 3) N- [ 2-cyano-2- [ [3, 5-dimethyl-4- [ (2-oxo-1, 3,4, 5-tetrahydro-1-benzazepine-
7-yl) oxy]Phenyl radical]Hydrazine fork]Acetyl group]Urethane 15c
7- (4-amino-2, 6-dimethyl-phenoxy) -1,3,4, 5-tetrahydro-1-benzazepin-2-one 15b (0.50g,1.7mmol) was dissolved in acetic acid (10mL), a solution of sodium nitrite (0.24g,3.4mmol) in water (5mL) was added at 0 deg.C, and after half an hour of reaction, N-cyanoacetylurethane (0.35g,2.2mmol) was added and the reaction was continued for 3 hours. To the reaction mixture was added water (10mL) at 0 deg.C, stirred for 10min, filtered, rinsed with water (10mL), the filter cake was collected and dried to give the title compound 15c (0.47g, 60% yield) as a yellow solid.
Step 4)2- [3, 5-dimethyl-4- [ (2-oxo-1, 3,4, 5-tetrahydro-1-benzazepin-7-yl) oxy]Benzene and its derivatives
Base of]-3, 5-dioxo-1, 2, 4-triazine-6-carbonitrile 15
Ethyl N- [ 2-cyano-2- [ [3, 5-dimethyl-4- [ (2-oxo-1, 3,4, 5-tetrahydro-1-benzazepin-7-yl) oxy ] phenyl ] hydrazono ] acetyl ] carbamate 15c (0.47g,1.0mmol) was dissolved in N, N-dimethylformamide (4mL), and sodium acetate (0.12g,1.5mmol) was added and reacted at 120 ℃ for 5 hours. The reaction was cooled to room temperature, water (10mL) was added, the filter cake was collected and dried, and the resulting solid was recrystallized at 85 ℃ (ethanol/ethyl acetate/petroleum ether ═ 2.5/5/10,17.5mL), filtered, and the filter cake was collected and dried under vacuum to give the title compound 15(0.23g, 54% yield, 98.59% HPLC purity) as a yellow solid.
MS(ESI,neg.ion)m/z:416.2[M-H]-;
1H NMR(400MHz,DMSO-d6)δ(ppm)9.35(s,1H),7.29(s,2H),6.90(d,J=8.6Hz,1H),6.74(d,J=2.6Hz,1H),6.57(dd,J=8.6,2.8Hz,1H),3.42(s,2H),2.63(t,J=6.6Hz,2H),2.11(s,6H),2.10-2.03(m,2H)。
Example 162- [3, 5-bromo-4- [ (2-oxo-1, 3,4, 5-tetrahydro-1-benzazepin-7-yl) oxy ] phenyl ] -3, 5-dioxo-1, 2, 4-triazine-6-carbonitrile (Compound 16)
Step 1)7- (2, 6-dibromo-4-nitro-phenoxy) -1,3,4, 5-tetrahydro-1-benzazepin-2-one 16a
7-hydroxy-1, 3,4, 5-tetrahydro-1-benzazepin-2-one 12a (0.10g,0.56mmol), 1, 3-dibromo-2-fluoro-5-nitro-benzene (0.20g,0.67mmol) were dissolved in N, N-dimethylformamide (5mL), and potassium carbonate (0.16g,1.2mmol) was added to react at 60 ℃ for 10 hours. After the reaction solution was cooled to room temperature, water (5mL) was added, stirred for 10 minutes, filtered, and the filter cake was collected and dried to give the title compound 16a (0.25g, yield 97%) as a pale yellow solid.
Step 2)7- (4-amino-2, 6-dibromo-phenoxy) -1,3,4, 5-tetrahydro-1-benzazepin-2-one 16b
7- (2, 6-dibromo-4-nitro-phenoxy) -1,3,4, 5-tetrahydro-1-benzazepin-2-one 16a (0.25g,0.55mmol) was dissolved in acetic acid (3mL), and iron powder (0.10g,1.6mmol) was added to the solution, followed by reaction at 60 ℃ for 5 hours. The reaction was cooled to room temperature, water (5mL) was added, stirred for 10min, filtered, washed with water (3mL × 2), and the filter cake was collected and dried to give the title compound 16b (0.19g, yield 81%) as a yellow solid.
Step 3) N- [ 2-cyano-2- [ [3, 5-dibromo-4- [ (2-oxo-1, 3,4, 5-tetrahydro-1-benzazepine-7-
Radical) oxy]Phenyl radical]Hydrazine fork]Acetyl group]Urethane 16c
7- (4-amino-2, 6-dibromo-phenoxy) -1,3,4, 5-tetrahydro-1-benzazepin-2-one 16b (0.19g,0.45mmol) was dissolved in acetic acid (3mL), a solution of sodium nitrite (46mg,0.67mmol) in water (1mL) was added at 0 ℃, and after 10 minutes of reaction, N-cyanoacetylurethane (90mg,0.56mmol) was added, followed by continuing the reaction at 0 ℃ for 1 hour. To the reaction was added water (3mL), stirred for 10min, filtered, washed with water (3mL), and the filter cake was collected and dried to give the title compound 16c (0.20g, 76% yield) as a yellow solid.
Step 4)2- [3, 5-dibromo-4- [ (2-oxo-1, 3,4, 5-tetrahydro-1-benzazepin-7-yl) oxy) benzene
Base of]-3, 5-dioxo-1, 2, 4-triazine-6-carbonitrile 16
Reacting N- [ 2-cyano-2- [ [3, 5-dibromo-4- [ (2-oxo-1, 3,4, 5-tetrahydro-1-benzazepin-7-yl) oxy group]Phenyl radical]Hydrazine fork]Acetyl group]Ethyl carbamate 16c (0.20g,0.34mmol) was dissolved in N, N-dimethylformamide (3mL), and sodium acetate (33mg,0.40mmol) was added to react at 120 ℃ for 5 hours. The reaction mixture was cooled to room temperature, water (5mL) was added, stirred for 10 minutes, filtered and collectedThe collected solid was separated and purified by preparative liquid chromatography [ 47% ACN/53% H ]2O (0.1% TFA), Kromasil standard: C1810. mu. m.times.50 mm.times.250 mm, flow rate: 100mL/min]To obtain the title compound 16(50mg, yield 27%, HPLC purity: 98.04%) as a white solid.
MS(ESI,neg.ion)m/z:546.0[M-H]-;
1H NMR(400MHz,DMSO-d6)δ(ppm)13.25(s,1H),9.42(s,1H),7.95(s,2H),6.94(d,J=8.8Hz,1H),6.85(d,J=2.4Hz,1H),6.64(dd,J=2.8,2.8Hz,1H),2.67(t,J=6.4Hz,2H),2.72-2.62(m,4H)。
Activity test examples
Firstly, the compounds of the invention detect the agonist activity of TR alpha or TR beta in a dual-luciferase reporter gene experiment
Test materials:
HEK293 cells, purchased from ATCC, Cat No. CRL-1573;
fugene HD transfection reagent, available from Promega, Cat No. E231A;
DMEM, available from Gibco, Cat No. 11995;
FBS, purchased from Biosera, Cat No. FB-1280/500;
0.25% Trypsin-EDTA, available from Gibco, Cat No. 25200-072;
Dual-Luciferase Reporter Assay System, available from Promega, Cat No. E1960;
96-well plate (round bottom) available from Corning, Cat No. 3365.
The test method comprises the following steps:
HEK293 cells were cultured in 10% FBS + DMEM in whole medium. pBind-TR alpha or pBind-TR beta (100 ng/. mu.l), pG5Luc (100 ng/. mu.l), FuGENE HD and Opti-MEM were mixed well and incubated at room temperature for 15min, while HEK293 cells were digested with 0.25% Trypsin-EDTA, resuspended in whole medium, the cell density was calculated, adjusted to 500,000cells/ml, the transcription mixture was added to mix well with the cell suspension, plated in 96-well plates (100. mu.L/well), and cultured at 37 ℃ for 24 h. After 24h, test compounds were dissolved in DMSO and diluted 3-fold for 10 concentrations, followed by dilution of the compounds with DMEM to 10% DMSOCompound solution, 5 μ L of compound was put in a 96-well plate, the compound DMSO content was 0.5% final, and the compound was co-cultured with cells for 18 h. After 18h, firefly fluorescence signal and renilla fluorescence signal were detected using the Dual-Luciferase Reporter Assay System. The F/R ratio was calculated by dividing the firefly fluorescence signal (F) by the Renilla fluorescence signal (R), and EC was calculated by plotting using Graph Pad Prism software50The value is obtained.
The test results show that: the compound has obvious agonistic activity and selectivity on TR beta.
Secondly, the in vitro binding activity detection of the compound of the invention to TR alpha or TR beta
Test materials:
LanthaScreen TR-FRET thyoid Receptor beta activator Assay kit purchased from Invitrogen, Cat.No. PV4686;
LanthaScreen TR-FRET Thyroid Receptor alfa Coactivator Assay kit was purchased from Invitrogen, Cat.No. PV4687.
The test method comprises the following steps:
the method uses the LanthaScreen TR-FRET Thyroid Receptor beta/alfa Coactivator Assay kit to perform the experiment. Test compounds were dissolved in DMSO and diluted 3-fold for 10 concentrations, followed by dilution with TR-FRET Coregulator Buffer C in the kit to a compound solution containing 2% DMSO. mu.L of compound solution containing 2% DMSO was placed in 384 well plates, then 5. mu.L of 4 XTR beta/alfa-LBD, 5. mu.L of a mixture containing 0.4. mu.M fluoroescein-SRC 2-2 and 8nM Tb anti-GST antibody was added to each well, mixed well and incubated at room temperature for 1h in the dark. After 1h, fluorescence values (RFU) were read at excitation 520nm and emission 495nm using a PHERAStar FSX microplate reader from BMG LABTECH. The TR-FRET ratio was calculated by dividing the emission signal at 520nm by the emission signal at 495 nm. Curve generation and EC calculation Using Graph Pad Prism 5 software50The value is obtained. The results of the experiment are shown in table 1.
Table 1:
the test results show that: the compound has stronger binding affinity and selectivity to TR beta.
Third, pharmacokinetic determination of the Compounds of the invention
For purposes of the test the following method was used to determine the pharmacokinetics of the compounds of the present invention.
Test materials:
the used experimental reagents and test articles are as follows: propranolol (internal standard)), methanol, ammonium acetate, K2EDTA (potassium ethylenediaminetetraacetate), formic acid, acetonitrile, MTBE (methyl tert-butyl ether), KolliphorHS15 (polyethylene glycol 12 hydroxystearate), DMSO (dimethyl sulfoxide) are all commercially available;
SD rat: male, 180-.
The test method comprises the following steps:
1. preparation of test article
The test solutions were prepared from 5% DMSO + 5% KolliphorHS15+ 90% physiological saline, and were adjusted to the solubility of each compound so that the compound was completely dissolved.
2. Design of animal experiments
3. Animal administration dose meter
Group of | Sex | Number of animals | Dosage to be administered | Concentration of drug administration | Volume of administration |
I.v. was injected intravenously. | Male sex | 3 | 1mg/kg | 1mg/mL | 1mL/kg |
P.O is administered orally. | Male sex | 3 | 5mg/kg | 1mg/mL | 5mL/kg |
4. Solution preparation
(1) Preparation of a stock solution of a test article: accurately weighing a proper amount of a test sample, dissolving the test sample in DMSO, diluting the test sample to 1mg/mL by using acetonitrile, and shaking up the test sample to obtain the test sample. Storing at-20 deg.C for use.
(2) Preparing an internal standard substance solution: a certain amount of 1mg/mL Propranol stock solution was precisely aspirated and diluted to 100ng/mL with water.
5. Sample analysis
Processing a sample by adopting a liquid-liquid extraction method, carrying out chromatographic separation, carrying out quantitative analysis on the sample by a triple quadrupole tandem mass spectrometer in a multiple reactive ion monitoring (MRM) mode, and calculating the concentration of the result by using instrument quantitative software.
6. Plasma sample pretreatment
Accurately sucking 30 μ L of plasma sample, adding 250 μ L of internal standard, and mixing by vortex. The extract was extracted once with 1mL of MTBE, centrifuged at 13,000rpm for 2min at 4 ℃, 800. mu.L of the supernatant was aspirated, evaporated in a 96-well nitrogen blower, and the residue was reconstituted with 150. mu.L of methanol/water (v/v. 50/50), vortexed, and injected in an amount of 8. mu.L.
7. Preparation of Standard samples
Accurately sucking a proper amount of compound stock solution, and adding acetonitrile to dilute to prepare a standard series solution. Accurately sucking 20 mu L of each standard series solution, adding 180 mu L of blank plasma, uniformly mixing by vortex, preparing plasma samples with plasma concentrations of 3,5, 10, 30, 100, 300, 1,000, 3,000, 5,000 and 10,000ng/mL, performing double-sample analysis according to the operation of 'plasma sample pretreatment', and establishing a standard curve.
8. Analytical method
The LC/MS method was used to determine the amount of test compound in rat plasma after administration of the different compounds.
9. Data processing
Pharmacokinetic parameters were calculated using WinNonlin 6.1 software, a non-compartmental model method.
The test results show that the compound of the invention shows excellent pharmacokinetic properties when administered by intravenous injection or oral administration.
Fourthly, pharmacodynamic evaluation of the compound of the invention
Test materials:
western diet: purchased from Research die, cat #: D12079B;
MCD die: purchased from southbound telofil fodder science ltd, cat #: TP 3006R;
ALT, AST, ALP, TG, CHO, HDL, LDL and GLU: purchased from Roche, and the respective cargo numbers are: 20764957322, 20764949322, 03333701190, 20767107322, 0303973190, 04399803190, 03038866322 and 04404483190;
male OB/OB mice 8 weeks old: purchased from Jiangsu Jiejiaokang Biotech limited;
8 week old male db/db mice: purchased from Jiangsu Jiejiaokang Biotech limited.
A. Compound on OB/OB mouse nonalcoholic steatohepatitis (NASH) model induced by Western diet
Evaluation of pharmacodynamics of (1)
OB/OB mice are mice with leptin gene deletion, and OB/OB mouse NASH model induced by Western diet is a common NASH in vivo efficacy evaluation model. The experiment was started 1 week after the animals were acclimated. OB/OB mice were fed Western diet, which was changed three times a week (Monday, three, five), and mice were dosed starting at the fifth week after feeding, once a day orally for 6 weeks, for a total experimental period of 10 weeks. The animals were monitored daily for baseline performance during the experiment and mouse body weights were recorded weekly. After the experiment, the test was performed overnight, and the mice were anesthetized, subjected to orbital bleeding to collect whole blood, centrifuged at 4 ℃ and 4,000rpm for 10min to obtain serum, and stored at-80 ℃. The serum was used for the detection of ALT, AST, ALP, TG, CHO, HDL, LDL and GLU. The mice were dissected, livers were removed and weighed. Liver midlobes were stored at-80 ℃ in EP tubes and used for intrahepatic TG and CHO content determination. Left lobe of liver was fixed in 10% formalin, HE stained and scored for NAS.
B. Efficacy of Compounds in MCD diet-induced db/db mouse non-alcoholic steatohepatitis (NASH) model
Evaluation of science
The db/db mouse is a leptin receptor gene deletion mouse, and the db/db mouse NASH model induced by MCD diet is a commonly used NASH in-vivo efficacy evaluation model. The experiment was started 1 week after the animals were acclimated. db/db mice were fed with MCD feed, which was changed three times a week (monday, wednesday, friday), and the mice were tested by dosing while molding, once a day for 8 weeks, with the entire test period of 8 weeks. The animals were monitored daily for baseline performance during the experiment and mouse body weights were recorded weekly. After the experiment, the mice were anesthetized, subjected to orbital bleeding to collect whole blood, centrifuged at 4 ℃ and 4,000rpm for 10min to obtain serum, and stored at-80 ℃. The serum was used for the detection of ALT, AST, ALP, TG, CHO, HDL, LDL and GLU. The mice were dissected, livers were removed and weighed. Liver midlobes were stored at-80 ℃ in EP tubes and used for intrahepatic TG and CHO content determination. Left lobe of liver was fixed in 10% formalin, HE stained and scored for NAS.
Test results show that the compound can effectively reduce fat accumulation in liver, relieve inflammation and improve hepatic fibrosis.
In the description herein, references to the description of the term "one embodiment," "some embodiments," "an example," "a specific example," or "some examples," etc., mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above are not necessarily intended to refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Furthermore, various embodiments or examples and features of different embodiments or examples described in this specification can be combined and combined by one skilled in the art without contradiction.
Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention, and that variations, modifications, substitutions and alterations can be made to the above embodiments by those of ordinary skill in the art within the scope of the present invention.
Claims (13)
1. A compound which is a compound of formula (I) or a stereoisomer, geometric isomer, tautomer, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt of a compound of formula (I) or a prodrug thereof,
wherein,
y is-O-),-NH-、-CH2-、-CH=CH-、-C(=O)-、-CH(OH)-、-CH(CH3)-、-C(CH3)2-or-S-;
R3a、R3b、R3cand R3dEach independently is H, deuterium, F, Cl, Br, I, -CN, -NO2、-COOH、-OH、-NH2、-SH、C1-6Alkyl radical, C1-6Alkoxy radical, C1-6Alkylthio radical, C1-6Alkylamino radical, C1-6Haloalkyl, C1-6Haloalkoxy, hydroxy C1-6Alkyl, amino C1-6Alkyl or cyano C1-6An alkyl group;
R1is H, deuterium, F, Cl, Br, I, -CN, -NO2、-COOH、-OH、-NH2、-SH、C1-6Alkyl radical, C2-6Alkenyl radical, C2-6Alkynyl, -C (═ O) -C1-6Alkoxy, -C (═ O) -C1-6Alkyl, -C (═ O) -C1-6Alkylamino, -C (═ O) NH2、-S(=O)2-C1-6Alkyl, -S (═ O)2-C1-6Alkylamino, -S (═ O)2NH2、C1-6Alkylamino radical, C1-6Alkoxy radical, C1-6Haloalkyl, C1-6Haloalkoxy, hydroxy C1-6Alkyl, amino C1-6Alkyl, carboxyl C1-6Alkyl or cyano C1-6An alkyl group;
R2is H, deuterium, C1-6Alkyl radical, C2-6Alkenyl radical, C2-6Alkynyl, C3-6Cycloalkyl, heterocyclic radical of 5-6 atoms, C6-10Aryl or heteroaryl of 5 to 6 atoms;
X is N or CH;
E1is- (CR)aRb)q-、-C(=O)-、-O-、-C(=CRjRk)-、-S-、-S(=O)-、-S(=O)2-or-NRg-; q is 0,1, 2 or 3;
E2is-CRcRd-、-C(=O)-、-C(=CRhRi)-、-O-、-S-、-S(=O)-、-S(=O)2-or-NRg-;
E3is-CReRf-、-C(=O)-、-C(=CRmRn)-、-O-、-S-、-S(=O)-、-S(=O)2-or-NRg-;
Each Ra、Rb、Rc、Rd、Re、Rf、Rh、Ri、Rj、Rk、RmAnd RnIndependently H, deuterium, F, Cl, Br, I, -CN, -NO2、-COOH、-OH、-NH2、-SH、C1-6Alkyl radical, C2-6Alkenyl radical, C2-6Alkynyl, C1-6Alkoxy radical, C1-6Alkylamino radical, C1-6Haloalkyl, C1-6Haloalkoxy, C3-6Cycloalkyl radical, C3-6cycloalkyl-C1-4Alkylene, heterocyclic group consisting of 5 to 6 atoms, (heterocyclic group consisting of 5 to 6 atoms) -C1-4Alkylene radical, C6-10Aryl radical, C6-10aryl-C1-4Alkylene, heteroaryl of 5 to 6 atoms or (heteroaryl of 5 to 6 atoms) -C1-4Alkylene, wherein said C1-6Alkyl radical, C2-6Alkenyl radical, C2-6Alkynyl, C1-6Alkoxy radical, C1-6Alkylamino radical, C1-6Haloalkyl, C1-6Haloalkoxy, C3-6Cycloalkyl radical, C3-6cycloalkyl-C1-4Alkylene, heterocyclic group consisting of 5 to 6 atoms, (heterocyclic group consisting of 5 to 6 atoms) -C1-4Alkylene radical, C6-10Aryl radical, C6-10aryl-C1-4Alkylene, heteroaryl of 5 to 6 atoms and (heteroaryl of 5 to 6 atoms) -C1-4Alkylene is each independently unsubstituted or substituted by 1,2 or 3Ry1Substituted;
or Ra、RbTogether with the carbon atom to which they are attached form C3-8Carbocyclic ring or heterocyclic ring of 5 to 6 atoms, or Rc、RdAnd the carbon atoms to which they are attachedTogether form C3-8Carbocyclic ring or heterocyclic ring of 5 to 6 atoms, or Re、RfTogether with the carbon atom to which they are attached form C3-8A carbocyclic ring or a heterocyclic ring of 5 to 6 atoms in which said C3-8The carbocycle and the heterocycle of 5 to 6 atoms are each independently unsubstituted or substituted by 1,2 or 3Ry1Substituted;
each R4And RgIndependently of one another H, deuterium, C1-6Alkyl radical, C2-6Alkenyl radical, C2-6Alkynyl, C1-6Haloalkyl, C3-6Cycloalkyl radical, C3-6cycloalkyl-C1-4Alkylene, heterocyclic group consisting of 5 to 6 atoms, (heterocyclic group consisting of 5 to 6 atoms) -C1-4Alkylene radical, C6-10Aryl radical, C6-10aryl-C1-4Alkylene, heteroaryl of 5 to 6 atoms or (heteroaryl of 5 to 6 atoms) -C1-4Alkylene, wherein said C1-6Alkyl radical, C2-6Alkenyl radical, C2-6Alkynyl, C1-6Haloalkyl, C3-6Cycloalkyl radical, C3-6cycloalkyl-C1-4Alkylene, heterocyclic group consisting of 5 to 6 atoms, (heterocyclic group consisting of 5 to 6 atoms) -C1-4Alkylene radical, C6-10Aryl radical, C6-10aryl-C1-4Alkylene, heteroaryl of 5 to 6 atoms and (heteroaryl of 5 to 6 atoms) -C1-4Alkylene is each independently unsubstituted or substituted by 1,2 or 3Ry1Substituted;
or Ra、RcAnd together with the carbon atom to which they are each attached form-C ═ C-;
or Rc、ReAnd together with the carbon atom to which they are each attached form-C ═ C-;
or R4、ReAnd together with the atom to which they are each attached form-N ═ C-;
each RyIndependently H, deuterium, F, Cl, Br, I, -CN, -OH, -NH2、C1-6Alkyl radical, C1-6Haloalkyl, C1-6Haloalkoxy, C1-6Alkoxy or C1-6An alkylamino group;
each Ry1Independently deuterium, F, Cl, Br, I, -CN, -OH, -NH2、C1-6Alkyl radical, C1-6Haloalkyl, C1-6Haloalkoxy, C1-6Alkoxy or C1-6An alkylamino group.
2. The compound of claim 1, wherein R is3a、R3b、R3cAnd R3dEach independently is H, deuterium, F, Cl, Br, I, -CN, -NO2、-COOH、-OH、-NH2-SH, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, methylthio, methylamino, -CF3、-CHF2、-CH2F、-CH2CF3、-CH2CHF2Trifluoromethoxy, difluoromethoxy, hydroxymethyl, aminomethyl or cyanomethyl.
3. The compound of claim 1 or 2, wherein R is1Is H, deuterium, F, Cl, Br, I, -CN, -NO2、-COOH、-OH、-NH2-SH, methyl, ethyl, n-propyl, isopropyl, -CH ═ CH2、-CH2CH=CH2、-CH=CHCH3、-C≡CH、-C(=O)-OCH3、-C(=O)-OCH2CH3、-C(=O)-OCH(CH3)2、-C(=O)-OCH2CH2CH3、-C(=O)-O(CH2)3CH3、-C(=O)-OCH2CH(CH3)2、-C(=O)-CH3、-C(=O)-CH2CH3、-C(=O)-NHCH3、-C(=O)-N(CH3)2、-C(=O)NH2、-S(=O)2-CH3、-S(=O)2-CH2CH3、-S(=O)2-NHCH3、-S(=O)2NH2Methylamino, ethylamino, methoxy, ethoxy, -CF3、-CHF2、-CH2F、-CH2CF3、-CH2CHF2Trifluoromethoxy group, difluoromethoxy group, hydroxymethyl group, aminomethyl groupCarboxymethyl or cyanomethyl.
4. A compound according to any one of claims 1-3, wherein R is2Is H, deuterium, methyl, ethyl, n-propyl, isopropyl, tert-butyl, -CH ═ CH2、-CH2CH=CH2、-CH=CHCH3C ≡ CH, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, heterocyclyl with 5-6 atoms, phenyl, naphthyl or heteroaryl with 5-6 atoms.
5. The compound of any one of claims 1-4, wherein each R isa、Rb、Rc、Rd、Re、Rf、Rh、Ri、Rj、Rk、RmAnd RnIndependently H, deuterium, F, Cl, Br, I, -CN, -NO2、-COOH、-OH、-NH2、-SH、C1-4Alkyl radical, C2-4Alkenyl radical, C2-4Alkynyl, C1-4Alkoxy radical, C1-4Alkylamino radical, C1-4Haloalkyl, C1-4Haloalkoxy, C3-6Cycloalkyl radical, C3-6cycloalkyl-C1-2Alkylene, heterocyclic group consisting of 5 to 6 atoms, (heterocyclic group consisting of 5 to 6 atoms) -C1-2Alkylene radical, C6-10Aryl radical, C6-10aryl-C1-2Alkylene, heteroaryl of 5 to 6 atoms or (heteroaryl of 5 to 6 atoms) -C1-2Alkylene, wherein said C1-4Alkyl radical, C2-4Alkenyl radical, C2-4Alkynyl, C1-4Alkoxy radical, C1-4Alkylamino radical, C1-4Haloalkyl, C1-4Haloalkoxy, C3-6Cycloalkyl radical, C3-6cycloalkyl-C1-2Alkylene, heterocyclic group consisting of 5 to 6 atoms, (heterocyclic group consisting of 5 to 6 atoms) -C1-2Alkylene radical, C6-10Aryl radical, C6-10aryl-C1-2Alkylene, heteroaryl of 5 to 6 atoms and (heteroaryl of 5 to 6 atoms) -C1-2Alkylene is each independently unsubstituted or substituted by 1,2 or3Ry1Substituted;
or Ra、RbTogether with the carbon atom to which they are attached form C3-8Carbocyclic ring or heterocyclic ring of 5 to 6 atoms, or Rc、RdTogether with the carbon atom to which they are attached form C3-8Carbocyclic ring or heterocyclic ring of 5 to 6 atoms, or Re、RfTogether with the carbon atom to which they are attached form C3-8A carbocyclic ring or a heterocyclic ring of 5 to 6 atoms in which said C3-8The carbocycle and the heterocycle of 5 to 6 atoms are each independently unsubstituted or substituted by 1,2 or 3Ry1And (4) substituting.
6. The compound of any one of claims 1-5, wherein each R isa、Rb、Rc、Rd、Re、Rf、Rh、Ri、Rj、Rk、RmAnd RnIndependently H, deuterium, F, Cl, Br, I, -CN, -NO2、-COOH、-OH、-NH2-SH, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, -CH ═ CH2、-CH2CH=CH2、-CH=CHCH3-C.ident.CH, methoxy, ethoxy, methylamino, -CF3、-CHF2、-CH2F、-CH2CF3、-CH2CHF2Trifluoromethoxy, difluoromethoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyl-CH2-, pyrrolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, (heterocyclyl consisting of 5 to 6 atoms) -C1-2Alkylene, phenyl-CH2-, phenyl-CH2CH2-, furyl, thienyl, imidazolyl, pyrimidinyl, pyridyl, pyrrolyl, pyrazinyl, thiazolyl, oxazolyl, furyl-CH2-, thienyl-CH2-, imidazolyl-CH2-, pyrimidinyl-CH2-, pyridinyl-CH2-or pyrrolyl-CH2-, wherein said methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butylButyl, -CH ═ CH2、-CH2CH=CH2、-CH=CHCH3-C.ident.CH, methoxy, ethoxy, methylamino, -CHF2、-CH2F、-CH2CF3、-CH2CHF2Difluoromethoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropyl-CH2-, pyrrolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, (heterocyclyl consisting of 5 to 6 atoms) -C1-2Alkylene, phenyl-CH2-, phenyl-CH2CH2-, furyl, thienyl, imidazolyl, pyrimidinyl, pyridyl, pyrrolyl, pyrazinyl, thiazolyl, oxazolyl, furyl-CH2-, thienyl-CH2-, imidazolyl-CH2-, pyrimidinyl-CH2-, pyridinyl-CH2-and pyrrolyl-CH2Each independently unsubstituted or substituted by 1,2 or 3Ry1Substituted;
or Ra、RbTogether with the carbon atom to which they are attached form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or a heterocyclic ring of 5 to 6 atoms, or Rc、RdTogether with the carbon atom to which they are attached form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or a heterocyclic ring of 5 to 6 atoms, or Re、RfTogether with the carbon atoms to which they are attached form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or a 5-6 atom heterocycle wherein the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and 5-6 atom heterocycle are each independently unsubstituted or substituted with 1,2, or 3Ry1And (4) substituting.
7. The compound of any one of claims 1-6, wherein each R is4And RgEach independently is H, deuterium, methyl, ethyl, n-propyl, isopropyl, -CH ═ CH2、-CH2CH=CH2、-CH=CHCH3、-C≡CH、-CF3、-CHF2、-CH2F、-CH2CHF2、-CH2CF3Cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C3-6cycloalkyl-C1-2Alkylene, heterocyclic group consisting of 5 to 6 atoms, (heterocyclic group consisting of 5 to 6 atoms) -C1-2Alkylene, phenyl-C1-2Alkylene, heteroaryl of 5 to 6 atoms or (heteroaryl of 5 to 6 atoms) -C1-2Alkylene, wherein the methyl, ethyl, n-propyl, isopropyl, -CH ═ CH2、-CH2CH=CH2、-CH=CHCH3、-C≡CH、-CHF2、-CH2F、-CH2CHF2、-CH2CF3Cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, C3-6cycloalkyl-C1-2Alkylene, heterocyclic group consisting of 5 to 6 atoms, (heterocyclic group consisting of 5 to 6 atoms) -C1-2Alkylene, phenyl-C1-2Alkylene, heteroaryl of 5 to 6 atoms and (heteroaryl of 5 to 6 atoms) -C1-2Alkylene is each independently unsubstituted or substituted by 1,2 or 3Ry1And (4) substituting.
8. The compound according to any one of claims 1-7, each RyIndependently H, deuterium, F, Cl, Br, I, -CN, -OH, -NH2Methyl, ethyl, n-propyl, isopropyl, -CF3、-CHF2Trifluoromethoxy, difluoromethoxy, methoxy, ethoxy, or methylamino;
each Ry1Independently deuterium, F, Cl, Br, I, -CN, -OH, -NH2Methyl, ethyl, n-propyl, isopropyl, -CF3、-CHF2Trifluoromethoxy, difluoromethoxy, methoxy, ethoxy or methylamino.
10. A pharmaceutical composition comprising a compound of any one of claims 1-9, optionally further comprising any one of a pharmaceutically acceptable carrier, excipient, adjuvant, vehicle, or any combination thereof.
11. Use of a compound according to any one of claims 1 to 9 or a pharmaceutical composition according to claim 10 for the manufacture of a medicament for agonising a thyroid hormone receptor; or for the prevention, treatment or alleviation of diseases modulated by thyroid hormone receptors.
12. The use of claim 11, wherein the thyroid hormone receptor is thyroid hormone beta receptor.
13. The use according to claim 11, wherein the disease modulated by thyroid hormone receptors is non-alcoholic fatty liver disease, atherosclerosis, coronary heart disease, hypertension, hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, dyslipidemia, obesity, diabetes, metabolic disorder, lipid metabolism disorder, glycogen storage disease type 1A, hypothyroidism or thyroid cancer;
wherein the non-alcoholic fatty liver disease is non-alcoholic simple fatty liver, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease-related cryptogenic cirrhosis or primary liver cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910831518 | 2019-09-04 | ||
CN2019108315182 | 2019-09-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112442013A true CN112442013A (en) | 2021-03-05 |
CN112442013B CN112442013B (en) | 2022-07-26 |
Family
ID=74736440
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010912749.9A Active CN112442013B (en) | 2019-09-04 | 2020-09-03 | Compound serving as thyroid hormone beta receptor agonist and application thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN112442013B (en) |
WO (1) | WO2021043185A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113979963A (en) * | 2021-12-24 | 2022-01-28 | 凯思凯旭(上海)医药科技有限公司 | Compound as thyroid hormone beta receptor agonist and application thereof |
WO2022057845A1 (en) * | 2020-09-17 | 2022-03-24 | 广东东阳光药业有限公司 | COMPOUND SERVING AS THYROID HORMONE β RECEPTOR AGONIST AND USES OF COMPOUND |
WO2022127699A1 (en) * | 2020-12-15 | 2022-06-23 | 中国科学院上海药物研究所 | THYROID HORMONE RECEPTOR β SELECTIVE AGONIST COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF |
WO2023125716A1 (en) * | 2021-12-28 | 2023-07-06 | 中国科学院上海药物研究所 | Class of quinoline compounds, preparation method therefor, pharmaceutical composition and use thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112021021718A2 (en) | 2019-05-08 | 2022-01-18 | Aligos Therapeutics Inc | Thr-ss modulators and methods of using them |
CA3197226A1 (en) * | 2020-11-06 | 2022-05-12 | David Craig Mcgowan | Oxindoles and methods of use thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040157844A1 (en) * | 1999-09-30 | 2004-08-12 | Dow Robert L. | 6-azauracil derivatives as thyroid receptor ligands |
US20050085541A1 (en) * | 2002-01-30 | 2005-04-21 | Hiroaki Shiohara | Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof |
CN101801960A (en) * | 2007-09-20 | 2010-08-11 | 霍夫曼-拉罗奇有限公司 | prodrugs to thyroid hormone analogs |
CN102459185A (en) * | 2009-04-20 | 2012-05-16 | 田边三菱制药株式会社 | Novel thyroid hormone beta receptor agonist |
JP2012106996A (en) * | 2010-10-19 | 2012-06-07 | Mitsubishi Tanabe Pharma Corp | NOVEL THYROID HORMONE β-RECEPTOR AGONIST |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1919878T3 (en) * | 2005-07-21 | 2010-10-25 | Hoffmann La Roche | Pyridazine derivatives as thyroid hormone receptor agonists |
BR112015005891A2 (en) * | 2012-09-17 | 2017-08-08 | F Hoffmann La Roche Ltd | method of synthesizing thyroid hormone analogs and polymorphs of these |
CN108727344A (en) * | 2018-05-14 | 2018-11-02 | 嘉兴特科罗生物科技有限公司 | A kind of compound and its synthetic method and application |
JP2022504706A (en) * | 2018-10-12 | 2022-01-13 | インベンティスバイオ カンパニー リミテッド | Thyroid hormone receptor agonist |
WO2020169069A1 (en) * | 2019-02-21 | 2020-08-27 | Nanjing Ruijie Pharma Co., Ltd. | Novel compounds and their uses as thyroid hormone receptor agonists |
-
2020
- 2020-09-03 WO PCT/CN2020/113115 patent/WO2021043185A1/en active Application Filing
- 2020-09-03 CN CN202010912749.9A patent/CN112442013B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040157844A1 (en) * | 1999-09-30 | 2004-08-12 | Dow Robert L. | 6-azauracil derivatives as thyroid receptor ligands |
US20050085541A1 (en) * | 2002-01-30 | 2005-04-21 | Hiroaki Shiohara | Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof |
CN101801960A (en) * | 2007-09-20 | 2010-08-11 | 霍夫曼-拉罗奇有限公司 | prodrugs to thyroid hormone analogs |
CN102459185A (en) * | 2009-04-20 | 2012-05-16 | 田边三菱制药株式会社 | Novel thyroid hormone beta receptor agonist |
JP2012106996A (en) * | 2010-10-19 | 2012-06-07 | Mitsubishi Tanabe Pharma Corp | NOVEL THYROID HORMONE β-RECEPTOR AGONIST |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022057845A1 (en) * | 2020-09-17 | 2022-03-24 | 广东东阳光药业有限公司 | COMPOUND SERVING AS THYROID HORMONE β RECEPTOR AGONIST AND USES OF COMPOUND |
WO2022127699A1 (en) * | 2020-12-15 | 2022-06-23 | 中国科学院上海药物研究所 | THYROID HORMONE RECEPTOR β SELECTIVE AGONIST COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF |
CN113979963A (en) * | 2021-12-24 | 2022-01-28 | 凯思凯旭(上海)医药科技有限公司 | Compound as thyroid hormone beta receptor agonist and application thereof |
CN113979963B (en) * | 2021-12-24 | 2022-03-11 | 凯思凯旭(上海)医药科技有限公司 | Compound as thyroid hormone beta receptor agonist and application thereof |
WO2023125716A1 (en) * | 2021-12-28 | 2023-07-06 | 中国科学院上海药物研究所 | Class of quinoline compounds, preparation method therefor, pharmaceutical composition and use thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2021043185A1 (en) | 2021-03-11 |
CN112442013B (en) | 2022-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112442013B (en) | Compound serving as thyroid hormone beta receptor agonist and application thereof | |
CN109983007B (en) | Amide derivative inhibitor and preparation method and application thereof | |
CN109988109B (en) | Amine compound for inhibiting SSAO/VAP-1 and application thereof | |
JP5406725B2 (en) | Compounds useful as protein kinase inhibitors | |
EP4036090A1 (en) | Chemical compound as thyroid hormone beta receptor agonist and use thereof | |
US11208418B2 (en) | Nitrogenous tricyclic compounds and uses thereof in medicine | |
WO2007037534A1 (en) | 2-heteroaryl-substituted indole derivative | |
UA127346C2 (en) | Somatostatin modulators and uses thereof | |
TW202012412A (en) | A pharmaceutical composition containing amide derivatives, its preparation method and application thereof | |
CN112771027A (en) | Lysophosphatidic acid receptor antagonists and process for their preparation | |
CN109988093B (en) | Amine compound for inhibiting SSAO/VAP-1 and application thereof in medicine | |
CN112789277B (en) | Guanidine derivatives and use thereof | |
CN114621207A (en) | Compound as thyroid hormone beta receptor agonist and application thereof | |
CN113045551B (en) | Compound serving as thyroid hormone beta receptor agonist and application thereof | |
US20240025875A1 (en) | A compound as a thyroid hormone beta receptor agonist and use thereof | |
CN113748104B (en) | Isoquinolinones for inhibiting SSAO/VAP-1 and application thereof | |
CN111630047A (en) | Benzoazaheterocycle compound containing carboxylic acid group and preparation method and application thereof | |
CN111630058A (en) | Glucopyranosyl derivative and use thereof | |
CN112300211B (en) | Compound serving as thyroid hormone beta receptor agonist and application thereof | |
CN115003296A (en) | Compounds and methods for treating cystic fibrosis | |
CN114728925B (en) | Amine derivative serving as SSAO/VAP-1 inhibitor and application thereof | |
TW202325701A (en) | A COMPOUND AS A THYROID HORMONE β RECEPTOR AGONIST AND USE THEREOF | |
CN111196806B (en) | Guanidine derivative and application thereof | |
WO2023169436A1 (en) | Benzo bicyclic compound, and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province Patentee after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd. Address before: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province Patentee before: SUNSHINE LAKE PHARMA Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder |